References on the Administration of Selected Enzyme Inhibitors Using ALZET® Osmotic Pumps
Note: See also the reference lists on Antidepressents, Antihypertensives, Antivirals, Nitric Oxide Synthase Inhibitors, and NSAIDs
1. 1400W
P8887 Hu,A.H., Jiao,X.Y., Gao,E.H., Li,Y.H., Sharifi-Azad,S., Grunwald,Z., Ma,X.L., Sun,J.Z. Tonic beta-adrenergic drive provokes proinflammatory and proapoptotic changes in aging mouse heart. REJUVENATION RESEARCH 2008; 11(-1-):215-226. >>> 1400W; Isoproterenol bitartrate; SC; Mice; 2002; 14 days; Controls received mp w/ vehicle; enzyme inhibitor (iNOS); animal info (C57BL/6, 3, 20 months old); ischemia (myocardial).
P8870 Chirino,Y.I., Trujillo,J., Sanchez-Gonzalez,D.J., Martinez-Martinez,C.M., Cruz,C., Bobadilla,N.A., Pedraza-Chaverri,J. Selective iNOS inhibition reduces renal damage induced by cisplatin. TOXICOLOGY LETTERS 2008; 176(-1-):48-57. >>> 1400W; cisplatin; Saline; SC; Rat; 2001; 3 days; Controls received mp w/ vehicle; enzyme inhibitor (iNOS); animal info (male, Wistar, 230-275g.).
P8466 Zhang,P., Xu,X., Hu,X.L., van Deel,E.D., Zhu,G.S., Chen,Y.J. Inducible nitric oxide synthase deficiency protects the heart from systolic overload-induced ventricular hypertrophy and congestive heart failure. Circulation Research 2007; 100(-7-):1089-1098. >>> 1400W; Saline; SC; Mice; 2002; 2 weeks; Controls received mp w/ vehicle; cardiovascular; animal info (2-3 months old, CS7BL16).
P7221 Perez-Asenio,F.J., Hurtado,O., Burguete,M.C., Moro,M.A., Salom,J.B., Lizasoain,I., Torregrosa,G., Leza,J.C., Alborch,E., Castillo,J., Knowles,R.G., Lorenzo,P. Inhibition of iNOS activity by 1400W decreases glutamate release and ameliorates stroke outcome after experimental ischemia. NEUROBIOLOGY OF DISEASE 2005; 18(-2-):375-384. >>> 1400W; IP; Rat; 2-72 hours; Controls received mp w/ saline or no treatment.
P6534 Hu,D.E., Dyke,S.O.M., Moore,A.M., Thomsen,L.L., Brindle,K.M. Tumor cell-derived nitric oxide is involved in the immune-rejection of an immunogenic murine lymphoma. Cancer Research 2004; 64(-1-):152-161. >>> 1400W; PBS; SC; Mice; 2001; ; Controls received mp w/ vehicle; enzyme inhibitor (iNOS); cancer (lymphoma).
P5175 Sharp,B.R., Jones,S.P., Rimmer,D.M., Lefer,D.J. Differential response to myocardial reperfusion injury in eNOS-deficient mice. American Journal of Physiology-Heart and Circulatory Physiology 2002; 282(--):H2422-H2426. >>> 1400W; IP; Mice (knockout); ; Cardiovascular; enzyme inhibitor; 1400W is an inducible nitric oxide synthase (iNOS) inhibitor.
P5028 Koarai,A., Ichinose,M., Sugiura,H., Yamagata,S., Hattori,T., Shirato,K. Allergic airway hyperresponsiveness and eosinophil infiltration is reduced by a selective iNOS inhibitor, 1400W, in mice. Pulmonary Pharmacology&Therapeutics 2000; 13(--):267-275. >>> 1400W; Saline; SC; mice; 1003D; 26 hours; Controls received mp w/ vehicle; immunology; 1400 W is a selective inducible Nitric Oxide Synthase (iNOS) inhibitor; asthma.
P4279 Rudd,M.A., Trolliet,M., Hope,S., Scribner,A.W., Daumerie,G., Toolan,G., Cloutier,T., Loscalzo,J. Salt-induced hypertension in Dahl salt-resistant and salt-sensitive rats with NOS II inhibition. Am.J.Physiol.(Heart Circ.Physiol.46) 1999; 277(--):H732-H739. >>> AMT; 1400W; Ethylisourea, S-; Rat; 12 days; Cardiovascular; agents are NOS II inhibitors; AMT is 2-amino-5,6-dihydro-6-methyl-4H-1,3-thiazine; S-ethylisourea is also known as EIT; enzyme inhibitors; nitric oxide synthase inhibitor;.
P3742 Thomsen,L.L., Scott,J.M.J., Topley,P., Knowles,R.G., Keerie,A.-J., Frend,A.J. Selective inhibition of inducible nitric oxide synthase inhibits tumor growth in vivo: studies with 1400W, a novel inhibitor. Cancer Res. 1997; 57(--):3300-3304. >>> 1400W; Water, sterile; SC; mice; 2002; 6, 12, 13 days; controls received mp w/ vehicle; functionality of mp verified by measurement of 1400W in plasma and tumor samples; stress/adverse reaction: unexpected symptoms in 2 mice in high dose group (12 mg/kg/h), not clear if compound toxicity or bacterial infection (see pg. 3303); cancer; 1400W is N-(3-(aminomethyl)benzyl)acetamidine, a NO synthase inhibitor.
2. 9050
P6687 Lee,B.J., Singh,A., Chiang,P., Kemp,S.J., Goldman,E.A., Weinhouse,M.I., Vlasuk,G.P., Rosenthal,P.J. Antimalarial activities of novel synthetic cysteine protease inhibitors. Antimicrobial Agents and Chemotherapy 2003; 47(-12-):3810-3814. >>> 9050; Cremophor, RH40; SC; Mice; 14 days; Controls received mp w/ vehicle; comparison of IP injections vs. SC mp; half-life (p. 3812), 87.1 min (injection) and 56.2 min (infusion); 12.5% cremophor used; agent is a novel synthetic cysteine protease enzyme inhibitor with antimalarial properties; pump model not listed.
3. AA-861
P9949 Okubo,M., Yamanaka,H., Kobayashi,K., Noguchi,K. Leukotriene Synthases and the Receptors Induced by Peripheral Nerve Injury in the Spinal Cord Contribute to the Generation of Neuropathic Pain. Glia 2010; 58(-5-):599-610. >>> AA-861; U-75302; SB203580; pranlukast; U0126; Ethanol; saline; DMSO; CSF/CNS (intrathecal, subarachnoid space); Rat; 2001; ; Controls received mp w/ saline; enzyme inhibitor (5-lipoxygenase); animal info (male, Sprague Dawley, 200-250 g); 0.02-0.2% ethanol used; 50% DMSO used; spinal nerve injury; behavioral testing (mechanical allodynia).
4. AG-490
P6904 Qiu,J., Cafferty,W.B.J., McMahon,S.B., Thompson,S.W.N. Conditioning injury-induced spinal axon regeneration requires signal transducer and activator of transcription 3 activation. Journal of Neuroscience 2005; 25(-7-):1645-1653. >>> AG-490; Saline; CSF/CNS (sciatic nerve); Rat; 2004; ; Controls received mp w/ vehicle; enzyme inhibitor (JAK2); silastic tubing and a gortex nerve cuff used.
P3017 Meydan,N., Grunberger,T., Dadi,H., Shahar,M., Arpaia,E., Lapidot,Z., Leeder,J.S., Freedman,M., Cohen,A., Gazit,A., Levitzki,A., Roifman,C.M. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 1996; 1996(--):645-648. >>> AG-490; SC; mice (SCID); no duration posted; controls received no treatment or mp with DMSO; cancer; ALZET not specifically mentioned, but confirmed pump paper via author; AG-490 is a protein tyrosine kinase (PTK) tynorphin inhibitor.
5. AG-1296
P7818 Dell,S., Peters,S., Muether,P., Kociok,N., Joussen,A.M. The role of PDGF receptor inhibitors and PI3-kinase signaling in the pathogenesis of corneal neovascularization. INVESTIGATIVE OPHTHALMOLOGY&VISUAL SCIENCE 2006; 47(-5-):1928-1937. >>> AG-1296; wortmannin; LY294002; PBS; IP; Mice; 2001; 1 week; Controls received mp w/ vehicle; dose-response (fig. 6); enzyme inhibitor (PDGF receptor kinase, phosphatidylinositol 3-kinase); animal info (male, C57BL/6,7-10wk old 20g.).
P6010 Liu,S.Q., Tieche,C., Tang,D.L., Alkema,P. Pattern formation of vascular smooth muscle cells subject to nonuniform fluid shear stress: role of PDGF-β receptor and Src. American Journal of Physiology-Heart and Circulatory Physiology 2003; 285(-3-):H1081-H1090. >>> AG-1296; PP1; IV (vena cava); Rat; 2001D; 10 days; AG-1296 and PP1 are selective PDGF-B receptor tyrosine kinase and SRC inhibitors; enzyme inhibitor (tyrosine kinase).
6. AG1478
Q0908 Benter,I.F., Canatan,H., Benboubetra,M., Yousif,M.H.M., Akhtar,S. Global upregulation of gene expression associated with renal dysfunction in DOCA-salt-induced hypertensive rats occurs via signaling cascades involving epidermal growth factor receptor: A microarray analysis. VASCULAR PHARMACOLOGY 2009; 51(-2-3-):101-109. >>> AG1478; Rat; 2ML1; ; Animal info (Wistar); enzyme inhibitor (EGFR tyrosine kinase).
P9197 Palen,D.I., Matrougui,K. Role of elevated EGFR phosphorylation in the induction of structural remodelling and altered mechanical properties of resistance artery from type 2 diabetic mice. DIABETES-METABOLISM RESEARCH AND REVIEWS 2008; 24(-8-):651-656. >>> AG-1478; Mice; 2 weeks; Animal info (type 2 diabetic, non diabetic, male, 12-14 wks old); AG-1478 is an epidermal growth factor receptor (EGFR) inhibitor; diabetes.
P7677 Ivanov,A., Gerzanich,V., Ivanova,S., DenHaese,R., Tsymbalyuk,O., Simard,J.M. Adenylate cyclase 5 and Kca1.1 channel are required for EGFR up-regulation of PCNA in native contractile rat basilar artery smooth muscle. JOURNAL OF PHYSIOLOGY-LONDON 2006; 570(-1-):73-84. >>> Epidermal growth factor; AG-1478; angiotensin II; iberiotoxin; CSF, artificial; saline; CSF/CNS (intrathecal, cisterna magna); SC; Rat; 2001; 2004; 1,3 days; 4 weeks; Controls received mp w/ aCSF; cardiovascular; peptides; animal info (female, wistar, 275-325 g); angiotensin II disolved in saline and was subcutaneously delivered for 4 weeks using the 2004 model pump; AG-1478 is an EGFR inhibitor.
7. AK275
P2615 Bartus,R.T., Baker,K.L., Heiser,A.D., Sawyer,S.D., Dean,R.L., Elliott,P.J., Straub,J.A. Postischemic administration of AK275, a calpain inhibitor, provides substantial protection against focal ischemic brain damage. J.Cereb.Blood Flow Metab. 1994; 14(-4-):537-544. >>> AK275; Dye, Evans-Blue fluorescent; CSF, artificial; DMSO; CSF/CNS (occipital cortex); rat; 2001D; 17-25 hours; controls received vehicles; functionality of mp verified by in vitro tests; dose-response (pg. 542); enzyme inhibitor; pumps coated w/ paraffin to decrease delivery volume; "supracortical perfusion method": PE-10 tubing inserted 3 mm along surface of occipital cortex (pg. 539); ischemia (cerebral).
8. AMT
P4279 Rudd,M.A., Trolliet,M., Hope,S., Scribner,A.W., Daumerie,G., Toolan,G., Cloutier,T., Loscalzo,J. Salt-induced hypertension in Dahl salt-resistant and salt-sensitive rats with NOS II inhibition. Am.J.Physiol.(Heart Circ.Physiol.46) 1999; 277(--):H732-H739. >>> AMT; 1400W; Ethylisourea, S-; Rat; 12 days; Cardiovascular; agents are NOS II inhibitors; AMT is 2-amino-5,6-dihydro-6-methyl-4H-1,3-thiazine; S-ethylisourea is also known as EIT; enzyme inhibitors; nitric oxide synthase inhibitor;.
9. AY9944
P8476 Fliesler,S.J., Vaughan,D.K., Jenewein,E.C., Richards,M.J., Nagel,B.A., Peachey,N.S. Partial rescue of retinal function and sterol steady-state in a rat model of Smith-Lemli-Opitz syndrome. PEDIATRIC RESEARCH 2007; 61(-3-):273-278. >>> AY9944; PBS; SC; Rat (pregnant); 2ML4; 4 weeks; Controls received no treatment; enzyme inhibitor (3 beta-hydroxysterol-d7-reductase); teratology; animal info (female, Sprague-Dawley, GD7).
10. AZD1152
P8504 Wilkinson,R.W., Odedra,R., Heaton,S.P., Wedge,S.R., Keen,N.J., Crafter,C., Foster,J.R., Brady,M.C., Bigley,A., Brown,E., Byth,K.F., Barrass,N.C., Mundt,K.E., Foote,K.M., Heron,N.M., Jung,F.H., Mortlock,A.A., Boyle,F.T., Green,S. AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clinical Cancer Research 2007; 13(-12-):3682-3688. >>> AZD1152; SC; Mice; 2001D; 48 hours; Controls received mp w/ vehicle; dose-response (p. 3684); comparison of IV or IP injections; enzyme inhibitor (aurora B kinase); cancer; xenograft; animal info (male, 8-12 weeks old, Swiss athymic).
P7964 Mortlock,A.A., Foote,K.M., Heron,N.M., Jung,F.H., Pasquet,G., Lohmann,J.J., Warin,N., Renaud,F., Savi,C.D., Roberts,N.J., Johnson,T., Dousson,C.B., Hill,G.B., Perkins,D., Hatter,G., Wilkinson,R.W., Wedge,S.R., Heaton,S.P., Odedra,R., Keen,N.J., Crafter,C., Brown,E., Thompson,K., Brightwell,S., Khatri,L., Brady,M.C., Kearney,S., McKillop,D., Rhead,S., Parry,T., Green,S. Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase. J.Med.Chem. 2007/3/21; Online only(--):-. >>> AZD1152; Tris buffer; SC; Mice; 2001D; 48 hours; Enzyme inhibitor (aurora kinase); cancer; animal info (male, Swiss, nu/nu); PK data; xenograft; tumor cells on dorsal flank.
11. Acetazolamide
P4773 Bagnis,C., Marshansky,V., Breton,S., Brown,D. Remodeling the cellular profile of collecting ducts by chronic carbonic anhydrase inhibition.. American Journal of Physiology-Renal Physiology 2001; 280(--):F437-F448. >>> Acetazolamide; SC;; rat;; 2 weeks;; Functionality of mp verified by aspiration of remaining contents after explant; enzyme inhibitor; Acetazolamide is a carbonic anhydrase inhibitor;.
P1765 Hott,M., Marie,P.J. Carbonic anhydrase activity in fetal rat bone resorbing cells: inhibition by acetazolamide infusion. J.Dev.Physiol. 1989; 12(--):277-281. >>> Acetazolamide; Tris buffer; SC; rat (pregnant); 7 days; teratology.
P0821 Lonnerholm,G., Wistrand,P.J., Barany,E. Carbonic anhydrase isoenzymes in the rat kidney. Effects of chronic acetazolamide treatment. Acta Physiol.Scand. 1986; 126(-1-):51-60. >>> Acetazolamide; Water; SC; rat; 2ML2; 2-9 weeks; mp replaced every other week; controls were sham operated; one control received mp w/ saline; stress/adverse reaction (4 animals died during replacement of mp); drug free interval between pumps; long-term study.
P0675 Kenny,A.D. Role of carbonic anhydrase in bone: partial inhibition of disuse atrophy of bone by parenteral acetazolamide. Calcif.Tissue Int. 1985; 37(-2-):126-133. >>> Acetazolamide sodium; Sodium hydroxide; SC; rat; 1701; 8 days; comparison of twice daily sc injec vs. mp infusion vs. admin. in diet; dose-response data; continuous infusion gave greatest protection against bone loss with smallest doses.
12. Alaproclate
P2654 Brodin,K., Ogren,S.-O., Brodin,E. Clomipramine and clonazepam increase cholecystokinin levels in rat ventral tegmental area and limbic regions. Eur.J.Pharmacol. 1994; 263(--):175-180. >>> Nortriptyline; Amitriptyline; Clomipramine; Alaproclate; Clonazepam; Alcohol; Saline; SC; rat; 2ML2; 14 days; antidepressant; controls received mp w/ vehicle; functionality of mp verified by plasma levels; dose-response (Table 1; pg. 177); enzyme inhibitor; clonazepam is a benzodiazepene; the others are monoamine uptake inhibitors.
13. Aliskiren
Q0844 Gross,O., Girgert,R., Rubel,D., Temme,J., Theissen,S., Mueller,G.A. Renal Protective Effects of Aliskiren Beyond Its Antihypertensive Property in a Mouse Model of Progressive Fibrosis. American Journal of Hypertension 2011; 24(-3-):355-361. >>> Aliskiren; SC; Mice; 2004; 4 weeks; Controls received mp w/ saline; animal info (COL4A3-/-, 6 wks old); stress/adverse reaction: skin necrosis (see pg. 359).
Q0816 Stegbauer,J., Lee,D.H., Seubert,S., Ellrichmann,G., Manzel,A., Kvakan,H., Muller,D.N., Gaupp,S., Rump,L.C., Gold,R., Linker,R.A. Role of the renin-angiotensin system in autoimmune inflammation of the central nervous system. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2009; 106(-35-):14942-14947. >>> Aliskiren; SC; Mice; ; Controls received mp w/ vehicle; animal info (C57BL/6, agtr -/-).
Q0675 van Esch,J.H.M., van Veghel,R., Garrelds,I.M., Leijten,F., Bouhuizen,A.M., Danser,A.H.J. Handle Region Peptide Counteracts the Beneficial Effects of the Renin Inhibitor Aliskiren in Spontaneously Hypertensive Rats. Hypertension 2011; 57(-4-):852-858. >>> Handle region peptide; aliskiren; Saline; SC; Rat; 2ML4; 3 weeks; Controls received mp w/ vehicle; animal info (male, SHRs, 280-300g); peptides; multiple pumps per animal (2).
Q0350 Schmerbach,K., Pfab,T., Zhao,Y., Culman,J., Mueller,S., Villringer,A., Muller,D.N., Hocher,B., Unger,T., Thoene-Reineke,C. Effects of Aliskiren on Stroke in Rats Expressing Human Renin and Angiotensinogen Genes. PLoS One 2010; 5(-11-):U241-U247. >>> Aliskiren; candesartan; SC; Rat; 12 days; Controls received sham operation; animal info (dTGR, 5-6 wks old, 125-135g); MRI; ischemia (MCAO, cerebral).
Q0323 Rakusan,D., Kujal,P., Kramer,H.J., Huskova,Z., Vanourkova,Z., Vernerova,Z., Mrazova,I., Thumova,M., Cervenka,L., Vaneckova,I. Persistent antihypertensive effect of aliskiren is accompanied by reduced proteinuria and normalization of glomerular area in Ren-2 transgenic rats. American Journal of Physiology-Renal Physiology 2010; 299(-4-):F758-F766. >>> Aliskiren; SC; Rat; 2004; 2006; 70 days; Control Hannover Sprague-Dawleys received aliskiren; animal info (male, heterozygous mRen2-27, normotensive control, Hannover Sprague-Dawley); pumps replaced with Model 2006 pumps after 28 days; long-term study.
Q0292 Stucchi,P., Cano,V., Ruiz-Gayo,M., Fernandez-Alfonso,M.S. Aliskiren reduces body-weight gain, adiposity and plasma leptin during diet-induced obesity. British Journal of Pharmacology 2009; 158(-3-):771-778. >>> Aliskiren; SC; Mice; 2004; 6 weeks; Controls received mp w/ saline; animal info (4 wks old, C57BL/6J); long-term study.
Q0255 Ino,J., Kojima,C., Osaka,M., Nitta,K., Yoshida,M. Dynamic Observation of Mechanically-Injured Mouse Femoral Artery Reveals an Antiinflammatory Effect of Renin Inhibitor. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY 2009; 29(-11-):1858-U385. >>> Aliskiren; PBS; Mice; 2001; 2 weeks; Controls received mp w/ vehicle; animal info (C57BL/6, 6-7 wks old; Oriental Yeast); dose-response (fig. 1).
Q0212 Yamamoto,E., Kataoka,K., Dong,Y.F., Nakamura,T., Fukuda,M., Tokutomi,Y., Matsuba,S., Nako,H., Nakagata,N., Kaneko,T., Ogawa,H., Kim-Mitsuyama,S. Aliskiren Enhances the Protective Effects of Valsartan Against Cardiovascular and Renal Injury in Endothelial Nitric Oxide Synthase-Deficient Mice. Hypertension 2009; 54(-3-):633-U360. >>> Valsartan; aliskiren; Mice; 4 weeks; Controls received mp w/ saline; animal info (male, eNOS -/-, wt).
P8773 Lu,H., Rateri,D.L., Feldman,D.L., Charnigo,RJ Jr, Fukamizu,A., Ishida,J.J., Oesterling,E.G., Cassis,L.A., Daugherty,A. Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. Journal of Clinical Investigation 2008; 118(-3-):984-993. >>> Aliskiren; PBS; SC; Mice; 2004; 4, 12 weeks; Controls received mp w/ vehicle; functionality of mp verified by plasma Aliskiren levels; dose-response (fig. 1); long-term study; pumps replaced every 28 days; no stress (see pg. 985); enzyme inhibitor (Renin); cardiovascular; animal info (male, C57BL/6, Ldlr -/-, 6-8 wks old, 30g.).
P7691 Shagdarsuren,E., Wellner,M., Braesen,J.H., Park,J.K., Fiebeler,A., Henke,N., Dechend,R., Gratze,P., Luft,F.C., Muller,D.N. Complement activation in angiotensin II - Induced organ damage. Circulation Research 2005; 97(-7-):716-724. >>> Aliskiren; SC; Rat (transgenic); 3 weeks; Aliskiren plasma levels; animal info (Sprague-Dawley); renin inhibitor.
P7690 Pilz,B., Shagdarsuren,E., Wellner,M., Fiebeler,A., Dechend,R., Gratze,P., Meiners,S., Feldman,D.L., Webb,R.L., Garrelds,I.M., Danser,A.H.J., Luft,F.C., Mueller,D.N. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 2005; 46(-3-):569-576. >>> Aliskiren; SC; Rat (transgenic); 3 weeks; Blood pressure taken; cardiovascular; animal info (male, DTGR, 5.5 weeks old).
14. Allylglycine
Q0949 Johnson,P.L., Truitt,W., Fitz,S.D., Minick,P.E., Dietrich,A., Sanghani,S., Traeskman-Bendz,L., Goddard,A.W., Brundin,L., Shekhar,A. A key role for orexin in panic anxiety. Nature Medicine 2010; 16(-1-):111-U149. >>> Allylglycine, L-; allylglycine, D-; sodium lactate; CSF/CNS (hypothalamus); IV; Rat; 5 days; 48 hours; Controls received mp w/ isotonic saline; animal info (adult, male, Sprague-Dawley, 300-350 g); enzyme inhibitor (glutamic acid decarboxylase); Plastics One cannula used.
P9875 Johnson,P.L., Lowry,C.A., Truitt,W., Shekhar,A. Disruption of GABAergic tone in the dorsomedial hypothalamus attenuates responses in a subset of serotonergic neurons in the dorsal raphe nucleus following lactate-induced panic. JOURNAL OF PSYCHOPHARMACOLOGY 2008; 22(-6-):642-652. >>> Allylglycine, d-; allylglycine, l-; CSF/CNS (dorsal medial hypothalamus); Rat; 1002; ; Animal info (male, Sprague Dawley, 300-350 g.); Plastics One cannula used; cannula placement verified by binocular microscope; brain tissue distribution.
P9282 Johnson,P.L., Truitt,W.A., Fitz,S.D., Lowry,C.A., Shekhar,A. Neural pathways underlying lactate-induced panic. Neuropsychopharmacology 2008; 33(-9-):2093-2107. >>> Allylglycine, L-; allylglycine, D-; CSF/CNS (dorsomedial hypothalamus); Rat; 2002; 5 days; Controls received mp w/ D-AG; stress/adverse reaction : (see pg. 2097) "some tissue damage at the site of implantation was noted to to the 26-gauge cannula."; enzyme inhibitor (glutamic acid decarboxylase); animal info (male, Sprague Dawley, 300-350 g.); behavioral testing (social interaction test).
P8384 Shekhar,A., Johnson,P.L., Sajdyk,T.J., Fitz,S.D., Keim,S.R., Kelley,P.E., Gehlert,D.R., DiMicco,J.A. Angiotensin-II is a putative neurotransmitter in lactate-induced panic-like responses in rats with disruption of GABAergic inhibition in the dorsomedial hypothalamus. Journal of Neuroscience 2006; 26(-36-):9205-9215. >>> Allylglycine, L-; CSF/CNS (Dorsomedial hypothalamus); Rat; 2002; 12 days; Controls received no treatment to contralateral DMH or no treatment at all; funcionality of mp verified by examination of brain sections; enzyme inhibitor (glutamic acid decarboxylase); animal info (male, Sprague-Dawley, 300-350g); cannula tip placement at reactive site confirmed with bicuculline methiodide injection; animal model of panic disorder.
P4987 Shekhar,A., Keim,S.R. LY354740, a potent group II metabotropic glutamate receptor agonist prevents lactate-induced panic-like response in panic-prone rats. Neuropharmacology 2000/4/27; 39(-7-):1139-1146. >>> Allylglycine, L-; CSF/CNS (dorsomedial hypothalamus); rat; 2002; ; functionality of mp verified by glutamic acid decarboxylase activity assay; peptides; GABA synthesis inhibitor; cannula patency verified by dye injection.
P4218 Shekhar,A., Keim,S.R. The circumventricular organs form a potential neural pathway for lactate sensitivity: implications for panic disorder. J.Neurosci. 1997; 17(-24-):9726-9735. >>> Allylglycine, L-; CSF/CNS (hypothalamus); rat; 2002; 14 days; enzyme inhibitor.
P3433 Shekhar,A., Keim,S.R., Simon,J.R., McBride,W.J. Dorsomedial hypothalamic GABA dysfunction produces physiological arousal following sodium lactate infusions. Pharmacol.Biochem.Behav. 1996; 55(-2-):249-256. >>> Allylglycine; CSF, artificial;; CSF/CNS (dorsomedial hypothalamus); CSF/CNS (paraventricular nucleus of hypothalamus); rat; 2002; 14 days; controls received mp w/ aCSF or d-allylglycine; dl-(racemic), l-(active), and d-(inactive) isomers of allylglycine used.
15. Aminoguanidine
R0140 Li,J, Billiar,T.R. Nitric oxide IV. determination of nitric oxide protection and toxicity in liver. Am.J.Physiol. 1999; 276(--):G1069-G1073. >>> L-NMMA; L-NAME; Aminoguanidine; IV (hepatic portal);; rat;; ; nitric oxide synthase inhibitors;.
P7565 Xia,W., Wang,Y., Appleyard,R., Smythe,G.A., Murrell,G.A.C. Spontaneous recovery of injured Achilles tendon in inducible nitric oxide synthase gene knockout mice. INFLAMMATION RESEARCH 2006; 55(-1-):40-45. >>> Aminoguanidine, HCl; IP; Mice; 2001; 7 days; Enzyme inhibitor (no synthase); animal info (8-12 wk. old, male); achilles tendon transection.
P6941 Jung,T.Y., Pashia,M.E., Nishimoto,S.Y., Faddis,B.T., Chole,R.A. A possible role for nitric oxide in osteoclastogenesis associated with cholesteatoma. OTOLOGY&NEUROTOLOGY 2004; 25(-5-):661-668. >>> Aminoguanidine; SC; Mice; 6 days; Controls received mp w/ saline; enzyme inhibitor (NOS II).
P5594 Sinz,E.H., Kochanek,P.M., Dixon,C.E., Clark,R.S.B., Carcillo,J.A., Schiding,J.K., Chen,M., Wisniewski,S.R., Carlos,T.M., Williams,D., DeKosky,S.T., Watkins,S.C., Marion,D., Billiar,T.R. Inducible nitric oxide synthase is an endogenous neuroprotectant after traumatic brain injury in rats and mice. J Clin.Invest 1999; 104(-5-):647-656. >>> Aminoguanidine; Lysine, L-N-iminoethyl-; saline; SC; rat; 5 days; controls received mp with vehicle; enzyme inhibitor (nitric oxide synthase).
P5471 Inuzuka,S., Koga,S., Nishikido,M., Miyata,Y., Kanda,S., Shimokawa,I., Tanaka,M., Saito,Y., Kanetake,H. Donor-specific blood transfusion prolongs cardiac allograft survival in rats by low nitric oxide production and elevated serum levels of prostaglandin E-2. Immunology Letters 2002; 83(-2-):119-124. >>> Aminoguanidine; Saline; IV (jugular); Rat; ; Aminoguanidine is an inhibitor of inducible nitric oxide synthase.
P4424 Worrall,N.K, Chang,K., Suau,G.M, Allison,W.S, Misko,T.P, Sullivan,P.M, Tilton,R.G, Williamson,J.R, Ferguson,Jr.,T.B. Inhibition of inducible nitric oxide synthase prevents myocardial and systemic vascular barrier dysfunction during early cardiac allograft rejection.. Circulation Research 1996/3; 78(--):769-779. >>> Aminoguanidine;; NaCl;; IV (jugular); rat;; 2ML1;; ; controls received mp w/vehicle; functionality of mp verified by plasma levels; cardiovascular; silicon catheter used;.
P4418 Schaffer,M.R., Tantry,U., Thornton,F.J, Barbul,A. Inhibition of nitric oxide synthesis in wounds: pharmacology and effect on accumulation of collagen in wounds in mice.. Eur.J.Surg. 1999; 165(--):262-267. >>> L-NMMA; Aminoguanidine hemisulphate; MITU;; PBS;; IP;; mice;; 10 days;; control received mp w/vehicle; comparison of IP injections vs. mp; wound healing study; MITU is S-methyl isothiouronium, a competitive NO synthase inhibitor..
P4241 Ou,J., Carlos,T.M., Watkins,S.C., Saavedra,J.E., Keefer,L.K., Kim,Y.-M., Harbrecht,B.G., Billiar,T.R. Differential effects of nonselective nitric oxide synthase (NOS) and selective inducible NOS inhibition on hepatic necrosis, apoptosis, ICAM-1 expression, and neutrophil accumulation during endotoxemia. Nitric Oxide: Biology&Chemistry 1997; 1(-5-):404-416. >>> Aminoguanidine; Lysine, L-N6-(1-imino-ethyl)-; V-PYRRO/NO; L-NAME; L-NMA; Saline; IV (jugular); IV (gastric); rat; 2001D; 16 hours; controls received mp w/vehicle; good methods (p. 406); nitric oxide synthase inhibitors; PE10 catheter tubing inserted in gastric vein; some animals implanted with one pump for gastric vein and one for jugular vein; NMA is NG-monomethyl-L-arginine.
P3437 Sorrells,D.L., Friend,C., Koltuksuz,C., Courcoulas,A., Boyle,P., Garrett,M., Watkins,S., Rowe,M.I., Ford,H.R. Inhibition of nitric oxide with aminoguanidine reduces bacterial translocation after endotoxin challenge in vivo. Arch Surg 1996; 131(--):1155-1163. >>> Aminoguanidine; SC; rat; 2ML1; 42 hours; controls received mp w/ saline.
16. Amlexanox
P1677 Sanjar,S., Aoki,S., Boubekeur,K., Burrows,L., Colditz,I., Chapman,I., Morley,J. Inhibition of PAF-induced eosinophil accumulation in pulmonary airways of guinea pigs by anti-asthma drugs. Jpn.J.Pharmacol. 1989; 51(--):167-172. >>> Amlexanox; Azelastine; Cromoglycate; Ibudilast; Oxatomide; Tranilast; Aminophylline; Dexamethasone; Ketotifen; Saline, bacteriostatic; SC; guinea-pig; 2001; 6 days; no comment posted.
17. Amprenavir
P7612 Gupta,A.K., Cerniglia,G.J., Mick,R., McKenna,W.G., Muschel,R.J. HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo. Cancer Research 2005; 65(-18-):8256-8265. >>> Amprenavir; SC; Mice (nude); 1-4, 2-15 days; Controls received mp w/ vehicle; functionality of mp verified by serum drug levels by HPLC; no stress (see pg.826); enzyme inhibitor (HIV protease); cancer (SQ208, head and neck, T24 bladder); animal info (female, Ncr- nu/nu); irradiation.
18. Apocynin
P9135 Wenzel,P., Mollnau,H., Oelze,M., Schulz,E., Wickramanayake,J.M.D., Mueller,J., Schuhmacher,S., Hortmann,M., Baldus,S., Gori,T., Brandes,R.P., Muenzel,T., Daiber,A. First evidence for a crosstalk between mitochondrial and NADPH oxidase-derived reactive oxygen species in nitroglycerin-triggered vascular dysfunction. ANTIOXIDANTS&REDOX SIGNALING 2008; 10(-8-):1435-1447. >>> Nitroglycerin; apocynin; glibenclamide; Ethanol; SC; Rat; 1003D; 1007D; 3, 7 days; Controls received mp w/ vehicle; multiple pumps per animal (2); animal info (male, Wistar, 250 g.).
P8461 Chan,E.C., Datla,S.R., Dilley,R., Hickey,H., Drummond,G.R., Dusting,G.J. Adventitial application of the NADPH oxidase inhibitor apocynin in vivo reduces neointima formation and endothelial dysfunction in rabbits. Cardiovascular Research 2007; 75(-4-):710-718. >>> Apocynin; DMSO; IA (carotid); Rabbit; 2001; ; Controls received mp w/vehicle, or no treatment; enzyme inhibitor (NADPH oxidase); cardiovascular; animal info (male, New Zealand White, 3-4kg); 0.1% DMSO; mp attached to catheter to hollow, nonoclusive silastic collar around common cartoid artery.
P8325 Armando,I., Wang,X.Y., Villar,V.A.M., Jones,J.E., Asico,L.D., Escano,C., Jose,P.A. Reactive oxygen species-dependent hypertension in dopamine D2 receptor-deficient mice. Hypertension 2007; 49(-3-):672-678. >>> Apocynin; spironolactone; Saline; DMSO; SC; Mice; 7, 10 days; Controls received mp w/ vehicle; enzyme inhibitor (NADPH Oxidase); antihypertensive; animal info (C57BL/6J, 6-8 months old); 12.5% DMSO.
P7575 Zhan,G.X., Serrano,F., Fenik,P., Hsu,R., Kong,L.H., Pratico,D., Klann,E., Veasey,S.C. NADPH oxidase mediates hypersomnolence and brain oxidative injury in a murine model of sleep apnea. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE 2005; 172(-7-):921-929. >>> Apocynin; DMSO; SC; Mice; 1002; 8 weeks; Controls received mp w/ vehicle or PBS; long-term study; pumps replaced; enzyme inhibitor (NADPH oxidase); animal info (male, C57BL/6J, 10 wk old).
19. Aprotinin
Q0374 Azurmendi,P.J., Oddo,E.M., Obika,L.F., Corbera,N.L., Martin,R.S., Ibarra,F.R., Arrizurieta,E.E. Gonadectomy Influences Blood Pressure through the Kallikrein-Kinin System. KIDNEY&BLOOD PRESSURE RESEARCH 2009; 32(-5-):342-348. >>> Aprotinin; HOE-140; SC; Rat; 3 days; Animal info (Wistar, male, female, 150 days old).
P5676 Ito,H., Hayashi,I., Izumi,T., Majima,M. Bradykinin inhibits development of myocardial infarction through B-2 receptor signalling by increment of regional blood flow around the ischaemic lesions in rats. British Journal of Pharmacology 2003; 138(-1-):225-233. >>> FR-190997; aprotinin; SBTI; Saline; water; HCl; IV (vena cava, cervical vein); Rat; 2001D; 24 hours; Controls received mp w/ vehicle; cardiovascular; FR-190997 (a nonpeptide mimic of bradykinin beta 2 agonist) was infused into the vena cava; aprotinin infused into the cervical vein; SBTI&aprotinin are plasma kallikrein inhibitors from soybeans.
P4270 Frautschy,S.A., Horn,D.L., Sigel,J.J., Harris-White,M.E., Mendoza,J.J., Yang,F., Saido,T.C., Cole,G.M. Protease inhibitor coinfusion with amyloid beta-protein results in enhanced deposition and toxicity in rat brain. Journal of Neuroscience 1998/10/15; 18(-20-):8311-8321. >>> Amyloid protein, beta; Aprotinin; Leupeptin;; HEPES;; CSF/CNS;; rat; 2004;; 4 weeks; controls received mp w/ vehicle; peptides; ALZET brain infusion kit used; beta-amyloid protein infused alone, or concomitantly with aprotinin or leupeptin; enzyme inhibitors.
P3324 Yosipiv,I.V., El-Dahr,S.S. Developmental regulation of ACE gene expression by endogenous kinins and angiotensin II. Am.J.Physiol.(Renal Fluid Electrolyte Physiol.38) 1995; 269(--):F172-F179. >>> Aprotinin; Hoe 140; Losartan; SC; rat; 5,7 days; controls received mp w/saline.
P3268 Majima,M., Yoshida,O., Mihara,H., Muto,T., Mizogami,S., Kuribayashi,Y., Katorim,M., Oh-ishi,S. High sensitivity to salt in kininogen-deficient brown Norway Katholiek rats. Hypertension 1993; 22(--):705-714. >>> Kininogen, bovine; Hoe 140; Aprotinin; Saline; SC; rat; 2001; 7 days; controls received mp w/saline.
P3035 Morin,N.J., Frau,A., Nonclercq,D., Toubeau,G., Zanen,J., Heuson-Stiennon,J.-A., Bergeron,M.G., Beauchamp,D., Laurent,G. Potentiation of gentamicin nephrotoxicity in the rat by infusion of aprotinin. Exp.Molecular Path. 1994; 60(--):197-213. >>> Aprotinin; IV; rat; 2ML1; 8 days; controls received mp with saline; immunology; toxicology.
P1987 Ivy,G.O. Protease inhibitors as a model for NCL disease, with special emphasis on the infantile and adult forms. Am.J.Med.Genet. 1992; 42(--):555-560. >>> E-64C; Aprotinin; Chloroquine; Leupeptin; CSF/CNS; rat; 2002; 2 weeks; no comment posted.
P1964 Majima,M., Katori,M., Hanazuka,M., Mizogami,S., Nakano,T., Nakao,Y., Mikami,R., Uryu,H., Okamura,R., Mohsin,S.S.J., Oh-ishi,S. Suppression of rat deoxycorticosterone-salt hypertension by kallikrein-kinin system. Hypertension 1991; 17(-6-):806-813. >>> Aprotinin; Saline; SC; rat; 2001; 7 days; no comment posted.
P1673 Pakzad,R. Influence of the trypsin inhibitors aprotinin (Trasylol) and TLCK, administered locally by osmotic minipumps, on the gelatinolytic activity of acrosin and the transport of spermatozoa in the female reproductive tract of rabbits. Z.Mikrosk.-Anat.Forsch. 1989; 103(-6-):957-966. >>> Lysine chloromethyl ketone, N-a-tosyl-L-; Aprotinin; intrauterine; rabbit; 6 days; German with English summary (p. 957); trypsin inhibitors; tissue perfusion (uterus).
20. B-428
P3535 Xing,R.H., Mazar,A., Henkin,J., Rabbani,S.A. Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428. Cancer Res. 1997; 57(--):3585-3593. >>> B-428; Saline; DMSO; BSA; IP; rat; 2ML4; 2ML2; 2 weeks; controls received mp w/ vehicle; enzyme inhibitor (urokinase); cancer; B-428 is an anti-proteolytic agent; pump model listed as 2MN4 is 2ML4.
21. B10715817
P7902 Husen,B., Huhtinen,K., Poutanen,M., Kangas,L., Messinger,J., Thole,H. Evaluation of inhibitors for 17 beta-hydroxysteroid dehydrogenase type 1 in vivo in immunodeficient mice inoculated with MCF-7 cells stably expressing the recombinant human enzyme. MOLECULAR AND CELLULAR ENDOCRINOLOGY 2006; 248(-1-2-):109-113. >>> Estrone; B10720512; B10721325; B10720440; B10720511; B10715817; DMSO; propanediol; SC; Mice (nude); 1002; 4 weeks; 14 days; Controls received mp w/ vehicle; replacement therapy (ovariectomy); dose-response (fig. 5); pumps replaced after 2 weeks; enzyme inhibitor (17 beta-hydroxysteroid dehydrogenase); cancer (breast carcinoma); animal info (female, Crl: NU/NU, 10-11 wk old); 50% DMSO.
22. B10720440
P7902 Husen,B., Huhtinen,K., Poutanen,M., Kangas,L., Messinger,J., Thole,H. Evaluation of inhibitors for 17 beta-hydroxysteroid dehydrogenase type 1 in vivo in immunodeficient mice inoculated with MCF-7 cells stably expressing the recombinant human enzyme. MOLECULAR AND CELLULAR ENDOCRINOLOGY 2006; 248(-1-2-):109-113. >>> Estrone; B10720512; B10721325; B10720440; B10720511; B10715817; DMSO; propanediol; SC; Mice (nude); 1002; 4 weeks; 14 days; Controls received mp w/ vehicle; replacement therapy (ovariectomy); dose-response (fig. 5); pumps replaced after 2 weeks; enzyme inhibitor (17 beta-hydroxysteroid dehydrogenase); cancer (breast carcinoma); animal info (female, Crl: NU/NU, 10-11 wk old); 50% DMSO.
23. B10720511
P7902 Husen,B., Huhtinen,K., Poutanen,M., Kangas,L., Messinger,J., Thole,H. Evaluation of inhibitors for 17 beta-hydroxysteroid dehydrogenase type 1 in vivo in immunodeficient mice inoculated with MCF-7 cells stably expressing the recombinant human enzyme. MOLECULAR AND CELLULAR ENDOCRINOLOGY 2006; 248(-1-2-):109-113. >>> Estrone; B10720512; B10721325; B10720440; B10720511; B10715817; DMSO; propanediol; SC; Mice (nude); 1002; 4 weeks; 14 days; Controls received mp w/ vehicle; replacement therapy (ovariectomy); dose-response (fig. 5); pumps replaced after 2 weeks; enzyme inhibitor (17 beta-hydroxysteroid dehydrogenase); cancer (breast carcinoma); animal info (female, Crl: NU/NU, 10-11 wk old); 50% DMSO.
24. B10720512
P7902 Husen,B., Huhtinen,K., Poutanen,M., Kangas,L., Messinger,J., Thole,H. Evaluation of inhibitors for 17 beta-hydroxysteroid dehydrogenase type 1 in vivo in immunodeficient mice inoculated with MCF-7 cells stably expressing the recombinant human enzyme. MOLECULAR AND CELLULAR ENDOCRINOLOGY 2006; 248(-1-2-):109-113. >>> Estrone; B10720512; B10721325; B10720440; B10720511; B10715817; DMSO; propanediol; SC; Mice (nude); 1002; 4 weeks; 14 days; Controls received mp w/ vehicle; replacement therapy (ovariectomy); dose-response (fig. 5); pumps replaced after 2 weeks; enzyme inhibitor (17 beta-hydroxysteroid dehydrogenase); cancer (breast carcinoma); animal info (female, Crl: NU/NU, 10-11 wk old); 50% DMSO.
25. B10721325
P8140 Husen,B., Huhtinen,K., Saloniemi,T., Messinger,J., Thole,H.H., Poutanen,M. Human hydroxysteroid (17-beta) dehydrogenase 1 expression enhances estrogen sensitivity of MCF-7 breast cancer cell xenografts. Endocrinology 2006; 147(-11-):5333-5339. >>> B10721325; estrone; DMSO; propanediol; SC; Mice (nude); 1002; 2 weeks; Controls received mp w/ vehicle; replacement therapy (ovariectomy); dose-response (p.5335); pumps replaced after 14 days; enzyme inhibitor (hydroxysteroid 17 beta dehydrogenase 1); cancer (breast); animal info (female, BALB/cA Bom-v, Crl: nu/nu, 10-11 wks old); 50%DMSO; endocrinology.
P7902 Husen,B., Huhtinen,K., Poutanen,M., Kangas,L., Messinger,J., Thole,H. Evaluation of inhibitors for 17 beta-hydroxysteroid dehydrogenase type 1 in vivo in immunodeficient mice inoculated with MCF-7 cells stably expressing the recombinant human enzyme. MOLECULAR AND CELLULAR ENDOCRINOLOGY 2006; 248(-1-2-):109-113. >>> Estrone; B10720512; B10721325; B10720440; B10720511; B10715817; DMSO; propanediol; SC; Mice (nude); 1002; 4 weeks; 14 days; Controls received mp w/ vehicle; replacement therapy (ovariectomy); dose-response (fig. 5); pumps replaced after 2 weeks; enzyme inhibitor (17 beta-hydroxysteroid dehydrogenase); cancer (breast carcinoma); animal info (female, Crl: NU/NU, 10-11 wk old); 50% DMSO.
26. BAPN
P9980 Kanematsu,Y., Kanematsu,M., Kurihara,C., Tsou,T.L., Nuki,Y., Liang,E.I., Makino,H., Hashimoto,T. Pharmacologically Induced Thoracic and Abdominal Aortic Aneurysms in Mice. Hypertension 2010; 55(-5-):1267-U309. >>> BAPN; angiotensin II; SC; Mice; 2 weeks; Peptides; enzyme inhibitor (lysyl oxidase); animal info (C57BL/6J, 9 wks old).
27. BE16627B
R0225 Watson,S.A., Tierney,G. Matrix Metalloproteinase Inhibitors. BioDrugs 1998; 9(-4-):325-335. >>> BE16627B; Mice; 3 weeks; Cancer (fibrosarcoma; colon); ALZET pumps mentioned on p. 332.
P4811 Kiyama,T., Onda,M., Tokunaga,A., Efron,D.T., Barbul,A. Effect of matrix metalloproteinase inhibition on colonic anastomotic healing in rats.. JOURNAL OF GASTROINTESTINAL SURGERY 2001; 5(--):303-311. >>> BE16627B; DMSO; ethylene glycol; SC; Rat; 1003D; 3 days; Controls received mp w/ vehicle; enzyme inhibitor; vehicle mix was 50:50 ratio; BE16627B is a matrix metalloproteinase inhibitor;.
P2788 Naito,K., Kanbayashi,N., Nakajima,S., Murai,T., Arakawa,K., Nishimura,S., Okuyama,A. Inhibition of growth of human tumor cells in nude mice by a metalloproteinase inhibitor. Int.J.Cancer 1994; 58(--):730-735. >>> BE16627B; Doxorubicin HCl; DMSO; Ethylene glycol; SC; mice (nude); 2001; 2002; 3 weeks, 18 days; controls received vehicle or no treatment; pumps replaced; stress/ adverse reaction: skin inflammation and necrosis around delivery site in mice treated with Adriamycin (pg. 733); BE166278B animals were fine; stability verified for 18 days by assay; cancer; enzyme inhibitor; BE16627B is a metalloproteinase inhibitor; 2002 replaced w/ 2001 after 20 days; adriamycin is doxorubicin HCl.
28. BMS-191563
P4759 Muthalif,M.M, Benter,I.F., Khandekar,Z, Gaber,L, Estes,A, Malik,S, Parmentier,J.-H, Manne,V, Malik,K.U. Contribution of Ras GPase/MAP kinase and cytochrome P450 metabolites to deoxycorticosterone-salt-induced hypertension.. Hypertension 2000; 35(-part 2-):457-463. >>> FPT III; BMS-191563; PD-98059; IP; Rat; 2ML1; 5 days; Controls received mp w/ vehicle; replacement therapy (uninephrectomy); cardiovascular; antihypertensive; enzyme inhibitor; FPT III and BMS-191563 are Ras farnesyl transferase enzyme inhibitors; PD-98059 is an MEK enzyme inhibitor; MEK is MAP (mean arterial pressure) kinase kinase inhibitor.
P4758 Muthalif,M.M, Karzoun,N.A, Gaber,L, Khandekar,Z, Benter,I.F., Saeed,A.E, Parmentier,J.-H, Estes,A, Malik,K.U. Contribution of Ras GTPase/Mitogen-activated protein kinase and cytochrome P450 metabolites.. Hypertension 2000; 36(--):604-609. >>> Angiotensin II; FPT III; BMS-191563;; Acetic acid; IP;; rat;; 6 days;; Controls received mp w/ vehicle; dose-response (graph p. 605); antihypertensive; enzyme inhibitor; FPT III and BMS - 191563 are Ras farnesyl transferase inhibitors infused along with Angiotensin II; Acetic acid vehicle was 0.001 N..
29. BMS-561392
P9529 Kim,M.L., Zhang,B. Effects of TACE inhibition on Amyloid-beta production and APP processing in vitro and in vivo. J Neurosci 2008; 28(-46-):12052-12061. >>> BMS-561392; Citric acid; CSF/CNS (hippocampus); Mice (transgenic); 2004; 14 days; Controls received mp w/ vehicle; enzyme inhibitor (TACE); animal info (6-8 months, wt); "direct infusion was necessary since BMS-561392 does not penetrate the blood brain barrier"; neurodegenerative (Alzheimer's Disease).
P9385 Kim,M.L., Zhang,B., Mills,I.P., Milla,M.E., Brunden,K.R., Lee,V.M.Y. Effects of TNF alpha-Converting Enzyme Inhibition on Amyloid-beta Production and APP Processing In Vitro and In Vivo. Journal of Neuroscience 2008; 28(-46-):12052-12061. >>> BMS-561392; TAPI-I; Citric acid; CSF/CNS; Mice (transgenic); 2004; 14 days; Controls received mp w/ vehicle; enzyme inhibitor (TNF-alpha converting enzyme (TACE)); animal info (Tg2576, wt, C57BL6/SJ6, 6-8 months old); neurodegenerative (Alzheimer's Disease); "Direct infusion was necessary because BMS-561392 does not penetrate the blood-brain barrier" (p. 12056); TAPI-I also known as [(N-R-12- hydroxyaminocarbonyl)methyl]-methylpentanoyl-L-napthylanyl-L-alanine 2 aminoethyl amide-I.
30. BVT.2733
P5736 Alberts,P., Engblom,L., Edling,N., Forsgren,M., Klingstrom,G., Larsson,C., Ronquist-Nii,Y., Ohman,B., Abrahmsen,L. Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia 2002; 45(-11-):1528-1532. >>> BVT.2733; Cyclodextrin, 2-beta-hydroxypropl- (molecusol); SC; Mice; 2001; 7 days; Functionality of mp verified by BVT.2733 plasma levels, p.1530; BVT.2733 is an enzyme inhibitor (11 beta-hydroxysteroid dehdrogenase type I).
31. Bafilomycin A1
P3388 Sundquist,K., Larson,E.K., Marks Jr,S.C. Altering tooth eruption by blocking bone resorption - the local delivery of bafilomycin A1. Connective Tissue Res. 1995; 32(-1-4-):159-163. >>> Bafilomycin A1; DMSO; Saline; bone; dog; 2002; no duration posted; contralateral controls received mp w/vehicle; tissue perfusion (bone crypts of mandibular fourth molar).
P3359 Marks Jr,S.C., Sundquist,K.T. Bafilomycin A1 in bone resorption and tooth eruption in dogs. Eur.J.Oral Sci. 1995; 103(--):231-235. >>> Bafilomycin A1; DMSO; Saline; bone; dog; 1, 3, 4 weeks; tissue perfusion (bone crypts of mandibular fourth molar); pumps replaced at 2 weeks.
P2976 Sundquist,K.T., Marks Jr,S.C. Bafilomycin A1 inhibits bone resorption and tooth eruption in vivo. J.Bone and Min.Res. 1994; 9(-10-):1575-1582. >>> Bafilomycin A1; DMSO; Saline; bone; dog; no duration posted; controls received mp w/ vehicle or no treatment; tissue perfusion (bone crypts of mandibular fourth molar); stability verified in vitro for 2 weeks at 37 degrees C; enzyme inhibitor; dogs given prophylactic im penicillin for first postoperative week; local infusion used because systemic delivery may cause lethal side effects; bafilomycin A1 is a specific inhibitor of vacuolar H+-ATPases.
32. Benzylguanine, 06-
P7702 Guarnieri,M., Biser-Rohrbaugh,A., Tyler,B.M., Gabikian,P., Bunton,T.E., Wu,Q.Z., Weingart,J., Carson Sr,B.S. Toxicity of intracranial and intraperitoneal O6-benzyl guanine in combination with BCNU delivered locally in a mouse model. Cancer Chemother.Pharmacol. 2002/11; 50(-5-):392-396. >>> Benzylguanine, 06-; Propylene glycol; ethanol; IP; CSF/CNS (parietal lobe); Mice; 2001; 7 days; Controls received mp w/ vehicle; functionality of mp verified by residual volume; dose-response (table 2); comparison of IP injection vs. mp; stability verified by 14 days at 37 C, UV spectra analysis; good methods (p. 393); cancer (glioma brain); toxicology; animal info (female, BALB/C, 6-12 weeks old); 10% ETOH.
P4297 Kreklau,E.L., Kurpad,C., Williams,D.A., Erickson,L.C. Prolonged inhibition of O6-methylguanine DNA methyltransferase in human tumor cells by O6-benzylguanine in vitro and in vivo. Journal of Pharmacology and Experimental Therapeutics 1999; 291(-3-):1269-1275. >>> Benzylguanine, 06-;; PEG 400; PBS;; SC;; mice (NOD/SCID);; 1003D;; 24 hours;; controls received mp w/ vehicle; cancer; "The four groups were comprised of control animals and those implanted s.c. w/ one, two, three Alzet pumps... per mouse" (p. 1270); enzyme inhibitor;.
P4297 Kreklau,E.L., Kurpad,C., Williams,D.A., Erickson,L.C. Prolonged inhibition of O6-methylguanine DNA methyltransferase in human tumor cells by O6-benzylguanine in vitro and in vivo. Journal of Pharmacology and Experimental Therapeutics 1999; 291(-3-):1269-1275. >>> Benzylguanine, 06-;; PEG 400; PBS;; SC;; mice (NOD/SCID);; 1003D;; 24 hours;; controls received mp w/ vehicle; cancer; "The four groups were comprised of control animals and those implanted s.c. w/ one, two, three Alzet pumps... per mouse" (p. 1270); enzyme inhibitor;.
33. Bromphenacyl Bromide, 4-
P2767 Nakamura,S. Effects of phospholipase a2 inhibitors on the antidepressant-induced axonal regeneration of noradrengeric locus coeruleus neurons. Microscopy Res.and Tech. 1994; 29(--):204-210. >>> Desipramine HCl; Mepacrine HCl; Bromphenacyl bromide, 4-; Saline; DMSO; CSF/CNS (cortex); rat; 2002; >2 weeks; antidepressant; mepacrine and 4-bromphenacyl bromide are phospholipase a2 inhibitors; 2 pumps implanted: one delivered just desipramine to one hemisphere, while the other infused desipramine and pla2 inhibitors to the other hemisphere.
34. Buthionine Sulfoximine
P8236 Lecanu,L., Greeson,J., Papadopoulos,V. Beta-amyloid and oxidative stress jointly induce neuronal death, amyloid deposits, gliosis, and memory impairment in the rat brain. Pharmacology 2006; 76(-1-):19-33. >>> Amyloid protein, beta 42; ferrous sulfate; buthionine sulfoximine; CSF, artificial; water, distilled; CSF/CNS; Rat; 2ML4; 4 weeks; Controls received mp w/ vehicle; stability verified by 14 days in mp at 37 C; animal info (male, Long-Evans, 3-4 month old, 300-325 grams); neurodegenerative (Alzheimer's disease).
P4244 Hu,B.H., McFadden,S.L., Salvi,R.J., Henderson,D. Intracochlear infusion of buthionine sulfoximine potentiates carboplatin ototoxicity in the chinchilla. Hear.Res. 1999; 128(--):125-134. >>> Sulfoximine, L,S-buthionine; Hank's solution; ear (cochlea); Chinchilla; 2ML4; 14 days; good methods (p. 127); "BSO infusion itself caused no long-term functional or morphological changes." (p. 125); tissue perfusion (cochlea).
P3757 Somfai-Relle,S., Suzukake,K., Vistica,B.P., Vistica,D.T. Reduction in cellular glutathione by buthionine sulfoximine and sensitization of murine tumor cells resistant to L-phenylalanine mustard. Biochem.Pharmacol. 1984; 33(-3-):485-490. >>> Sulfoximine, DL-buthionine-S,R-; PBS; IP; mice; 2001; no duration posted; comparison of injections vs. mp; sulfoximine is an enzyme inhibitor; cancer; immunology.
P2913 Malaker,K., Hurwitz,S.J., Bump,E.A., Griffith,O.W., Lai,L.L., Riese,N., Coleman,C.N. Pharmacodynamics of prolonged treatment with L,S-buthionine sulfoximine. Int.J.Radiat.Oncol.Biol.Phys. 1994; 29(-2-):407-412. >>> Sulfoximine, L,S-buthionine; SC; mice (nude); no duration posted; agent is a glutathione depletor; cancer.
35. CGP-29287
P1622 Wood,J.M., Jobber,R.A., Baum,H.-P., de Gasparo,M., Nussberger,J. Biochemical effects of prolonged renin inhibition in marmosets. J.Hypertens. 1989; 7(-8-):615-618. >>> CGP-29287; Methylcellulose; Saline; IP; monkey (marmoset); 2002; 7 days; dose-response; CGP-29287 is a renin inhibitor.
P1292 Wood,J.M., Baum,H.-P., Jobber,R.A., Neisius,D. Sustained reduction in blood pressure during chronic administration of a renin inhibitor to normotensive marmosets. J.Cardiovasc.Pharmacol. 1987; 10(-7-):S96-S98. >>> CGP-29287; IP; monkey (marmoset); 2002; 14 days; dose-response; only high dose affected bp; mp removed after delivery.
P1114 Wood,J.M., Jobber,R.A., Baum,H.-P., Hofbauer,K.G. Comparison of chronic inhibition of renin and converting enzyme in the marmoset. Clin.and Exper.-Theory and Practice 1987; A9(-2/3-):337-343. >>> CGS-14831; CGP-29287; Saline; IP; monkey; 2002; 7 days; CGS-14831 is a convert. enzyme inhibitor; CGP-29287 is a renin inhibitor; controls received 3 mps w/saline; 2 experiments; limited solubility of CGP-29287 necessitated use of 3 mp's for infusion.
36. CGP-40215A
P3645 Bacchi,C.J., Brun,R., Croft,S.L., Alicea,K., Buhler,Y. In vivo trypanocidal activities of new S-adenosylmethionine decarboxylase inhibitors. Antimicrob.Agents Chemother. 1996; 40(-6-):1448-1453. >>> CGP-40215A; Water, distilled; SC; mice; 2001; 2002; no duration posted; comparison of daily IP injections vs. mp; CGP 40215A is an antiparasitic and a bicyclic analog of methylglyoxal bis (guanylhydrazone) (MGBG); agent inhibits polyamine synthesis enzyme.
37. CGS-14831
P1114 Wood,J.M., Jobber,R.A., Baum,H.-P., Hofbauer,K.G. Comparison of chronic inhibition of renin and converting enzyme in the marmoset. Clin.and Exper.-Theory and Practice 1987; A9(-2/3-):337-343. >>> CGS-14831; CGP-29287; Saline; IP; monkey; 2002; 7 days; CGS-14831 is a convert. enzyme inhibitor; CGP-29287 is a renin inhibitor; controls received 3 mps w/saline; 2 experiments; limited solubility of CGP-29287 necessitated use of 3 mp's for infusion.
38. CGS-15855A
P1291 Altar,C.A., Berner,B., Beall,P., Carlsen,S.F., Boyar,W.C. Dopamine release and metabolism after chronic delivery of selective or nonselective dopamine autoreceptor agonists. Mol.Pharmacol. 1988; 33(--):690-695. >>> CGS-15855A; Apomorphine; Dopamine, antagonists; Ascorbic acid; Saline; SC; rat; 2ML2; 2, 14 days; comparison of ip injections vs. mp infusion; functionality of mp verified by serum, brain levels; stability verified at 14 days by HPLC.
39. CGS-22652
P2678 Boussairi,E.H., Sacquet,J., Benzoni,D., Sassard,J. Blood pressure effects of thromboxane A2 blockade in spontaneously hypertensive rats. Clin.Exp.Pharmacol.Physiol. 1993; 20(--):679-687. >>> CGS-22652; DMSO; Sodium hydroxide; SC; rat; 2002; 2 weeks; controls received mp w/ vehicle; comparison of oral administration, sc injections and mp; stability verified by preliminary study; CGS 22652 is a thromboxane A2 synthase inhibitor and TxA2 prostaglandin H2 receptor.
40. CGS-26303
P7315 Emoto,N., Raharjo,S.B., Isaka,D., Masuda,S., Adiarto,S., Jeng,A.Y., Yokoyama,M. Dual ECE/NEP inhibition on cardiac and neurohumoral function during the transition from hypertrophy to heart failure in rats. Hypertension 2005; 45(-6-):1145-1152. >>> CGS-24592; CGS-26303; temocapril; NaHCO3; SC; Rat; 6 weeks; Controls received mp w/ vehicle; enzyme inhibitor (ACE, Neutral endopeptidase, ECE); antihypertensive.
P5255 Tikkanen,I., Tikkanen,T., Cao,Z., Allen,T.J., Davis,B.J., Lassila,M., Casley,D., Johnston,C.I., Burrell,L.M., Cooper,M.E. Combined inhibition of neutral endopeptidase with angiotensin converting enzyme or endothelin converting enzyme in experimental diabetes. J Hypertens 2002/4; 20(-4-):707-714. >>> CGS-26303; Rat; 2ML4; 4 weeks; Controls received mp w/ vehicle; functionality verified by CGS-26303 plasma levels; antihypertensive; enzyme inhibitor; CGS-26303 is a combined neutral endopeptidase inhibitor and endothelin-converting enzyme inhibitor.
P5127 Pham,D., Jeng,A.Y., Plante,S., Escher,E., Battistini,B. Inhibition of endothelin-converting enzyme for protection against neointimal proliferation following balloon angioplasty of the rat carotid artery. Canadian Journal of Physiology and Pharmacology 2002; 80(--):450-457. >>> CGS-26303; CGS-24592; CGS-26393; Sodium hydroxide; Sodium carbonate; IP; IV (jugular); rat; 2ML2; 14 days; controls received mp w/ vehicle; functionality of mp verified by plasma drug levels; dose-response (p. 454); cardiovascular; enzyme inhibitors (neutral endopeptidase, endothelin-converting enzyme).
P4698 Feldman,D.L, Mogelesky,T.C, Chou,M., Jeng,A.Y. Attenuation of puromycin aminonucleoside-induced glomerular lesions in rats by CGS 26303, a dual neutral endopeptidase/endothelin-converting enzyme inhibitor.. Journal of Cardiovascular Pharmacology 2000; 36(-Suppl. 1-):S342-S345. >>> CGS-26303; Sodium bicarbonate; SC; Rat; 4 weeks; Controls received mp w/ vehicle; CGS 26303 is an endothelin-converting enzyme inhibitor (ECE).
P3435 Caner,H.H., Kwan,A.L., Arthur,A., Jeng,A.Y., Lappe,R.W., Kassell,N.F., Lee,K.S. Systemic administration of an inhibitor of endothelin-converting enzyme for attenuation of cerebral vasospasm following experimental subarachnoid hemorrhage. J.Neurosurg. 1996; 85(--):917-922. >>> CGS-26303; Sodium bicarbonate buffer; IP; Rabbit; 2ML1; no duration posted; controls received mp w/ vehicle; CGS 26303 is an endothelin-converting enzyme inhibitor; 4 pumps implanted in each animal.
41. CGS 27023A
P4285 Prescott,M.F., Sawyer,W.K., Von Linden-Reed,J., Jeune,M., Chou,M., Caplan,S.L., Jeng,A.Y. Effect of matrix metalloproteinase inhibition on progression of atherosclerosis and aneurysm in LDL receptor-deficient mice overexpressing MMP-3, MMP-12, and MMP-13 and on restenosis in rats after balloon injury. Annals of the New York Academy of Sciences 1999/6/30; 878(--):179-190. >>> CGS 27023A;; DMSO; SC;; rat;; 2ML2; 2ML4;; 9-47 days; cardiovascular; enzyme Inhibitor; CGS 27023A is an orally active hydroxamic acid matrix metalloproteinase inhibitor.
42. CP-690550
P9023 Milici,A.J., Kudlacz,E.M., Audoly,L., Zwillich,S., Changelian,P. Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis. ARTHRITIS RESEARCH&THERAPY 2008; 10(-1-):U175-U183. >>> CP-690550; PEG 300; SC; Rat; mice; 2004; 2ML2; 2 weeks; 28 days; Controls received mp w/ vehicle or no pump; dose-response (fig. 1); enzyme inhibitor (JAK3, janus kinase 3); animal info (male, DBA/J1, male, Lewis); "it was necessary to administer CP-690550 via osmotic pumps due to the poor (PK) properties of this compound in rodents.".
P8819 Kudlacz,E., Conklyn,M., Andresen,C., Whitney-Pickett,C., Changelian,P. The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia. European Journal of Pharmacology 2008; 582(-1-3-):154-161. >>> CP-690550; Water, distilled; ethanol; SC; Mice; 2001; 2002; 3, 14 days; Controls received mp w/ vehicle; functionality of mp verified by plasma agent levels; dose-response (Fig. 6); enzyme inhibitor (Janus Kinase 3 (JAK-3)); animal info (female, Balb/c wt, IL-4 -/-, 4-6 wks old); 5% EtOH used.
P6672 Kudlacz,E., Perry,B., Sawyer,P., Conklyn,M., McCurdy,S., Brissette,W., Flanagan,M., Changelian,P. The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models. AMERICAN JOURNAL OF TRANSPLANTATION 2004; 4(-1-):51-57. >>> CP-690550; PEG 300; ethanol; water; SC; Mice; 2002; 2004; 14, 21, 28 days; Controls received mp w/ vehicle; agent is a small molecule inhibitor of JAK-3; enzyme inhibitor (Jak3 tyrosine kinase inhibitor); Immunosuppressant.
43. Calphostin C
Q0669 Martin,F., Laorden,M.L., Milanes,M.V. Morphine withdrawal regulates phosphorylation of cAMP response element binding protein (CREB) through PKC in the nucleus tractus solitarius-A(2) catecholaminergic neurons. Journal of Neurochemistry 2009; 110(-5-):1422-1432. >>> Calphostin C; SC; Rat; 2001; 7 days; Controls received mp w/ saline; animal info (male, Sprague-Dawley, 220-240 g); enzyme inhibitor (PKC, protein kinase C).
Q0460 Almela,P., Atucha,N.M., Milanes,M.V., Laorden,M.L. Cross-Talk between Protein Kinase A and Mitogen-Activated Protein Kinases Signalling in the Adaptive Changes Observed during Morphine Withdrawal in the Heart. Journal of Pharmacology and Experimental Therapeutics 2009; 330(-3-):771-782. >>> HA-1004; calphostin C; Water; DMSO; SC; Rat; 2001; 7 days; Animal info (male, Sprague Dawley, 220-240 g); dependence; enzyme inhibitor (PKA, PKC); 0.6% DMSO used.
P9085 Almela,P., Milanes,M.V., Laorden,M.L. The PKs PKA and ERK 1/2 are involved in phosphorylation of TH at Serine 40 and 31 during morphine withdrawal in rat hearts. British Journal of Pharmacology 2008; 155(-1-):73-83. >>> HA-1004; calphostin C; DMSO; water; SC; Rat; 2001; 7 days; Controls received mp w/ vehicle; animal info (male, Sprague Dawley, 220-240 g.); enzyme inhibitor (protein kinase C, protein kinase A); pumps were primed for 5 hours prior to implantation.
P7899 Almela,P., Cerezo,M., Milanes,M.V., Laorden,M.L. Role of PKC in regulation of Fos and TH expression after naloxone induced morphine withdrawal in the heart. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY 2006; 372(-5-):374-382. >>> Calphostin C; Water, Milli-Q; DMSO; SC; Rat; 2001; 7 days; Controls received mp w/ vehicle; no stress (see pg. 378); enzyme inhibitor (protein kinase c); animal info (male, Sprague-Dawley, 220-240g.); mp primed 5 hours in 37 celsius saline; 0.06% DMSO; "Animals infused with calphostin c showed no untoward effects: their weights were equivalent to those of vehicle injected groups, and the rats showed no behavioural changes." (pg.378).
P7499 Benavides,M., Laorden,M.L., Marin,M.T., Milanes,M.V. Role of PKC-alpha, gamma isoforms in regulation of c-Fos and TH expression after naloxone-induced morphine withdrawal in the hypothalamic PVN and medulla oblongata catecholaminergic cell groups. Journal of Neurochemistry 2005; 95(-5-):1249-1258. >>> Calphostin C; DMSO; water; SC; Rat; 2001; 7 days; Animal info (male, Sprague-Dawley, 220-240 g); enzyme inhibitor (protein kinase C); 0.06% DMSO used.
P5457 Cerezo,M., Laorden,A.L., Milanes,A.V. Inhibition of protein kinase C but not protein kinase A attenuates morphine withdrawal excitation of rat hypothalamus-pituitary-adrenal axis. European Journal of Pharmacology 2002; 452(-1-):57-66. >>> HA-1004; calphostin C; Water, sterile; DMSO; SC; Rat; 2001; 7 days; Controls received mp w/ vehicle; enzyme inhibitor (protein kinase A, protein kinase C).
P4570 Chen,C-L, Chen,H., Zhu,D-M, Uckun,F.M. Quantitative high-performance liquid chromatography-based detection method for calphostin C, a naturally occurring perylenequinone with potent antileukemic activity.. Journal of Chromatography B 1999; 724(--):157-162. >>> Calphostin C;; DMSO; Tween 80; PBS;; mice;; 1007D;; 7 days;; functionality of mp verified by in vitro incubation and HPLC analysis; cancer; enzyme inhibitor (protein kinase C);.
P2315 Hermenegildo,C., Felipo,V., Minana,M.-D., Romero,F.J., Grisolia,S. Sustained recovery of Na+-K+-ATPase activity in sciatic nerve of diabetic mice by administration of H7 or calphostin C, inhibitors of PKC. Diabetes 1993; 42(--):257-262. >>> H7; Calphostin C; DMSO; Water; SC; mice; 3,7,10 or 14 days; controls were nondiabetic mice and untreated diabetic mice; comparison of bolus ip injections vs. mp; no stress (see pg. 259,260); enzyme inhibitor; calphostin C and H7 are PKC inhibitors; "treatment [w/ mp] did not produce any untoward effect nor affect the blood glucose levels." (pg. 260); H7 is unstable after 4 hours; Calphostin C is stable for 2 weeks.
44. Candoxatrilat
P2519 Zhao,L., Hughes,J.M.B., Winter,R.J.D. Reversal of pulmonary vascular remodelling following hypoxic exposure: no effect of infusion of atrial natriuretic factor and neutral endopeptidase inhibitor. Cardiovasc.Res. 1994; 28(--):519-523. >>> Atrial natriuretic factor; Candoxatrilat; Saline; IV (jugular); rat; 7,14 days; enzyme inhibitor; candoxatrilat also called UK 73,967 and neutral endopeptidase 24.11 inhibitor; peptides.
45. Captopril
Q0569 de Kloet,A.D., Krause,E.G., Kim,D.H., Sakai,R.R., Seeley,R.J., Woods,S.C. The Effect of Angiotensin-Converting Enzyme Inhibition Using Captopril on Energy Balance and Glucose Homeostasis. Endocrinology 2009; 150(-9-):4114-4123. >>> Captopril; Saline; SC; Rat; 2ML2; 14 days; Controls received mp w/ vehicle; animal info (Adult, male, Long Evans, 250-300 g); enzyme inhibitor (ACE); wound clips used; Research Diets.
Q0008 Cho,Y.K., Eom,G.H., Kee,H.J., Kim,H.S., Choi,W.Y., Nam,K.I., Ma,J.S., Kook,H. Sodium Valproate, a Histone Deacetylase Inhibitor, but Not Captopril, Prevents Right Ventricular Hypertrophy in Rats. CIRCULATION JOURNAL 2010; 74(-4-):760-770. >>> Captopril; DMSO; SC; Rat; 14 days; Cardiovascular; enzyme inhibitor (ACE); animal info (male, Sprague-Dawley, 3 weeks old); functionality of mp verified by plasma ang I and ang II levels; right ventricular hypertrophy by pulmonary artery banding.
P8463 Shen,X.Z., Li,P., Weiss,D., Fuchs,S., Xiao,H.D., Adams,J.A., Williams,I.R., Capecchi,M.R., Taylor,W.R., Bernstein,K.E. Mice with enhanced macrophage angiotensin-converting enzyme are resistant to melanoma. American Journal of Pathology 2007; 170(-6-):2122-2134. >>> Captopril; losartan; SC; Mice; 2 weeks; Functionality of mp verified by systolic blood pressure; enzyme inhibitor (ACE); cancer (melanoma); immunology; animal info (C56BL/6, wt, ACE 10/10, 8wks old).
P8199 DiNicolantonio,R., Hutchinson,J.S., Mendelsohn,F.A.O. Exaggerated salt appetite of spontaneously hypertensive rats is decreased by central angiotensin-converting enzyme blockade. Nature 1982; 298(-5877-):846-848. >>> Captopril; CSF, artificial; CSF/CNS; Rat; 7 days; Controls received mp w/ vehicle; dose-response (p. 847); no stress (see pg. 846); animal info (male, Wistar Kyoto, Okamoto SHR, 320-410 grams).
P6655 Li,X., Simard,J.M. Increase in Cx45 gap junction channels in cerebral smooth muscle cells from SHR. Hypertension 2002; 40(-6-):940-946. >>> Angiotensin II; L-NAME; captopril; SC; Rat; 4 weeks; Enzyme inhibitor (nitric oxide synthase); cardiovascular; antihypertensive.
P6240 Martinez,L.A., Villalobos-Molina,R.V. Early and chronic captopril or losartan therapy reduces infarct size and avoids congestive heart failure after myocardial infarction in rats. Archives of Medical Research 2003; 34(-5-):357-361. >>> Captopril; losartan; SC; Rat; 2ML4; 4 weeks; Cardiovascular; enzyme inhibitor (ACE); losartan is an AT1 receptor antagonist.
P4053 Lai,F.M., Tanikella,T., Herzlinger,H., Thibault,L., Cervoni,P. Effects of continuous angiotensin I-converting enzyme blockade on blood pressure, sympathetic activity and renin-angiotensin system in stroke-prone spontaneously hypertensive rats. Life Sci. 1981; 28(--):1309-1316. >>> Captopril; Saline; IP; rat; 14 days; controls received mp w/saline; pumps replaced after 8 days; ACE inhibitor; antihypertensive; cadiovascular.
P3647 Laycock,S.K., Kane,K.A., McMurray,J., Parratt,J.R. Captopril and norepinephrine-induced hypertrophy and haemodynamics in rats. J.Cardiovasc.Pharmacol. 1996; 27(--):667-672. >>> Norepinephrine; Captopril; Ascorbic acid; Saline; SC; rat; 2ML4; 28 days; controls received vehicle infusion; antihypertensive; multiple pumps per animal (1 or 2).
P3615 Kohzuki,M., Yasujima,M., Liu,P.F., Obara,K., Kanazawa,M., Yoshida,K., Saito,T., Sato,T., Abe,K. Cardiovascular and renal protective effects of losartan in spontaneously hypertensive rats with diabetes mellitus. Clin.Exp.Pharmacol.Physiol. 1995; SUPPL(-1-):S366-S367. >>> Losartan; Captopril; IP; rat; 2ML4; 8 weeks; controls received no treatment; antihypertensive; cardiovascular; agents given singly and together.
P3366 Fitts,D.A. Angiotensin and captopril increase alcohol intake. Pharmacol.Biochem.Behav. 1993; 45(--):35-43. >>> Angiotensin II; Captopril; Saline, sterile; SC; CSF/CNS; 2001; 2002; 2ML2; 7, 12 days; controls received mp w/saline; peptides; antihypertensive; captopril rats allowed 1 week recovery after ventricular cannula placement.
P3299 Morrell,N.W., Morris,K.G., Stenmark,K.R. Role of angiotensin-converting enzyme and angiotensin II in development of hypoxic pulmonary hypertension. Am.J.Physiol.(Heart Circ.Physiol.38) 1995; 269(--):H1186-H1194. >>> Captopril; PD123319; CP-0597; Losartan; PBS; IP; rat; 2ML2; 14 days; controls received mp w/PBS; antihypertensive; CP-0597 is a B2-receptor antagonist.
P3146 Tokita,Y., Oda,H., Franco-Saenz,R., Mulrow,P.J. Role of the tissue renin-angiotensin system in the action of angiotensin-converting enzyme inhibitors. P.S.E.B.M. 1995; 208(--):391-396. >>> Captopril; Perindopril; Saline; IP; rat; 6 days; controls received mp with saline; antihypertensive.
P2931 Fitts,D.A. Forebrain circumventricular organs mediate captopril-enhanced ethanol intake in rats. Pharmacol.Biochem.Behav. 1993; 45(--):811-816. >>> Captopril; Saline, sterile; SC; rat; 2ML2; 14 days; controls received sham surgery; enzyme inhibitor; betadine applied topically and .2 ml gentamicin given IM to control post-surgical infection; antihypertensive.
P2790 Kohzuki,M., Yasujima,M., Kanazawa,M., Yoshida,K., Fu,L.P., Obara,K., Saito,T., Abe,K. Antihypertensive and renal-protective effects of losartan in streptozotocin diabetic rats. J.Hypertens. 1995; 13(--):97-103. >>> Losartan; Captopril; IP; rat; 2ML4; 8 weeks; controls received mp w/ vehicle; long-term study, pumps replaced; agents infused separately and concomitantly; antihypertensive.
P2704 Crofton,J.T., Ota,M., Share,L. Role of vasopressin, the renin-angiotensin system and sex in Dahl salt-sensitive hypertension. J.Hypertens. 1993; 11(-10-):1031-1038. >>> Captopril; Saline, sterile; SC; rat; 2ML1; 12 days; controls received mp w/ vehicle (pH lowered to 2); pumps replaced after 6 days; antihypertensive.
P2452 Janssen,B.J.A., Tyssen,C.M., Struyker-Boudier,H.A.J. Modification of circadian blood pressure and heart rate variability by five different antihypertensive agents in spontaneously hypertensive rats. J.Cardiovasc.Pharmacol. 1991; 17(--):494-503. >>> Captopril; Metoprolol; Hydralazine; Clonidine; Prazosin; Water; DMSO; Ethanol; PEG 400; Saline; IV; rat; 2001; 2ML1; 4-6 days; controls received mp w/ vehicle; antihypertensive.
P2145 van Krimpen,C., Smits,J.F.M., Cleutjens,J.P.M., Debets,J.J.M., Schoemaker,R.G., Struyker Boudier,H.A.J., Bosman,F.T., Daemen,M.J.A.P. DNA synthesis in the non-infarcted cardiac interstitium after left coronary artery ligation in the rat: effects of captopril. J.Mol.Cell.Cardiology 1991; 23(--):1245-1253. >>> Captopril; Hydralazine; Uridine, bromodeoxy-; SC; rat; 2001; 1,7,14 days; pumps replaced at 7 days; toxicology; enzyme inhibitor (ACE); pumps used for drug admin. and cell labeling (1D and 7D labeling); multiple pumps per animal (2); antihypertensive.
P2064 Menasche,P., Grousset,C., Peynet,J., Mouas,C., Bloch,G., Piwnica,A. Pretreatment with captopril improves myocardial recovery after cardioplegic arrest. J.Cardiovasc.Pharmacol. 1992; 19(--):402-407. >>> Captopril; Enalapril; SC; rat; 2ML1; 48 hours; enzyme inhibitor (ace); antihypertensive.
P2045 Kitami,Y., Hiwada,K., Murakami,E., Muneta,S., Kokubu,T. The effect of the renin inhibitor ES-1005 on the expression of the kidney renin gene in sodium-depleted marmosets. J.Hypertens. 1990; 8(--):1143-1146. >>> ES-1005; Captopril; Saline; IP; monkey; 2001; 7 days; renin inhibitor; pump captopril infusion, but not acute administration, significantly increased kidney renin gene expression; antihypertensive.
P2039 van Krimpen,C., Schoemaker,R.G., Cleutjens,J.P.M., Smits,J.F.M., Struyker-Boudier,H.A.J., Bosman,F.T., Daemen,M.J.A.P. Angiotensin I converting enzyme inhibitors and cardiac remodeling. Basic Res.Cardiol. 1991; 86(-51-):149-155. >>> Captopril; Uridine, bromodeoxy-; SC; rat; 1,2,3 weeks; Multiple pumps per animal (2); antihypertensive.
P1899 Kuo,Y.-J., Keeton,T.K. Captopril increases norepinephrine spillover rate in conscious spontaneously hypertensive rats. J.Pharmacol.Exp.Ther. 1991; 258(-1-):223-231. >>> Minoxidil HCl; Captopril; Enalaprilat; Acetic acid; Ethanol; Propylene glycol; Saline; Water; SC; rat; 5 days; no comment posted; antihypertensive.
P1868 Pauletto,P., Nascimben,L., Piccolo,D., Secchiero,S., Vescovo,G., Scannapieco,G., Libera,L.D., Carraro,U., Pessina,A.C., Palu,C.D. Ventricular myosin and creatine-kinase isoenzymes in hypertensive rats treated with captopril. Hypertension 1989; 14(--):556-562. >>> Captopril; SC; rat; 4 weeks; antihypertensive.
P1734 Mabie,W.C., Ahokas,R.A., Sibai,B.M. Maternal and uteroplacental hemodynamic effects of chronic captopril in the hypertensive, term-pregnant rat. American Journal of Obstetrics and Gynecology 1990; 163(-6-):1861-1867. >>> Captopril; Ethanol; IP; rat (pregnant); 2001; 14 days; dose-response (graph); vehicle was 50% ethanol; antihypertensive.
P1550 Maisel,A.S., Philips,C., Michel,M.C., Ziegler,M.G., Carter,S.M. Regulation of cardiac B-adrenergic receptors by captopril. Circulation 1989; 80(--):669-675. >>> Captopril; Isoproterenol; SC; guinea-pig; 2 weeks; antihypertensive.
P1424 Nakagawa,M., Nasjletti,A. Plasma kinin concentration in deoxycorticosterone-salt hypertension. Hypertension 1988; 11(--):411-415. >>> Captopril; IP; rat; 2001; 3 days; antihypertensive.
P1329 Rebuffat,P., Belloni,A.S., Malendowicz,L.K., Mazzochi,G., Gottardo,G., Nussdorfer,G.G. Zona glomerulosa morphology and function in streptozotocin-induced diabetic rats. Endocrinology 1988; 123(-2-):949-955. >>> ACTH; Angiotensin II; Captopril; Dexamethasone; Insulin; Saline; SC; rat; 2002; 2 weeks; dose-response (text); functionality of mp verified by plasma levels; replacement t; antihypertensive therapy (streptozotocin-induced diabetes); peptides; antihypertensive.
P1237 Ng,C.F., Gautieri,R.F., Lemke,P.M. The effect of chronic administration of indomethacin in captopril-treated renal hypertensive rats. Res.Commun.Chem.Pathol.Pharmacol. 1988; 59(-3-):321-338. >>> Captopril; Water; SC; rat; 2002; 14 days; controls received mp w/ water; normal and RH rats used in this study; antihypertensive.
P1219 Berecek,K.H., Coshatt,G., Narkates,A.J., Oparil,S., Wilson,K.M., Robertson,J. Captopril and the response to stress in the spontaneously hypertensive rat. Hypertension 1988; 11(-I-):I144-I147. >>> Captopril; HCl; Saline; CSF/CNS; rat; 2002; 4 weeks; controls received mp w/ vehicle; pump replaced after 2 weeks; antihypertensive.
P1123 Atkinson,J., Sonnay,M., Sautel,M., Fouda,A.-K. Chronic treatment of the spontaneously hypertensive rat with captopril attenuates responses to noradrenaline in vivo but not in vitro. Naunyn-Schmiedeberg's Arch.Pharmacol. 1987; 335(--):624-628. >>> Captopril; Ethanol; Water; IV (jugular); rat; 2001; 2002; 4,15,17 days; controls received sham op or mp w. ethanol; mp connected to cannula in jugular vein; SHR rats; functionality of mp verified in separate group of rats w/ mp filled w/ [51Cr] EDTA; antihypertensive.
P1062 Attallah,A.A. Captopril reduces renal excretion of prostaglandin E2 in the sodium-depleted rabbit. Eur.J.Pharmacol. 1987; 134(--):361-363. >>> Captopril; SC; rabbit; 2ML1; 6 days; no vehicle for Captopril specified; antihypertensive.
P1036 Berecek,K.H., Kirk,K.A., Nagahama,S., Oparil,S. Sympathetic function in spontaneously hypertensive rats after chronic administration of captopril. Am.J.Physiol. 1987; 252(--):H796-H806. >>> Captopril; HCl; Saline; CSF/CNS; rat; 2002; 4 weeks; controls received mp w/vehicle; mp connected to catheter in lateral ventricle; pumps replaced after 2 weeks; stability of captopril stated; antihypertensive.
P0942 Piryova,B., Ikonomov,O., Stoynev,A., Natcheff,N. Renin-angiotensin system and renal excretory function under conditions of hypovolemia and limited sodium intake. Acta Physiol.Pharmacol.Bulg. 1987; 12(-2-):21-26. >>> Captopril; SC; rat; 2001; 8 days; comparison of ip injections vs. mp infusion; antihypertensive.
P0910 Berecek,K.H., Shier,D.N. Alterations in renal vascular reactivity induced by chronic central administration of captopril in the spontaneously hypertensive rat. Clin.Exp.Hypertens. 1986; A8(-7-):1081-1106. >>> Captopril; Saline; CSF/CNS; IV (jugular); rat; 2002; 4 weeks; controls received mp w/saline; mp connected to cannula in ventricle or jugular; pumps replaced after 2 weeks; stability of captopril verified; antihypertensive.
P0882 Itaya,Y., Suzuki,H., Matsukawa,S., Kondo,K., Saruta,T. Central renin-angiotensin system and the pathogenesis of DOCA-salt hypertension in rats. Am.Physiol.Soc. 1986; (--):261-268. >>> Captopril; Saline; CSF/CNS; rat; 2002; 7 days; controls received mp w/vehicle; mp connected to cannula in lateral ventricle; hypertension; DOCA-salt hypertensive rats; antihypertensive.
P0658 Chan,J.Y.H., Hutchinson,J.S. Central angiotensin converting enzyme blockade and salt preference in renovascular hypertensive rats. Ann.Acad.Med.Singapore 1985; 14(-1-):137-142. >>> Captopril; Saline; CSF/CNS; IP; rat; 2001; 1 week; comparison of icv vs. ip mp infusion; icv infusion into right lateral ventricle; antihypertensive.
P0527 Yasujima,M., Abe,K., Kasai,Y., Tanno,M., Tajima,J., Seino,M., Chiba,S., Sato,K., Goto,T., Omata,K., Yoshinaga,K. Renal kallikrein-kinin system and the depressor effect of angiotensin converting enzyme inhibitors MK 421, SA 446, and captopril in rats. Clin.Exp.Hypertens. 1984; A6(-6-):1207-1225. >>> SA-446; Captopril; MK-421; Saline; IP; rat; 6 days; comparison of agents effects; antihypertensive.
P0502 Villarreal,D., Freeman,R.H., Davis,J.O., Garoutte,G., Sweet,W.D. Pathogenesis of one-kidney, one-clip hypertension in rats after renal denervation. Am.J.Physiol. 1984; 247(--):H61-H66. >>> Captopril; Saline, bacteriostatic; IP; rat; 2002; 16 days; 2 mp/animal; antihypertensive.
P0488 Muller,J., Hofstetter,L., Schwendener-Canlas,P., Brunner,D.B., Lund,E.-G. Role of the renin-angiotensin system in the regulation of late steps in aldosterone biosynthesis by sodium intake of potassium-deficient rats. Endocrinology 1984; 115(-1-):350-356. >>> Angiotensin II; Captopril; SC; rat; 1 week; comparison of agents effects; 1-2 pumps/animal; rats were fed sodium and potassium deficient diets; peptides; antihypertensive.
P0482 Schulz,R., Wuster,M., Herz,A. Receptor preference of dynorphin A fragments in the mouse vas deferens determined by different techniques. J.Pharmacol.Exp.Ther. 1984; 230(-1-):200-204. >>> Dynorphin A(1-8); Bestatin; Captopril; Dynorphin A; Enkephalin agonist DADL; Fentanyl; Thiorphan; Saline; SC; vas deferens; Mice; 2001; 2ML1; no duration posted; Comparison of agents effects; 2ML1 pump used w/ captopril, thiorphan, and bestatin; DADL&FEN admin. sc; peptides; antihypertensive.
P0414 Okuno,T., Nagahama,S., Lindheimer,M.D., Oparil,S. Attenuation of the development of spontaneous hypertension in rats by chronic central administration of captopril. Hypertension 1983; 5(--):653-662. >>> Captopril; Radio-isotopes; 14C tracer; HCl; Saline; CSF/CNS; IV (jugular); rat; 2002; 2 and 4 weeks; comparison of iv vs. icv mp infusion; pump replaced after 2 weeks; peptides; antihypertensive; antihypertensive.
P0396 Berecek,K.H., Okuno,T., Nagahama,S., Oparil,S. Altered vascular reactivity and baroflex sensitivity induced by chronic central administration of captopril in the spontaneously hypertensive rat. Hypertension 1983; 5(-5-):689-700. >>> Captopril; HCl; Saline; CSF/CNS; IV (jugular); rat; 2002; 4 weeks; comparison of iv vs. icv mp infusion; pump replaced after 2 weeks; antihypertensive.
P0269 Muller,J., Lund,E.-G., Hofstetter,L., Brunner,D.B., Haldy,P. Stimulation of aldosterone biosynthesis by sodium sequestration: role of angiotensin II. Am.J.Physiol. 1982; 243(--):E450-E457. >>> Angiotensin II; Captopril; SC; rat; no duration posted; 1 or 2 pumps/animal; separate&simultaneous infusion of agents; peptides; antihypertensive.
P0192 Schiffrin,E.L., Genest,J. Mechanism of captopril-induced drinking. Am.J.Physiol. 1982; 242(--):R136-R140. >>> Angiotensin II; Captopril; Saline; CSF/CNS; IP; rat; 2001; 5-7 days; captopril icv only, AII ip&icv; peptides; antihypertensive.
P0131 Seymour,A.A., Davis,J.O., Freeman,R.H., DeForrest,J.M., Rowe,B.P., Stephens,G.A., Williams,G.M. Sodium and angiotensin in the pathogenesis of experimental renovascular hypertension. Am.J.Physiol. 1981; 240(--):H788-H792. >>> Captopril; IP; rat; 12 days; pumps replaced after 6 days; antihypertensive.
P0088 Douglas,J.G. Potassium ion as a regulator of adrenal angiotensin II receptors. Am.J.Physiol. 1980; 239(-5-):E317-E321. >>> Angiotensin II; Captopril; Saline; IP; SC; rat; 3 days; captopril in drinking water&by pump sc; angio II pump ip; peptides; antihypertensive.
P0078 Schirar,A., Capponi,A., Catt,K.J. Elevation of uterine angiotensin II receptors during early pregnancy in the rat. Endocrinology 1980; 106(-5-):1521-1527. >>> Captopril; Ascorbic acid; Saline; IP; rat; 6 days; antihypertensive.
P0050 Seymour,A.A., Davis,J.O., Freeman,R.H., DeForrest,J.M., Rowe,B.P., Stephens,G.A., Williams,G.M. Hypertension produced by sodium depletion and unilateral nephrectomy: a new experimental model. Hypertension 1980; 2(-2-):125-129. >>> Captopril; IP; rat; 13 days; antihypertensive.
46. DMAG, 17-
P8635 Milkiewicz,M., Doyle,J.L., Fudalewski,T., Ispanovic,E., Aghasi,M., Haas,T.L. HIF-1 alpha and HIF-2 alpha play a central role in stretch-induced but not shear-stress-induced angiogenesis in rat skeletal muscle. JOURNAL OF PHYSIOLOGY-LONDON 2007; 583(-2-):753-766. >>> DMAG, 17-; Dextrose, sterile; SC; IM (extensor digitorum longus); Rat; 2002; 7, 14 days; Controls received mp w/ vehicle; enzyme inhibitor (Hsp 90); post op. care (butorphanol); ischemia (muscle); animal info (male, Sprague-Dawley, 200-250g); agent also known as NSC 707545, a geldanamycin derivative.
47. DMPPO
P4231 Eddahibi,S., Raffestin,B., Le Monnier de Gouville,A.-C., Adnot,S. Effect of DMPPO, a phosphodiesterase type 5 inhibitor, on hypoxic pulmonary hypertension in rats. Br.J.Pharmacol. 1998; 125(--):681-688. >>> DMPPO; PEG; Saline; Dimethylacetamide, N-N-; IV (jugular); rat; 2002; 15 days; controls received mp w/vehicle; phosphodiesterase-5 inhibitor.
48. Donepezil
R0189 Woodruff-Pak,D.S., Lander,C., Geerts,H. Nicotinic cholinergic modulation: Galantamine as a prototype. CNS DRUG REVIEWS 2002; 8(-4-):405-426. >>> Donepezil; galantamine; Rat; 35 days; Enzyme inhibitor (acetyl cholinesterase); aricept; reminyl; p. 410, 414.
P8796 Van Dam,D., Coen,K., De Deyn,P.P. Cognitive evaluation of disease-modifying efficacy of donepezil in the APP23 mouse model for Alzheimer's disease. Psychopharmacology 2008; 197(-1-):37-43. >>> Donepezil, HCL; Saline; IP; Mice (transgenic); 2004; 8 weeks; Controls received mp w/ vehicle; pumps replaced after 4 weeks; good methods (pg. 39); enzyme inhibitor (acetyl cholinesterase); animal info (transgenic APP23); neurodegenerative (Alzheimer's disease).
P8363 Potier,B., Jouvenceau,A., Epelbaum,J., Dutar,P. Age-related alterations of GABAergic input to CA1 pyramidal neurons and its control by nicotinic acetylcholine receptors in rat hippocampus. Neuroscience 2006; 142(-1-):187-201. >>> Donepezil; SC; Rat; 2ML4; 30 days; Controls received mp w/ saline; enzyme inhibitor (cholinesterase); animal info (Sprague-Dawley, 3-4 or 25-28 months old).
P5354 Luine,V.N., Mohan,G., Tu,Z., Efange,S.M.N. Chromaproline and Chromaperidine, nicotine agonists, and Donepezil, cholinesterase inhibitor, enhance performance of memory tasks in ovariectomized rats. Pharmacology Biochemistry and Behavior 2002; 74(-1-):213-220. >>> Donepezil; chromaproline; chromaperidine; SC; Rat; 2002; 11, 25 days; Controls received empty gelatin capsules similar size and shape as pumps from Lilly; pumps replaced after 2 wks; enzyme inhibitor; chromaproline and chromaperidine are nicotinic agonists; donepezil is an acetylcholinesterase inhibitor; behavioral testing.
49. Doxorubicin
R0221 Frydman,B., Basu,H.S. Prostate-specific antigen: a diagnostic marker and a tool for targeted delivery of drugs to prostate tumours. Expert Opin.Ther.Parents 2002; 12(-7-):1035-1046. >>> Doxorubicin, heptapeptide conjugate; Mice (nude); 10 days; Cancer (prostate); ALZET pumps mentioned on pg. 1039.
P9568 Loch,T., Vakhrusheva,O., Piotrowska,I., Ziolkowski,W., Ebelt,H., Braun,T., Bober,E. Different extent of cardiac malfunction and resistance to oxidative stress in heterozygous and homozygous manganese-dependent superoxide dismutase-mutant mice. Cardiovascular Research 2009; 82(-3-):448-457. >>> Doxorubicin; PBS; SC; Mice; 2002; 2 weeks; Controls received mp w/vehicle; animal info (4.5 mo. old).
P8944 Wenzel,P., Mueller,J., Zurmeyer,S., Schuhmacher,S., Schulz,E., Oelze,M., Pautz,A., Kawamoto,T., Wojnowski,L., Kleinert,H., Muenzel,T., Daiber,A. ALDH-2 deficiency increases cardiovascular oxidative stress - Evidence for indirect antioxidative properties. Biochemical and Biophysical Research Communications 2008; 367(-1-):137-143. >>> Nitroglycerin; acetaldehyde; doxorubicin; Ethanol; SC; IP; Mice; 3, 4 days; Controls received mp w/ vehicle; cardiovascular; animal info (10 wks old, male, ALDH-2 null); nitroglycerin also known as glycerol trinitrate, GTN; "chronic (in contrast to short term/acute) treatment with doxorubicin lead to a more pronounced increase in mitochondrial ROS formation and to a greater extent of endothelial as well as smooth muscle dysfunction" pg. 141.
P7394 Guarnieri,M., Carson,B.S., Khan,A., Penno,M., Jallo,G.I. Flexible versus rigid catheters for chronic administration of exogenous agents into central nervous system tissues. Journal of Neuroscience Methods 2005; 144(-2-):147-152. >>> Doxorubicin; carboblatin; Dextrose solution; saline; CSF/CNS (parenchyma); Rat; 2001; ; Animal info (F, Fischer, 220 g); Functionality of mp verified by pump examination, post infusion; stability verified by previous studies, 14 days; good methods (p. 148); cancer (glioma); brain tissue distribution; Plastics One cannula used (stainless steel); "replacement of rigid infusion tubes [cannulae] with flexible tubing increases the reliability of local CNS drug infusions. Rigid catheters [cannulae] may allow backflow of the infused drug along the path of the catheters into the subdural space." (P. 147).
P7120 Khan,A., Jallo,G.I, Liu,Y.J, Carson,B.S., Guarnieri,M. Infusion rates and drug distribution in brain tumor models in rats. Journal of Neurosurgery (Pediatrics 1) 2005; 102(--):53-58. >>> Carboplatin; doxorubicin; transferrin-doxorubicin; CSF/CNS; Rat; 2ML1; 2001; 7 days; Cancer (glioma, gliosarcoma); brain tissue distribution; CNS infusion rate study; "...the use of intratumoral infusions significantly increase survival in comparison with bolus injections and conventional systemic treatments." P. 53; flexible tipped cannula components were from Plastics One; in some cases the tubing/cannula were left empty after implantation to allow the tissue to seal before fluid flow.
P6033 Boengler,K., Pipp,F., Fernandez,B., Ziegelhoeffer,T., Schaper,W., Deindl,E. Arteriogenesis is associated with an induction of the cardiac ankyrin repeat protein (carp). Cardiovascular Research 2003; 59(-3-):573-581. >>> Monocyte chemoattractant protein-1; doxorubicin; transforming growth factor-B1; IA (femoral); Rabbit; 2ML1; 24 hours; Cardiovascular.
P5729 Boengler,K., Pipp,F., Fernandez,B., Richter,A., Schaper,W., Deindl,E. The ankyrin repeat containing SOCS box protein 5: a novel protein associated with arteriogenesis. Biochemical and Biophysical Research Communications 2003; 302(-1-):17-22. >>> Monocyte chemoattractant protein-1; Transforming Growth Factor-B; Doxorubicin; IA (femoral); Rabbit; 2ML1; 24 hours; Cardiovascular; peptides; MCP-1 is monocyte chemoattractant protein 1.
P2788 Naito,K., Kanbayashi,N., Nakajima,S., Murai,T., Arakawa,K., Nishimura,S., Okuyama,A. Inhibition of growth of human tumor cells in nude mice by a metalloproteinase inhibitor. Int.J.Cancer 1994; 58(--):730-735. >>> BE16627B; Doxorubicin HCl; DMSO; Ethylene glycol; SC; mice (nude); 2001; 2002; 3 weeks, 18 days; controls received vehicle or no treatment; pumps replaced; stress/ adverse reaction: skin inflammation and necrosis around delivery site in mice treated with Adriamycin (pg. 733); BE166278B animals were fine; stability verified for 18 days by assay; cancer; enzyme inhibitor; BE16627B is a metalloproteinase inhibitor; 2002 replaced w/ 2001 after 20 days; adriamycin is doxorubicin HCl.
P2389 Slate,D.L., Fraser-Smith,E.B., Rosete,J.D., Freitas,V.R., Kim,Y.N., Casey,S.M. Modulation of doxorubicin efficacy in P388 leukemia following co-administration of verapamil in mini-osmotic pumps. Invivo 1993; 7(--):519-524. >>> Doxorubicin; Verapamil; PBS; IP; mice; 2001; 7 days; functionality of mp verified by plasma levels; dose-response (table, p. 520); comparison of i.p. injections vs. mp; cancer; authors used ALZET pumps to "..mimic prolonged i.v. coadministration in the clinic and to compare the efficacy and toxicity of this delivery scheme with more traditional bolus i.p. regimens.".
P2007 Rodgers,K.E., Girgis,W., diZerega,G.S. Effect of tolmetin sodium dihydrate on adhesion formation by intraperitoneal administration of antineoplastic agents. Cancer Chemother.Pharmacol. 1992; 29(--):248-251. >>> Doxorubicin HCl; Mitoxantrone; Tolmetin sodium; Bleomycin; Cisplatin; Methotrexate; PBS; IP; rat; 2ML1; 7 days; Antibiotic; cancer; no stress (see p249).
50. Dutasteride
P8636 Shao,T.C., Li,H., Ittmann,M., Cunningham,G.R. Effects of dutasteride on prostate growth in the large probasin-large T antigen mouse model of prostate cancer. Journal of Urology 2007; 178(-4-):1521-1527. >>> Dutasteride; DMSO; PEG 400; SC; Mice (transgenic); 2004; 4, 8 weeks; Controls received mp w/ vehicle; comparison of oral admin. vs. mp; long-term study; pumps replaced after 4 weeks; no stress (see pg. 1522); enzyme inhibitor (5a-reductase); cancer (prostate); animal info (male, LPB-Tag, tg, wt, 6-7 and 10-11 wks old); 40% DMSO; "Dutasteride greatly decreased prostate tumor growth... without significant negative effects." p. 1526.
51. E-64
Q0505 Amaral,F.A., Lemos,M.T.R., Dong,K.E., Bittencourt,M.F.Q.P., Caetano,A.L., Pesquero,J.B., Viel,T.A., Buck,H.S. Participation of kinin receptors on memory impairment after chronic infusion of human amyloid-beta 1-40 peptide in mice. Neuropeptides 2010; 44(-2-):93-97. >>> Amyloid protein, beta (1-40); E-64; HEPES; CSF/CNS; Mice; 1004; 28 days; Controls received mp w/ vehicle; enzyme inhibitor (cystein protease); ALZET brain infusion kit 3 used; animal info (male, C57BL/6, wt, KOB1 KOB2, 28031 g, 12 wks old); behavioral testing (active avoidance); neurodegenerative (Alzheimer's Disease); "infusion (of beta-amyloid protein) could provide a tissue response closer to that observed in the pathogenesis of AD." pg 94.
Q0252 Shinohara,M., Sato,N., Kurinami,H., Takeuchi,D., Takeda,S., Shimamura,M., Yamashita,T., Uchiyama,Y., Rakugi,H., Morishita,R. Reduction of Brain beta-Amyloid (A-beta) by Fluvastatin, a Hydroxymethylglutaryl-CoA Reductase Inhibitor, through Increase in Degradation of Amyloid Precursor Protein C-terminal Fragments (APP-CTFs) and A-beta Clearance. Journal of Biological Chemistry 2010; 285(-29-):22091-22102. >>> Leupeptin; E-64a; CSF, artificial; CSF/CNS; Mice (transgenic); 2002; 1 week; Controls received mp w/ vehicle; peptides; ALZET brain infusion kit 3 used; no stress (see pg 22092); neurodegenerative (Alzheimer's Disease); animal info (male, C57BL/6, APP23 Tg, 8 wks old); Lysosomal inhibitor.
P9798 Viel,T.A., Caetano,A.L., Nasello,A.G., Lancelotti,C.L., Nunes,V.A., Araujo,M.S., Buck,H.S. Increases of kinin B1 and B2 receptors binding sites after brain infusion of amyloid-beta 1-40 peptide in rats. NEUROBIOLOGY OF AGING 2008; 29(-12-):1805-1814. >>> Amyloid protein, beta (1-40), human; E-64; CSF/CNS; Rat; 2004; 5 weeks; Controls received mp w/ enzyme inhibitor (cystein protease); ALZET brain infusion kit 1 used; peptides; animal info (male, Wistar, 200-250 g.); neurodegenerative (Alzheimer's Disease).
P8142 Iores-Marcal,L.M., Viel,T.A., Buck,H.S., Nunes,V.A., Gozzo,A.J., Cruz-Silva,I., Miranda,A., Shimamoto,K., Ura,N., Araujo,M.S. Bradykinin release and inactivation in brain of rats submitted to an experimental model of Alzheimer's disease. Peptides 2006; 27(-12-):3363-3369. >>> Amyloid protein, beta (1-40), human; E-64; HEPES; E-64; CSF/CNS; Rat; 2004; 28 days; Controls received mp w/ vehicle; brain tissue distribution; peptides; animal info (male, Wistar, 3 mo. old); neurodegenerative (Alzheimer's disease); cathepsin B inhibitor.
P6627 Doh-ura,K., Ishikawa,K., Murakami-Kubo,I., Sasaki,K., Mohri,S., Race,R., Iwaki,T. Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models. JOURNAL OF VIROLOGY 2004; 78(-10-):4999-5006. >>> Quinacrine; chloroquine; amphotericin B; E-64d; pentosan polysulfate; PBS; water, distilled; DMSO; SC; CSF/CNS; Rat; mice; dog (mongrel); 2 months; 4 weeks; Controls received mp w/ vehicle; dose-response (fig. 2); no stress (see pg. 5004); stress/adverse reaction: (see pg. 5002) PPS at highest dose (20mg/kg/day) showed hemorrhage in the SC area surrounding the mp; enzyme inhibitor (cysteine protease [E-64d]);.
P4944 Layton,G.T., Harris,S.J., Bland,F.A., Lee,S.R., Fearn,S., Kaleta,J., Wood,M.L., Bond,A., Ward,G. Therapeutic effects of cysteine protease inhibition in allergic lung inflammation: Inhibition of allergen-specific T lymphocyte migration. INFLAMMATION RESEARCH 2001; 50(--):400-408. >>> E-64; DMSO; Water; SC; mice; 2001; 7 days; functionality of mp verified by lung tissue protease levels; immunology; enzyme inhibitor; E64 is a cysteine protease inhibitor; vehicle was 50% DMSO, 50% water..
P4382 Conway,J.G., Trexler,S.J., Wakefield,J.A., Marron,B.E., Emerson,D.L., Bickett,D.M., Deaton,D.N., Garrison,D., Elder,M., McElroy,A., Willmott,N., Dockerty,A.J.P., McGeehan,G.M. Effect of matrix metalloproteinase inhibitors on tumor growth and spontaneous metastasis. Clin.Exp.Metastasis 1996; 14(--):115-124. >>> E-64; GI168; GI173; GI179; GI184;; DMSO; Saline; EtOH; Buffer, sodium citrate; Tappsol HPB-20;; SC;; mice;; 2001; 2002;; 2, 7, 14 days;; controls received mp w/ vehicle; cancer; matrix metalloproteinase inhibitors; mice received 2 pumps each; enzyme inhibitors.
P3263 Karran,E.H., Dodgson,K., Harris,S.J., Markwell,R.E., Harper,G.P. A simple in vivo model of collagen degradation using collagen-gelled cotton buds: the effects of collagenase inhibitors and other agents. Inflamm.Res. 1995; 44(--):36-46. >>> Collagenase inhibitor A; Collagenase inhibitor B; Collagenase inhibitor C; tempol; Superoxide dismutase-PEG; Cytochalasin B; Pepstatin; APMSF; TLCK; SBTI; Leupeptin; E-64; Methylamine; SC; Rat; 2001; 2ML1; 7 days; controls received mp w/vehicle; no stress (see pg. 39); immunology; pumps connected with catheter tubing to 14C-collagen-gelled cotton buds.
P2096 Redwood,S.M., Liu,B.C.S., Weiss,R.E., Hodge,D.E., Droller,M.J. Abrogation of the invasion of human bladder tumor cells by using protease inhibitor(s). Cancer 1992; 69(-5-):1212-1219. >>> E-64; PBS; IV (jugular); mice (nude); no duration posted; cancer; immunology; enzyme inhibitor (cysteine protease).
P1987 Ivy,G.O. Protease inhibitors as a model for NCL disease, with special emphasis on the infantile and adult forms. Am.J.Med.Genet. 1992; 42(--):555-560. >>> E-64C; Aprotinin; Chloroquine; Leupeptin; CSF/CNS; rat; 2002; 2 weeks; no comment posted.
P0943 Tamai,M., Matsumoto,K., Omura,S., Koyama,I., Ozawa,Y., Hanada,K. In vitro and in vivo inhibition of cysteine proteinases by est, a new analog of E-64. J.Pharmacobiodyn. 1986; 9(-8-):672-677. >>> E-64; EST; IP; rat; no duration posted; muscular dystrophy; refers to previous work done w/mp only; E-64 and EST are cysteine protease inhibitors.
52. Elafin
Q0039 Cowan,B, Baron,O, Crack,J, Coulber,C, Wilson,G.J., Rabinovich,M. Elafin, a Serine Elastase Inhibitor, Attenuates Post-Cardiac Transplant Coronary Arteriopathy and Reduces Myocardial Necrosis in Rabbits After Heterotopic Cardiac Transplantation. J.Clin.Invest 1996; 97(-11-):2452-2468. >>> Elafin, recomb human; Saline, physiological; IV (jugular); IV (superior vena cava); Rabbit; 2ML1; 7 days; Controls received mp w/ vehicle; peptides; cardiovascular; enzyme inhibitor (serine elastase).
53. Ethylisourea, S-
P4279 Rudd,M.A., Trolliet,M., Hope,S., Scribner,A.W., Daumerie,G., Toolan,G., Cloutier,T., Loscalzo,J. Salt-induced hypertension in Dahl salt-resistant and salt-sensitive rats with NOS II inhibition. Am.J.Physiol.(Heart Circ.Physiol.46) 1999; 277(--):H732-H739. >>> AMT; 1400W; Ethylisourea, S-; Rat; 12 days; Cardiovascular; agents are NOS II inhibitors; AMT is 2-amino-5,6-dihydro-6-methyl-4H-1,3-thiazine; S-ethylisourea is also known as EIT; enzyme inhibitors; nitric oxide synthase inhibitor;.
54. Etodolac
P4989 Kollman-Bauerly,K.A., Thomas,D.L., Adrian,T.E., Lien,E.L., Vanderhoof,J.A. The role of eicosanoids in the process of adaptation following massive bowel resection in the rat. JOURNAL OF PARENTERAL AND ENTERAL NUTRITION 2001; 25(--):275-281. >>> Etodolac; Guaiaretic acid, nordihydro-; DMSO; SC; rat; 2002; 2ML2; 14 days; controls received mp w/ vehicle; etodolac is a cyclo-oxygenase-2 (COX II) enzyme inhibitor administered by 2002 pump in 70% DMSO vehicle; Eicosanoids; Nordihydroguaiaretic acid is a lipoxygenase inhibitor administered in 2ML2 pump in 70% DMSO vehicle..
55. Etoposide
P9777 Giraud,S., Bessette,B., Boda,C., Lalloue,F., Petit,D., Mathonnet,M., Jauberteau,M.O. In vitro apoptotic induction of human glioblastoma cells by Fas ligand plus etoposide and in vivo antitumour activity of combined drugs in xenografted nude rats. INTERNATIONAL JOURNAL OF ONCOLOGY 2007; 30(--):273-281. >>> Fas ligand; etoposide; dexamethasone; CSF, artificial; CSF/CNS (intratumoral); Rat (nude); 1002; 15 days; Tissue perfusion (tumor); functionality of mp verified by residual volume; cancer (glioblastoma); animal info (female 2 months old, 159 g.).
P5213 Peng,D., Qian,C., Sun,Y., Barajas,M.A., Prieto,J. Transduction of hepatocellular carcinoma (HCC) using recombinant adeno- associated virus (rAAV): in vitro and in vivo effects of genotoxic agents. J Hepatol. 2000/6; 32(-6-):975-985. >>> Etoposide; IP; Rat; 1 week; Functionality of mp verified by measuring etoposide concentration in tumor tissue; cancer; etoposide (VP-16) is a chemotherapeutic agent.
P2546 de Haan,G., Engel,C., Dontje,B., Loeffler,M., Nijhof,W. Hemotoxicity by prolonged etoposide administration to mice can be prevented by simultaneous growth factor therapy. Cancer Res. 1995; 55(--):324-329. >>> Erythropoietin; Colony-stimulating factor, G; Etoposide; SC; mice; 7 days; dose-response curves (pg. 326-328); cancer; peptides; etoposide is VP-16-213; EPO and VP-16-213 given in same pump initially, but this inactived the G-CSF; multiple pumps per animal (1-2) for G-CSF/VP-16 mice.
P2305 Claessen,A.M.E., Bloemena,E., Bril,H., Meijer,C.J.L.M., Scheper,R.J. Locoregional administration of etoposide, but not of interleukin 2, facilitates active specific immunization in guinea pigs with advanced carcinoma. Cancer Res. 1992; 52(--):2440-2446. >>> Interleukin-2; Etoposide; SC; guinea-pig; 2001; 2002; 1 and 2 weeks; comparison of local injections vs. mp (table, p. 2442); cancer.
P1471 Claessen,A.M., Valster,H., Bril,H., Meyer,S., Scheper,R.J. Cell-mediated immunity is enhanced by cytostatic drugs continuously released at the site of antigenic stimulation. Cancer Immunol.Immunother. 1989; 28(--):131-135. >>> Etoposide; Fluorouracil, 5-; SC; guinea-pig; 2001; 7 days; comparison of sc injections vs. mp infusion; cancer/immunology; VP-16-213 is etoposide.
56. FPT III
P6396 Benter,I.F., Juggi,J.S., Khan,I., Akhtar,S. Inhibition of Ras-GTPase, but not tyrosine kinases or Ca2+/calmodulin-dependent protein kinase II, improves recovery of cardiac function in the globally ischemic heart. MOLECULAR AND CELLULAR BIOCHEMISTRY 2004; 259(-1-2-):35-42. >>> FPT III; KN-93; Genistein; Saline; IP; Rat; 2ML1; 6 days; Controls received mp w/ vehicle; enzyme inhibitor (tyrosine kinase, CaMKII); cardiovascular; ischemia (cardiac).
P4759 Muthalif,M.M, Benter,I.F., Khandekar,Z, Gaber,L, Estes,A, Malik,S, Parmentier,J.-H, Manne,V, Malik,K.U. Contribution of Ras GPase/MAP kinase and cytochrome P450 metabolites to deoxycorticosterone-salt-induced hypertension.. Hypertension 2000; 35(-part 2-):457-463. >>> FPT III; BMS-191563; PD-98059; IP; Rat; 2ML1; 5 days; Controls received mp w/ vehicle; replacement therapy (uninephrectomy); cardiovascular; antihypertensive; enzyme inhibitor; FPT III and BMS-191563 are Ras farnesyl transferase enzyme inhibitors; PD-98059 is an MEK enzyme inhibitor; MEK is MAP (mean arterial pressure) kinase kinase inhibitor.
P4758 Muthalif,M.M, Karzoun,N.A, Gaber,L, Khandekar,Z, Benter,I.F., Saeed,A.E, Parmentier,J.-H, Estes,A, Malik,K.U. Contribution of Ras GTPase/Mitogen-activated protein kinase and cytochrome P450 metabolites.. Hypertension 2000; 36(--):604-609. >>> Angiotensin II; FPT III; BMS-191563;; Acetic acid; IP;; rat;; 6 days;; Controls received mp w/ vehicle; dose-response (graph p. 605); antihypertensive; enzyme inhibitor; FPT III and BMS - 191563 are Ras farnesyl transferase inhibitors infused along with Angiotensin II; Acetic acid vehicle was 0.001 N..
57. Fadrozole
P9794 Lyou,S., Kawano,S., Yamada,T., Okuyama,S., Terashima,T., Hayase,K., Yokogoshi,H. Role of estrogen receptors and aromatase on brain protein synthesis rates in ovariectomized female rats fed genistein. NUTRITIONAL NEUROSCIENCE 2008; 11(-4-):155-160. >>> ICI 182,780; fadrozole; DMSO; saline; SC; CSF/CNS; Rat; 2001; 2002; ; Controls received mp w/ vehicle; animal info (female, Wistar, 10 wks old, OVX).
P8914 Huddleston,G.G., Paisley,J.C., Clancy,A.N. Effects of estrogen in the male rat medial amygdala: Infusion of an aromatase inhibitor lowers mating and bovine serum albumin-conjugated estradiol implants do not promote mating. Neuroendocrinology 2006; 83(-2-):106-116. >>> Fadrozole; Saline; CSF/CNS (medial amygdala); Rat; 2002; 2004; 4 weeks; Controls received mp w/ vehicle; functionality of mp verified by residual volume; pumps replaced after 13 days; enzyme inhibitor (aromatase); animal info (male, Sprague Dawley, > 70 days old); behavioral testing (sexual/mating behavior); cannula placement confirmed; endocrinology.
P8812 Minnaard-Huiban,M., Emmen,J.M.A., Roumen,L., Beugels,I.P.E., Cohuet,G.M.S., van Essen,H., Ruijters,E., Pieterse,K., Hilbers,P.A.J., Ottenheijm,H.C.J., Plate,R., de Gooyer,M.E., Smits,J.F.M., Hermans,J.J.R. Fadrozole reverses cardiac fibrosis in spontaneously hypertensive heart failure rats: Discordant enantioselectivity Versus reduction of plasma aldosterone. Endocrinology 2008; 149(-1-):28-31. >>> Fadrozole, R-; fadrozole, S-; Sodium phosphate buffer; PEG 400; SC; Rat; 2ML4; 8 weeks; Controls received mp w/ vehicle; dose-response (Fig. 1); long-term study; pumps replaced after 4 weeks; no stress (see pg. 29); cardiovascular; animal info (male, lean SHHF, 40 wks old, 450g.); aldosterone biosynthesis inhibitor.
P7534 Veiga,S., Azcoitia,I., Garcia-Segura,L.M. Extragonadal synthesis of estradiol is protective against kainic acid excitotoxic damage to the hippocampus. NeuroReport 2005; 16(-14-):1599-1603. >>> Fadrozole; Saline; SC; Rat; 2002; 2 weeks; Controls received mp w/ vehicle; replacement therapy (gonadectomy); enzyme inhibitor (aromatase); neurodegenerative; animal info (male and female, Wistar albino, 4 weeks old); agent also known as CGS16949A.
P6744 Hoyk,Z., Parducz,A., Garcia-Segura,L.M. Dehydroepiandrosterone regulates astroglia reaction to denervation of olfactory glomeruli. Glia 2004; 48(-3-):207-216. >>> Fadrozole; Sodium chloride; SC; Rat; 2002; 2 weeks; Controls received mp w/ vehicle; enzyme inhibitor (aromatase).
P6710 Tamada,H., Mizuta,Y., Kawate,N., Inaba,T., Sawada,T. Delayed implantation induced by fadrozole hydrochloride in rats. Contraception 2003; 68(-1-):65-68. >>> Fadrozole HCL; Saline; SC; Rat (pregnant); 2001; 7 days; Controls received mp w/ vehicle; enzyme inhibitor (aromatase); teratology.
P6708 Huddleston,G.G., Michael,R.P., Zumpe,D., Clancy,A.N. Estradiol in the male rat amygdala facilitates mounting but not ejaculation. PHYSIOLOGY&BEHAVIOR 2003; 79(-2-):239-246. >>> Fadrozole; Saline; SC; Rat; 2004; 8 weeks; Functionality of mp verified by residual volume; long-term study; pumps replaced after 26 days; enzyme inhibitor (aromatase); post op. care (penicillin, banamine); fadrozole is also termed CGS-15949A.
P6397 Soma,K.K., Tramontin,A.D., Featherstone,J., Brenowitz,E.A. Estrogen contributes to seasonal plasticity of the adult avian song control system. Journal of Neurobiology 2004; 58(-3-):413-422. >>> Fadrozole; Saline; SC; Bird (song sparrow); 1002; 2 weeks; Controls received mp w/ vehicle; enzyme inhibitor (aromatase); the pumps had a changed infusion rate of 0.31 ul/hr with the 41 degree Celsius temperature; ALZET pump was implanted using topical analgesics (4% lidocaine); skin sealed with adhesive and sutures.
P6375 Tamada,H., Shimizu,Y., Inaba,T., Kawate,N., Sawada,T. The effects of the aromatase inhibitor fadrozole hydrochloride on fetuses and uteri in late pregnant rats. Journal of Endocrinology 2004; 180(-2-):337-345. >>> Fadrozole, hydrochloride; Saline; SC; Rat (pregnant); 2001; 1 week; Controls received mp w/ vehicle; FAD plasma levels taken; teratology.
P5903 McCullough,L.D., Blizzard,K., Simpson,E.R., Oez,O.K., Hurn,P.D. Aromatase cytochrome P450 and extragonadal estrogen play a role in ischemic neuroprotection. Journal of Neuroscience 2003; 23(-25-):8701-8705. >>> Fadrozole; Saline; SC; Mice (transgenic); 2002; 7 days; Controls received mp w/ vehicle; fadrozole is a selective aromatose inhibitor; ischemia (cerebral).
P4889 Fusani,L., Gahr,M., Hutchison,J.B. Aromatase inhibition reduces specifically one display of the ring dove courtship behavior. General and Comparative Endocrinology 2001; 122(--):23-30. >>> Fadrozole; Saline; SC; bird (pigeon); 1007D; 6 days; controls received mp w/ vehicle; functionality of mp verified by plasma androgen and estrogen levels, residual volume; enzyme inhibitor; fadrozole is a non-steroidal aromatase inhibitor; plasma androstenedione, 5a-dihydrotestosterone, testosterone, estrone, 17B -estradiol level:. Aromatase operates on these compounds, indicates aromatase activity..
P4660 Cooper,T.T, Clancy,A.N., Karom,M, Moore,T.O, Albers,H.E. Conversion of testosterone to estradiol may not be necessary for the expression of mating behavior in male Syrian hamsters.. Hormones and Behavior 2000; 37(--):237-245. >>> Fadrozole;; Saline;; SC;; hamster;; 2004; 2002;; 8 weeks;; Controls received empty mp; functionality of mp verified by weighing residual fluid; long-term study, pumps replaced every 2 or 4 weeks; enzyme inhibitor (nonsteroidal aromatase inhibitor);.
P3821 Vagell,V.E., McGinnis,M.Y. The role of aromatization in the restoration of male rat reproductive behavior. J.Neuroendocrinology 1997; 9(--):415-421. >>> Fadrozole HCl; Propylene glycol; ETOH; CSF/CNS; rat; 2002; 14 days; controls received propylene glycol.
P3385 Shetty,G., Bhatnagar,A.S., Moudgal,N.R. Blockade of estrogen synthesis with an aromatase inhibitor affects luteal function of the pseudopregnant rat. J.Steroid Biochem.Molec.Biol. 1995; 55(-3/4-):347-353. >>> Fadrozole HCl; Estradiol-3-benzoate; SC; rat; 2002; 3 days; no comment posted.
P3081 Zumpe,D., Michael,R.P. Combined effects of Depo-Provera and fadrozole on the sexual behavior of intact male cynomolgus monkeys (Macaca fascicularis). Physiol.Behav. 1994; 56(-4-):665-669. >>> Fadrozole; SC; monkey; 2ML4; 8 weeks; controls received mp with water; pumps replaced with opposite treatment (control or fadrozole) pump after 4 weeks; mp implanted in flank.
P2974 Selvaraj,N., Bhatnagar,A.S., Moudgal,N.R. Is there a role for estrogen in follicular maturation in the primate?. Endocrine 1995; 3(--):245-249. >>> Fadrozole HCl; Saline; monkey; 2002; 11 days; controls received mp with saline.
P2973 Selvaraj,N., Shetty,G., Vijayalakshmi,K., Bhatnagar,A.S., Moudgal,N.R. Effect of blocking oestrogen synthesis with a new generation aromatase inhibitor CGS 16949A on follicular maturation induced by pregnant mare serum gonadotrophin in the immature rat. J.Endocrinol. 1994; 142(--):563-570. >>> Fadrozole HCl; Saline; rat; 2002; no duration posted; controls received mp with saline.
P2659 Clancy,A.N., Zumpe,D., Michael,R.P. Intracerebral infusion of an aromatase inhibitor, sexual behavior and brain estrogen receptor-like immunoreactivity in intact male rats. Neuroendocrinology 1995; 61(--):98-111. >>> Fadrozole; Saline; SC; CSF/CNS (cerebral cortex); CSF/CNS (lateral preoptic area); CSF/CNS (medial preoptic area); rat; 2002; no duration posted; controls received mp w/ saline or no operation; functionality of mp verified by residual volume; long-term study, pumps replaced every 10-14 days; bilateral delivery via Y-connector; 2 pumps implanted concomitantly--1 for sc delivery, and one for delivery to the brain.
P2658 Clancy,A.N., Michael,R.P. Effects of testosterone and aromatase inhibition on estrogen receptor-like immunoreactivity in male rat brain. Neuroendocrinology 1994; 59(--):552-560. >>> Fadrozole; Water; SC; rat; 2002; no duration posted; Fadrazole is a nonsteroidal aromatase inhibitor; rats received benzathine&procaine penicillin G im, prophylactically.
P2209 Zumpe,D., Bonsall,R.W., Michael,R.P. Effects of the nonsteroidal aromatase inhibitor, fadrozole, on the sexual behavior of male cynomolgus monkeys (macaca fascicularis). Horm.Behav. 1993; 27(--):200-215. >>> Fadrozole; Water; SC; monkey; 2ML4; 4,12 weeks; controls received mp/water; long-term study, pumps replaced every 3 weeks; stability verified by plasma levels; pumps implanted in flank.
P2208 Bonsall,R.W., Clancy,A.N., Michael,R.P. Effects of the nonsteroidal aromatase inhibitor, fadrozole, on sexual behavior in male rats. Horm.Behav. 1992; 26(--):240-254. >>> Fadrozole; Water; SC; rat; 2002; 6 weeks; 14 days; controls received mp w/water; long-term study, pumps replaced every 14 days; stability verified by measuring residual solution in pumps; CGS 16949A is fadrozole.
58. Fasudil
Q0632 Fujimura,M., Usuki,F., Kawamura,M., Izumo,S. Inhibition of the Rho/ROCK pathway prevents neuronal degeneration in vitro and in vivo following methylmercury exposure. TOXICOLOGY AND APPLIED PHARMACOLOGY 2011; 250(-1-):1-9. >>> Fasudil; Water, sterile; SC; Rat; 2004; 4 weeks; Controls received mp w/ sterile saline; animal info (male, Wistar, 6 wks old, 260-310 g); enzyme inhibitor (Rho kinase, ROCK).
Q0326 de Frutos,S., Caldwell,E., Nitta,C.H., Kanagy,N.L., Wang,J.A., Wang,W., Walker,M.K., Bosc,L.V.G. NFATc3 contributes to intermittent hypoxia-induced arterial remodeling in mice. American Journal of Physiology-Heart and Circulatory Physiology 2010; 299(-2-):U133-U140. >>> Fasudil; SC; Mice; 3 days; Animal info (adult, male, 9x-NFAT-luciferase reporter, NFATc3 knockout, BalB/C wild-type, 25-30 g); enzyme inhibitor (Rho kinase).
Q0287 Furuya,T., Hashimoto,M., Koda,M., Okawa,A., Murata,A., Takahashi,K., Yamashita,T., Yamazaki,M. Treatment of rat spinal cord injury with a Rho-kinase inhibitor and bone marrow stromal cell transplantation. Brain Research 2009; 1295(-;-):192-202. >>> Fasudil; Saline; CSF/CNS (intrathecal, subarachnoid space); Rat; 2004; 4 weeks; Controls received mp w/ vehicle; animal info (female, Sprague-Dawley, 8-10 wks old, 174-236 g); post op. care (Bacitramin); spinal cord injury.
P8694 Ito,T., Ohtori,S., Hata,K., Inoue,G., Moriya,H., Takahashi,K., Yamashita,T. Rho kinase inhibitor improves motor dysfunction and hypoalgesia in a rat model of lumbar spinal canal stenosis. Spine 2007; 32(-19-):2070-2075. >>> Fasudil hydrochloride hydrate; CSF/CNS (intrathecal); Rat; 2002; 14 days; Enzyme inhibitor (Rho-kinase); animal info (6 week, male, Sprague-Dawley, 200-250g); pain; silastic tubing used; neuroprotection.
P8286 Ying,H., Biroc,S.L., Li,W.W., Alicke,B., Xuan,J.A., Pagila,R., Ohashi,Y., Okada,T., Kamata,Y., Dinter,H. The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. MOLECULAR CANCER THERAPEUTICS 2006; 5(-9-):2158-2164. >>> Fasudil; Saline; SC; Mice (nude); 21 days; Controls received mp w/ vehicle; cancer (lung); enzyme inhibitor (rho kinase).
P6997 Wesselman,J.P.M., Kuijs,R., Hermans,J.J.R., Janssen,G.M.J., Fazzi,G.E., van Essen,H., Evelo,C.T.A., Struijker-Boudier,H.A.J., De Mey,J.G.R. Role of the Rhoa/Rho kinase system in flow-related remodeling of rat mesenteric small arteries in vivo. JOURNAL OF VASCULAR RESEARCH 2004; 41(-3-):277-290. >>> Fasudil; SC; Rat; 2004; 4 weeks; Controls received mp w/ physiological saline; functionality of mp verified by fasudil and hydroxyfasudil plasma levels; enzyme inhibitor (rho kinase); cardiovascular.
59. Finasteride
P3139 Tutrone Jr,R.F., Ball,R.A., Ornitz,D.M., Leder,P., Richie,J.P. Benign prostatic hyperplasia in a transgenic mouse: a hormonally responsive investigatory model. Urol.Repro.Biol. 1993; 149(-3-):697-700. >>> Testosterone; Finasteride; SC; mice; 30 days; controls received sham castration; replacement therapy (castration); enzyme inhibitor; finasteride is Proscar, a 5-alpha reductase inhibitor.
60. Fluoromethylhistidine, A-
P5589 Langlais,P.J., McRee,R.C., Nalwalk,J.A., Hough,L.B. Depletion of brain histamine produces regionally selective protection against thiamine deficiency-induced lesions in the rat. METABOLIC BRAIN DISEASE 2002; 17(-3-):199-210. >>> Fluoromethylhistidine, a-; CSF, artificial; CSF/CNS; rat; 2001; 7 days; controls received mp with vehicle; ALZET brain infusion kit used; "... this is the first report of the effectiveness of chronic ICV administration of FMH in depleting histamine and histidine decarboxylase activity within the thalamus." (p.206).
P5304 Fujiwara,K., Karasuyama,M., Murata,I., Tanabe,T., Yabuuchi,M., Inoue,Y., Tsuru,D. Immunoelectron-microscopic demonstration of histamine depletion in the gastric enterochromaffin-like cells of rats treated with alpha- fluoromethylhistidine. Cell Tissue Res 2001/11; 306(-2-):295-300. >>> Fluoromethylhistidine, a-; Saline; SC; Rat; 2ML1; 12 or 24 hours; Controls received mp w/ vehicle; immunology.
P3696 Andersson,K., Zhao,C.-M., Chen,D., Sundler,F., Hakanson,R. Effect of a-fluoromethylhistidine-evoked histamine depletion on ultrastructure of endocrine cells in acid-producing mucosa of stomach in mouse, rat and hamster. Cell Tissue Res. 1996; 286(--):375-384. >>> Fluoromethylhistidine, a-; SC; rat; mice; hamster; 2ML1; 1003D; 24 hours; controls received mp w/ saline; agent is histidine decarboxylase inhibitor; smaller pumps used in mice and hamsters.
P3304 Hosoda,S., Hosoda,R., Konishi,T. Effect of (S)-a-fluoromethylhistidine and SMS 201-995 on growth of histamine-producing gastric carcinoid of Mastomys natalensis. Agents Actions 1993; 38(-SConf-):C158-C160. >>> Fluoromethylhistidine, 5-a-; Octreotide; SC; mastomys (African rodent); no duration posted; comparison of IP injections vs. mp.
P2403 Orthen-Gambill,N., Salomon,M. FMH-induced decrease in central histamine levels produces increased feeding and body weight in rats. Physiol.Behav. 1992; 51(--):891-893. >>> Fluoromethylhistidine, a-; Saline; SC; rat; 2ML2; 13 days; controls received mp w/ vehicle; enzyme inhibitor; a-fluoromethylhistidine inhibits histamine synthesis.
P2168 Andersson,K., Chen,D., Hakanson,R., Mattsson,H., Sundler,F. Enterochromaffin-like cells in the rat stomach: effect of a-fluoromethylhistidine-evoked histamine depletion. Cell Tissue Res. 1992; 270(--):7-13. >>> Fluoromethylhistidine, a; Saline; SC; rat; 2ML1; 24 hours; enzyme inhibitor (histidine decarboxylase); pumps primed in saline at 37C for 4 hours.
P2067 Andersson,K., Hakanson,R., Mattsson,H., Ryberg,B., Sundler,F. Hyperplasia of histamine-depleted enterochromaffinlike cells in rat stomach using omeprazole and a-fluoromethylhistidine. Gastroenterology 1992; 103(--):897-904. >>> Fluoromethylhistidine, a-; Saline; SC; rat; 2ML1; 6 weeks; controls received mp w/ vehicle; pumps replaced every 6 days.
P0906 Bouclier,M., Jung,M.J., Gerhart,F. Effect of prolonged inhibition of histidine decarboxylase on tissue histamine concentrations. Experientia 1983; 39(-11-):1303-1305. >>> Fluoromethylhistidine, a-; Water; IP; rat; 2001; 21 days; controls were sham operated; pumps replaced every 7 days; comparison of ip injection vs. ip mp infusion.
P0789 Krishna,A., Terranova,P.F., Matteri,R.L., Papkoff,H. Histamine and increased ovarian blood flow mediate LH-induced superovulation in the cyclic hamster. J.Reprod.Fertil. 1986; 76(-1-):23-29. >>> Fluoromethylhistidine, a-; Luteinizing hormone; Albumin, bovine serum; PBS; SC; hamster; 2001; 5 days; Multiple pumps per animal (2) in some groups-one pump per agent; comparison of fluromethylhistidine or cimetidine injections vs. mp infusion; peptides; ovine LH used.
P0648 Lagunoff,D., Ray,A., Rickard,A. Effect on mast cell histamine of inhibiting histamine formation in vivo with a-fluoromethylhistidine. Biochem.Pharmacol. 1985; 34(-8-):1205-1209. >>> Fluoromethylhistidine, a-; Balanced salt solution; SC; rat; 2001; 2ML2; 6 or 14 days; comparison of single iv injec vs. mp infusion.
P0333 Bouclier,M., Jung,M.J., Gerhart,F. Histamine receptor blockade (H2) versus inhibition of histamine synthesis in stress ulceration in rats. Eur.J.Pharmacol. 1983; 90(--):129-132. >>> Fluoromethylhistidine, a-; IP; rat; 2001; 2 weeks; no comment posted.
61. Fluvastatin
P3443 Corsini,A., Bernini,F., Quarato,P., Donetti,E., Bellosta,S., Fumagalli,R., Paoletti,R., Soma,V.M.R. Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Cardiology 1996; 87(--):458-468. >>> Mevalonate; Fluvastatin; Saline, physiological; IP; perivascular (arterial collar); 5 days; tissue perfusion (lesion site-carotid collar); enzyme inhibitor (HMG-CoA reductase).
P3457 Soma,M.R., Parolini,C., Donetti,E., Fumagalli,R., Paoletti,R. Inhibition of isoprenoid biosynthesis and arterial smooth-muscle cell proliferation. J.Cardiovasc.Pharmacol. 1995; 25(-S 4-):S20-S24. >>> Mevalonate; Fluvastatin; IP; perivascular (arterial collar); rabbit; no duration posted; controls received mp w/ saline; tissue perfusion (carotid artery collar); cardiovascular; enzyme inhibitor (HMG-CoA reductase).
62. GC7
Q0172 Maier,B., Ogihara,T., Trace,A.P., Tersey,S.A., Robbins,R.D., Chakrabarti,S.K., Nunemaker,C.S., Stull,N.D., Taylor,C.A., Thompson,J.E., Dondero,R.S., Lewis,E.C., Dinarello,C.A., Nadler,J.L., Mirmira,R.G. The unique hypusine modification of eIF5A promotes islet beta cell inflammation and dysfunction in mice. Journal of Clinical Investigation 2010; 120(-6-):2156-2170. >>> GC7; Saline; SC; Mice; 8 days; Controls received mp w/ vehicle; enzyme inhibitor (deoxyhypusine synthase); animal info (male, C57BL/6J, NOD/SCID/Il2rg-null, 10 weeks old); comparison of IP injections vs. mp; endocrinology; agent also known as N1-guanyl-1,7-diaminoheptane.
63. GS4898
Q0183 Ren,B., Deng,Y., Mukhopadhyay,A., Lanahan,A.A., Zhuang,Z.W., Moodie,K.L., Mulligan-Kehoe,M.J., Byzova,T.V., Peterson,R.T., Simons,M. ERK1/2-Akt1 crosstalk regulates arteriogenesis in mice and zebrafish. Journal of Clinical Investigation 2010; 120(-4-):1217-1228. >>> GS4898; Saline; DMSO; IP; Mice; 1002; 3, 7-14 days; Controls received mp w/ vehicle; cardiovascular; enzyme inhibitor (PI3 kinase); animal info (wt, Synectin -/-, 8-10 weeks old; Ldlr-/- ApoB48-modified, 24 weeks old); ischemia (hindlimb).
64. H7
P9653 Miyamoto,N., Tanaka,R., Zhang,N., Shimura,H., Onodera,M., Mochizuki,H., Hattori,N., Urabe,T. CRUCIAL ROLE FOR Ser133-PHOSPHORYLATED FORM OF CYCLIC AMP-RESPONSIVE ELEMENT BINDING PROTEIN SIGNALING IN THE DIFFERENTIATION AND SURVIVAL OF NEURAL PROGENITORS UNDER CHRONIC CEREBRAL HYPOPERFUSION. Neuroscience 2009; 162(-2-):525-536. >>> H7; Saline; CSF/CNS; Rat; 1002; 7 days; Controls received mp w/vehicle; animal info (adult, male, wistar, 9 wks, 250-270); H7 is a novel PKA/PKC inhibitor; ALZET brain infusion kit used.
P5245 Tokuyama,S., Ho,I.K., Yamamoto,T. A protein kinase inhibitor, H-7, blocks naloxone-precipitated changes in dopamine and its metabolites in the brains of opioid-dependent rats. Brain Res Bull. 2000/7/15; 52(-5-):363-369. >>> Morphine; Butorphanol; H7; Saline; CSF/CNS; Rat; 2001; 3 days; Controls received mp w/ vehicle; enzyme inhibitor; dependence; H7 is a protein kinase C inhibitor; tygon tubing used; one week recovery period; guide cannula with stylet used to ensure patency; concomitant infusion of H7 and opioids performed by mixing agents in the same pump.
P4172 Tokuyama,S., Zhu,H., Wakabayashi,H., Feng,Y.Z., Ho,I.K. The role of glutamate in the locus coeruleus during opioid withdrawal and effects of H-7, a protein kinase inhibitor, on the action of glutamate in rats. J.Biomed.Sci. 1998; 5(--):45-53. >>> Morphine; butorphanol; H7; Saline; CSF/CNS; rat; 2001; 3 days; controls received mp w/vehicle; cannula placement verified by presence of CSF; stylets were placed in guide cannula to maintain patency; one week recovery period; agents infused singly or concomitantly; dependence.
P3332 Tokuyama,S., Feng,Y., Wakabayashi,H., Ho,I.K. Possible involvement of protein kinases in physical dependence on opioids: studies using protein kinase inhibitors, H-7 and H-8. Eur.J.Pharmacol. 1995; 284(--):101-107. >>> Morphine HCl; Butorphanol tartrate; H7; H8; CSF/CNS; rat; 2001; 3 days; controls received mp w/saline; dependence; stylet maintained cannula patency during 1 week recovery period; opioid&H7 or H8 given concomitantly.
P2981 Felipo,V., Minana,M.-D., Cabedo,H., Perez-Minguez,F., Llombart-Bosch,A., Grisolia,S. H7, an inhibitor of protein kinase C, inhibits tumour cell division in mice bearing ascitic Ehrlich's carcinoma. Eur.J.Cancer 1994; 30A(-4-):525-527. >>> H7; DMSO; Water; SC; mice; 2002; no duration posted; comparison of ip injections vs. mp; stability verified earlier up to 24 hours in vivo at 37 degrees C; enzyme inhibitor; half-life of H7 in sciatic nerve of diabetic mice is about 1 hour; cancer.
P2769 Narita,M., Feng,Y., Makimura,M., Hoskins,B., Ho,I.K. A protein kinase inhibitor, h-7, inhibits the development of tolerance to opioid antinociception. Eur.J.Pharmacol. 1994; 271(--):543-545. >>> Morphine; Butorphanol; H7; Saline; CSF/CNS; rat; 2001; 3 days; controls received mp w/saline; tolerance; enzyme inhibitor; H7 administered alone or concomitantly w/morphine and butorphanol in the same pump; one week recovery allowed after icv surgery.
P2315 Hermenegildo,C., Felipo,V., Minana,M.-D., Romero,F.J., Grisolia,S. Sustained recovery of Na+-K+-ATPase activity in sciatic nerve of diabetic mice by administration of H7 or calphostin C, inhibitors of PKC. Diabetes 1993; 42(--):257-262. >>> H7; Calphostin C; DMSO; Water; SC; mice; 3,7,10 or 14 days; controls were nondiabetic mice and untreated diabetic mice; comparison of bolus ip injections vs. mp; no stress (see pg. 259,260); enzyme inhibitor; calphostin C and H7 are PKC inhibitors; "treatment [w/ mp] did not produce any untoward effect nor affect the blood glucose levels." (pg. 260); H7 is unstable after 4 hours; Calphostin C is stable for 2 weeks.
65. H89
Q0627 Miyamoto,N., Tanaka,R., Shimosawa,T., Yatomi,Y., Fujita,T., Hattori,N., Urabe,T. Protein kinase A-dependent suppression of reactive oxygen species in transient focal ischemia in adrenomedullin-deficient mice. Journal of Cerebral Blood Flow and Metabolism 2009; 29(-11-):1769-1779. >>> H89; CSF/CNS; Mice; 1002; 8 days; Controls received mp w/ saline; animal info (8 wks old, male, AM+/-, C57BL/6 Wt); enzyme inhibitor (PKA, protein kinase A); middle cerebral artery occlusion (MCAO).
P9278 Nasr,R., Guillemin,M.C., Ferhi,O., Soilihi,H., Peres,L., Berthier,C., Rousselot,P., Robledo-Sarmiento,M., Lallemand-Breitenbach,V., Gourmel,B., Vitoux,D., Pandolfi,P.P., Rochette-Egly,C., Zhu,J., The,H. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nature Medicine 2008; 14(-12-):1333-1342. >>> Bortezomib; cyclic AMP; H89; SC; Mice (nude); mice (transgenic); 1, 3, 6, 7 days; Controls received no treatment; enzyme inhibitor (PKA); cancer (acute promyelocytic leukemia); animal info (nude, PLZF-RARA-RARA-PLZF; PML-RARA5873A Tg); Bortezomib is a proteasome inhibitor.
P5269 Qiu,J., Cai,D., Dai,H., McAtee,M., Hoffman,P.N., Bregman,B.S., Filbin,M.T. Spinal axon regeneration induced by elevation of cyclic AMP. Neuron 2002/6/13; 34(-6-):895-903. >>> H89; Saline; CSF/CNS (intrathecal); Rat; 1 week; Controls received mp w/ vehicle; 1 week stability verified (results not shown); enzyme inhibitor; H89 is a protein kinase A inhibitor.
66. HA-1004
P9333 Almela,P., Milanes,M.V., Laorden,M.L. Tyrosine hydroxylase phosphorylation after naloxone-induced morphine withdrawal in the left ventricle. Basic Research In Cardiology 2009; 104(-4-):366-376. >>> HA-1004; Water, sterile; SC; Rat; 2001; 7 days; Controls received mp w/ vehicle; enzyme inhibitor (protein kinase); dependence; animal info (male, Sprague Dawley, 220-240 g.); HA-1004 is a protein kinase selective inhibitor; pumps primed for 5 hours.
P9085 Almela,P., Milanes,M.V., Laorden,M.L. The PKs PKA and ERK 1/2 are involved in phosphorylation of TH at Serine 40 and 31 during morphine withdrawal in rat hearts. British Journal of Pharmacology 2008; 155(-1-):73-83. >>> HA-1004; calphostin C; DMSO; water; SC; Rat; 2001; 7 days; Controls received mp w/ vehicle; animal info (male, Sprague Dawley, 220-240 g.); enzyme inhibitor (protein kinase C, protein kinase A); pumps were primed for 5 hours prior to implantation.
P8249 Almela,P., Cerezo,M., Gonzalez-Cuello,A., Milanes,M.V., Laorden,M.L. Differential involvement of 3', 5'-cyclic adenosine monophosphate-dependent protein kinase in regulation of Fos and tyrosine hydroxylase expression in the heart after naloxone induced morphine withdrawal. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY 2007; 374(-4-):293-303. >>> HA-1004; Water, sterile; SC; Rat; 2001; 7 days; Controls received mp w/ vehicle; enzyme inhibitor (protein kinase A); cardiovascular; tolerance; dependence; animal info (male, Sprague-Dawley, 220-240g).
P6875 Benavides,M., Laorden,M.L., Milanes,M.V. Involvement of 3',5';-cyclic adenosine monophosphate-dependent protein kinase in regulation of Fos expression and tyrosine hydroxylase levels during morphine withdrawal in the hypothalamic paraventricular nucleus and medulla oblongata catecholaminergic cell groups. Journal of Neurochemistry 2005; 92(-2-):246-254. >>> HA-1004; Water, sterile; SC; Rat; 2001; 7 days; Controls received mp w/ vehicle; no stress (see pg. 249); enzyme inhibitor (cAMP-dependent protein kinase A); dependence.
P5457 Cerezo,M., Laorden,A.L., Milanes,A.V. Inhibition of protein kinase C but not protein kinase A attenuates morphine withdrawal excitation of rat hypothalamus-pituitary-adrenal axis. European Journal of Pharmacology 2002; 452(-1-):57-66. >>> HA-1004; calphostin C; Water, sterile; DMSO; SC; Rat; 2001; 7 days; Controls received mp w/ vehicle; enzyme inhibitor (protein kinase A, protein kinase C).
67. HOE 140
Q0374 Azurmendi,P.J., Oddo,E.M., Obika,L.F., Corbera,N.L., Martin,R.S., Ibarra,F.R., Arrizurieta,E.E. Gonadectomy Influences Blood Pressure through the Kallikrein-Kinin System. KIDNEY&BLOOD PRESSURE RESEARCH 2009; 32(-5-):342-348. >>> Aprotinin; HOE-140; SC; Rat; 3 days; Animal info (Wistar, male, female, 150 days old).
P9797 Phipps,J.A., Clermont,A.C., Sinha,S., Chilcote,T.J., Bursell,S.E., Feener,E.P. Plasma Kallikrein Mediates Angiotensin II Type 1 Receptor-Stimulated Retinal Vascular Permeability. Hypertension 2009; 53(-2-):175-U127. >>> Angiotensin II; Hoe 140; PBS; polyethylene glycol; saline; SC; Rat; 8 weeks; 1, 3, 6 days; Controls received mp w/ vehicle; peptides; animal info (8 wks old, male, Sprague Dawley, diabetes mellitus).
P7708 Gohlke,P., Linz,W., Scholkens,B.A., Kuwer,I., Bartenbach,S., Schnell,A., Unger,T. Angiotensin-converting enzyme inhibition improves cardiac function. Role of bradykinin. Hypertension 1994/4; 23(-4-):411-418. >>> Hoe 140; Saline, physiological; SC; Rat; 14 weeks; Controls received mp w/ vehicle; long-term study; pumps replaced every 2 weeks; cardiovascular; animal info (SHR, stroke prone, 6 weeks old, male).
P6558 Aartsen,W.M., Hilgers,R.H.P., Schiffers,P.M.H., Daemen,M.J.A.P., De Mey,J.G.R., Smits,J.F.M. Changes in vascular distensibility during angiotensin-converting enzyme inhibition involve bradykinin type 2 receptors. JOURNAL OF VASCULAR RESEARCH 2004; 41(-1-):18-27. >>> Hoe 140; Saline; SC; Mice; 2002; 14 days; No stress (see pg.20); cardiovascular.
P6544 Buffin-Meyer,B., Younes-Ibrahim,M., El Mernissi,G., Cheval,L., Marsy,S., Grima,M., Girolami,J.P., Doucet,A. Differential regulation of collecting duct Na+,K+-ATPase and K+ excretion by furosemide and piretanide: Role of bradykinin. Journal of the American Society of Nephrology 2004; 15(-4-):876-884. >>> Furosemide; dexmethasone; diretanide; aldosterone; Hoe 140; Saline; SC; IP; Rat; 6 days; Controls received mp w/ vehicle; replacement therapy (adrenalectomy); solution was a pH 9.0; a third group was adrenalectomized and given dexamethasone and aldosterone by a SC ALZET pump; in a fifth set of experiments Hoe140 was infused SC.
P6425 Duguay,D., Der Sarkissian,S., Kouz,R., Ongali,B., Couture,R., deBlois,D. Kinin B2 receptor is not involved in enalapril-induced apoptosis and regression of hypertrophy in spontaneously hypertensive rat aorta: possible role of B1 receptor. British Journal of Pharmacology 2004; 141(-4-):728-736. >>> Hoe 140; enalpril; Saline; SC; Rat; 2ML4; 4 weeks; Controls received mp w/ vehicle; blood pressure taken.
P6404 Jover,B., Stuit,L., Mimran,A. Systemic and renal effect of chronic omapatrilat in sodium-restricted, one-kidney, one-clip hypertensive rats. Journal of Hypertension 2004; 22(-2-):383-388. >>> Hoe 140; SC; Rat; 2001; 1 week; Cardiovascular; antihypertensive; Hoe140 is a bradykinin B2-receptor antagonist.
P5899 Kurisu,S., Ozono,R., Oshima,T., Kambe,M., Ishida,T., Sugino,H., Matsuura,H., Chayama,K., Teranishi,Y., Iba,O., Amano,K., Matsubara,H. Cardiac angiotensin II type 2 receptor activates the kinin/NO system and inhibits fibrosis. Hypertension 2003; 41(-1-):99-107. >>> Angiotensin II; HOE 140; L-NAME; Saline; SC; Mice (transgenic); 2002; 14 days; Controls received mp w/ vehicle; enzyme inhibitor (no); cardiovascular; HOE140 is a bradykinin B2 receptor antagonist; L-NAME is a nitric oxide synthase inhibitor; table on p. 101 for weights, blood pressure, heart rate, etc..
P5875 Shiuchi,T., Cui,T.X., Wu,L., Nakagami,H., Takeda-Matsubara,Y., Iwai,M., Horiuchi,M. ACE inhibitor improves insulin resistance in diabetic mouse via bradykinin and NO. Hypertension 2002; 40(-3-):329-334. >>> Hoe 140; IP; Mice; 1002; 14 days; Hoe140 is a bradykinin B2 receptor antagonist.
P5721 Yamaguchi-Sase,S., Hayashi,I., Okamoto,H., Nara,Y., Matsuzaki,S., Hoka,S., Majima,M. Amelioration of hyperalgesia by kinin receptor antagonists or kininogen deficiency in chronic constriction nerve injury in rats. INFLAMMATION RESEARCH 2003; 52(-4-):164-169. >>> Hoe 140; bradykinin, des-Arg9-Leu8-; Saline; SC; Rat; 2001; 7 days; Controls received mp w/ vehicle; Kinin B, and B2 receptor antagonists.
P5674 Tschope,C., Seidl,U., Reinecke,A., Riester,U., Graf,K., Schultheiss,H.P., Hilgenfeldt,U., Unger,T. Kinins are involved in the antiproteinuric effect of angiotensin-converting enzyme inhibition in experimental diabetic nephropathy. INTERNATIONAL IMMUNOPHARMACOLOGY 2003; 3(-3-):335-344. >>> Hoe 140; Ramipril; SC; Rat; 2002; 14 days; Antihypertensive; Hoe 140 is a B2-receptor antagonist also called icatibant; agents infused together in same pump in some animals..
P5105 Murakami,H, Yayama,K, Miao,R.Q., Wang,C, Chao,L, Chao,J. Kallikrein gene delivery inhibits vascular smooth muscle cell growth and neointima formation in the rat artery after balloon angioplasty. Hypertension 1999; 34(--):164-170. >>> Hoe 140; IP; rat; 2002; 2ML2; up to 14 days; cardiovascular; Hoe 140 is icatibant, a specific bradykinin B2 receptor antagonist; first experiment used 2ML2 pumps, second used 2002 pumps.
P5013 Rouleau,J.L., Kapuku,G., Pelletier,S., Gosselin,H., Adam,A., Gagnon,C., Lambert,C., Meloche,S. Cardioprotective effects of ramipril and losartan in right ventricular pressure overload in the rabbit - Importance of kinins and influence on angiotensin II type 1 receptor signaling pathway. Circulation 2001; 104(--):939-944. >>> Bradykinin, Lys-Leu8-des-Arg9; HOE 140;; SC; rabbit; 20 days; cardiovascular; Lys-(leu8)desArg bradykinin is a bradykinin B1 receptor blocker, HOE 140 is a bradykinin B2 receptor blocker.
P4977 Nakamura,Y., Ono,H., Zhou,X.Y., Frohlich,E.D. Angiotensin type 1 receptor antagonism and ACE inhibition produce similar renoprotection in N-omega-nitro-L-arginine methyl ester/spontaneously hypertensive rats. Hypertension 2001; 37(--):1262-1267. >>> Hoe 140; SC; rat; 2ML4; 3 weeks; antihypertensive; Hoe 140 is an Icatibant agent (bradykinin receptor antagonist); 9 groups, mp used only in 1 group; bradykinin antagonist;.
P4927 Gorlach,C., Hortobagyi,T., Hortobagyi,S., Benyo,Z., Relton,J., Whalley,E.T., Wahl,M. Bradykinin B-2, but not B-1, receptor antagonism has a neuroprotective effect after brain injury. Journal of Neurotrauma 2001; 18(-8-):833-838. >>> Hoe 140; B9858; Saline; SC; rat; mice; 2001D; 24 hours; controls received mp w/ vehicle; peptides; agents given in separate pumps to prevent interaction of the drugs; 2 pmps per animal;.
P4625 Kim,S., Zhan,Y., Izumi,Y, Yasumoto,H, Yano,M., Iwao,H. In vivo activation of rat aortic platelet-derived growth factor and epidermal growth factor receptors by angiontensin II and hypertension.. Arterioscler.Thromb.Vasc.Biol. 2000; 20(--):2539-2545. >>> Hoe 140;; Saline;; SC;; rat;; 4 weeks;; Controls received mp w/ vehicle; antihypertensive; cardiovascular;.
P4503 Mukai,H, Fitzgibbon,W.R, Ploth,D.W, Margolius,H.S. Effect of chronic bradykinin B2 receptor blockade on blood pressure of conscious Dahl salt-resistant rats.. British Journal of Pharmacology 1998; 124(--):197-205. >>> Hoe 140;; NaCl;; SC;; rat;; 2001; 2002;; 1, 3 weeks;; controls received mp w/vehicle; pump replaced after one week; cardiovascular;.
P4470 Hirawa,N., Uehara,Y., Suzuki,T, Kawabata,Y., Numabe,A., Gomi,T., Ikeda,T., Kizuki,K., Omata,M. Regression of glomerular injury by kallikrein infusion in Dahl salt-sensitive rats is a bradykinin B2-receptor-mediated event.. Nephron 1999; 81(--):183-193. >>> Hoe 140; Kallikrein;; Saline;; IV (jugular);; rat;; 2002;; 4 weeks;; controls received mp w/vehicle; functionality of mp verified by plasma levels; pumps replaced every 2 weeks; rat urinary kallikrein used; kallikrein infused IV and Hoe 140 infused SC;.
P4455 MacLaughlin,M, Monserrat,A.J, Muller,A, Matoso,M, Amorena,C. Role of kinins in the renoprotective effect of angiotensin-converting enzyme inhibitors in experimental chronic renal failure. Kidney Blood Press Res. 1998; 21(--):329-334. >>> Hoe 140; Saline, physiological;; SC;; rat;; 2002;; 14 weeks;; controls received mp w/vehicle; functionality of mp verified by plasma levels; long-term study, pumps replaced every other week;.
P4015 Demeilliers,B., Jover,B., Mimran,A. Contrasting renal effects of chronic administrations of enalapril and losartan on one-kidney, one clip hypertensive rats. J.Hypertens. 1998; 16(--):1023-1029. >>> Hoe 140; SC; rat; 2001; no duration posted; no comment posted.
P4010 Rumble,J.R., Komers,R., Cooper,M.E. Kinins or nitric oxide, or both, are involved in the antitrophic effects of angiotensin converting enzyme inhibitors on diabetes-associated mesenteric vascular hypertrophy in the rat. J.Hypertens. 1996; 14(--):601-607. >>> Hoe 140; SC; rat; 2002; no duration posted; comparison of sc injections vs. mp; bradykinin receptor antagonist.
P3826 Kohzuki,M., Kanazawa,M., Liu,P.F., Kamimoto,M., Yoshida,K., Saito,T., Yasujima,M., Sato,T., Abe,K. Kinin and angiontensin II receptor antagonists in rats with chronic renal failure: chronic effects on cardio- and renoprotection of angiotensin converting enzyme inhibitors. J.Hypertens. 1995; 13(--):1785-1790. >>> Hoe 140; IP; rat; 2002; 4 weeks; controls received cilazapril; comparison of ip injections vs mp; antihypertensive; cardiovascular.
P3724 Blais,C.Jr, Couture,R., Drapeau,G., Colman,R.W., Adam,A. Involvement of endogenous kinins in the pathogenesis of peptidoglycan-induced arthritis in the lewis rat. Arthritis Rheum. 1997; 40(-7-):1327-1333. >>> Hoe 140; Bradykinin, Lys-Leu8-des-Arg9; Saline, sterile; SC; rat; 1007D; 6 days; controls received mp w/ vehicle; peptides; agents administered singly and in combination.
P3687 Tomiyama,H., Kushiro,T., Abeta,H., Ishii,T., Takahashi,A., Furukawa,L., Asagami,T., Hino,T., Saito,F., Otsuka,Y., Kurumatani,H., Kobayashi,F., Kanmatsuse,K., Kajiwara,N. Kinins contribute to the improvement of insulin sensitivity during treatment with angiotensin converting enzyme inhibitor. Hypertension 1994; 23(--):450-455. >>> Hoe 140; Bradykinin; Saline, normal; SC; IV (inferior vena cava); rat; 2002; 2 weeks, 13 days; controls received mp w/ normal saline; first agent is a kinin antagonist; several pump experiments conducted; PE-10 tubing used for IV infusion.
P3536 Gohlke,P., Kuwer,I., Schnell,A., Mall,G., Unger,T. Blockade of bradykinin b2 receptors prevents the increase in capillary density induced by chronic angiotensin-converting enzyme inhibitor treatment in stroke-prone spontaneously hypertensive rats. Hypertension 1997; 29(-2-):478-482. >>> Hoe 140; Saline; SC; rat; 14 weeks; controls received mp w/ saline; long-term study, pumps replaced every 2 weeks; cardiovascular; Hoe 140 is icatibant.
P3374 Madeddu,P., Anania,V., Parpaglia,P.P., Demontis,M.P., Varoni,M.V., Fattaccio,M.C., Glorioso,N. Chronic kinin receptor blockade induces hypertension in deoxycorticosterone-treated rats. Br.J.Pharmacol. 1993; 108(--):651-657. >>> Hoe 140; Saline, physiological; SC; rat; 2ML4; 6 weeks; controls received mp w/saline; long-term study, pumps replaced after 28 days; agent bradykinin antagonist; author states, "...osmotic pump implantation might have amplified the functional importance of B1 receptors&stimulated the generation of T-kinin" (p. 655) but concludes that this is unlikely.
P3355 Jover,B., Herizi,A., Mimran,A. Chronic kinin blockade and effect of ramipril in renal adaptation to sodium restriction. Hypertension 1996; 27(--):79-84. >>> Hoe 140; Dextrose solution; SC; rat; 9 days; controls received mp w/vehicle.
P3324 Yosipiv,I.V., El-Dahr,S.S. Developmental regulation of ACE gene expression by endogenous kinins and angiotensin II. Am.J.Physiol.(Renal Fluid Electrolyte Physiol.38) 1995; 269(--):F172-F179. >>> Aprotinin; Hoe 140; Losartan; SC; rat; 5,7 days; controls received mp w/saline.
P3272 Madeddu,P., Parpaglia,P.P., Demontis,M.P., Varoni,M.V., Fattaccio,M.C., Glorioso,N. Chronic inhibition of bradykinin b2-receptors enhances the slow vasopressor response to angiotensin II. Hypertension 1994; 23(--):646-652. >>> Angiotensin II; Hoe 140; IP; rat; 4 weeks; controls received mp w/saline; stability verified by injection of AII-pump infusate; peptides; agents given singly or together.
P3269 Majima,M., Mizogami,S., Kuribayashi,Y., Katori,M., Oh-ishi,S. Hypertension induced by a nonpressor dose of angiotensin II in kininogen-deficient rats. Hypertension 1994; 24(--):111-119. >>> Angiotensin II; Kininogen, bovine; Hoe 140; Saline; SC; rat; 2001; 2002; 2 weeks, 7 days; controls received mp w/saline; peptides; low molecular weight kininogen used.
P3268 Majima,M., Yoshida,O., Mihara,H., Muto,T., Mizogami,S., Kuribayashi,Y., Katorim,M., Oh-ishi,S. High sensitivity to salt in kininogen-deficient brown Norway Katholiek rats. Hypertension 1993; 22(--):705-714. >>> Kininogen, bovine; Hoe 140; Aprotinin; Saline; SC; rat; 2001; 7 days; controls received mp w/saline.
P2929 Rudichenko,V.M., Carretero,O.A., Beierwaltes,W.H. Neither endogenous nor exogenous bradykinin stimulates aldosterone in vivo. Endocrinology 1993; 133(-6-):2469-2473. >>> Hoe 140; SC; rat; 1007D; 7 days; controls received mp with saline.
P2889 Madeddu,P., Parpaglia,P.P., Demontis,M.P., Varoni,M.V., Fattaccio,M.C., Anania,V., Glorioso,N. Early blockade of bradykinin B2-receptors alters the adult cardiovascular phenotype in rats. Hypertension 1995; 25(--):453-459. >>> Hoe 140; Saline, physiological; IP; rat; rat (pregnant); 8 weeks; controls received mp with vehicle; long-term study, pumps replaced.
P2888 Madeddu,P., Parpaglia,P.P., Demontis,M.P., Varoni,M.V., Fattaccio,M.C., Anania,V., Glorioso,N. Effects of kinin blockade on the blood pressure of salt-loaded pregnant rats. Hypertension 1995; 25(-part2-):823-827. >>> Hoe 140; IP; rat (pregnant); rat; no duration posted; controls received mp with vehicle; teratology.
P2761 Madeddu,P., Glorioso,N., Varoni,M.V., Demontis,M.P., Fattaccio,M.C., Anania,V. Cardiovascular effects of brain kinin receptor blockade in spontaneously hypertensive rats. Hypertension 1994; 23(-1-):I189-I192. >>> Hoe 140; CSF, artificial; CSF/CNS; rat; 2002; 2 weeks; infusion started 5 days after cannula placement.
P2760 Madeddu,P., Parpaglia,P.P., Demontis,M.P., Varoni,M.V., Fattaccio,M.C., Tonolo,G., Troffa,G., Glorioso,N. Bradykinin B2-receptor blockade facilitates deoxycorticosterone-salt hypertension. Hypertension 1993; 21(--):980-984. >>> Hoe 140; Saline; SC; rat; 2ML4; 4 weeks; no comment posted.
P2759 Cachofeiro,V., Maeso,R., Rodrigo,E., Navarro,J., Ruilope,L.M., Lahera,V. Nitric oxide and prostaglandins in the prolonged effects of losartan and ramipril in hypertension. Hypertension 1995; 26(--):236-243. >>> Hoe 140; SC; rat; 1 week; enzyme inhibitor.
P2744 da Silva,V.J.D., da Silva,S.V., Salgado,M.C.O., Salgado,H.C. Chronic converting enzyme inhibition facilitates baroreceptor resetting to hypertensive levels. Hypertension 1994; 23(-1 Supp-):I68-I72. >>> Enalapril; Hoe 140; SC; rat; 2001; 7 days; comparison of oral dosing vs. mp; enzyme inhibitor; enalapril is an antihypertensive.
P2729 Gohlke,P., Lamberty,V., Kuwer,I., Bartenbach,S., Schnell,A., Linz,W., Scholkens,B.A., Wiemer,G., Unger,T. Long-term low-dose angiotensin converting enzyme inhibitor treatment increases vascular cyclic guanosine 3',5'-monophosphate. Hypertension 1993; 22(-5-):682-687. >>> Hoe 140; Sodium chloride; SC; rat; 14 weeks; controls received mp w/ vehicle; long-term study, pumps replaced every 2 weeks.
P2175 Bao,G., Gohlke,P., Unger,T. Role of bradykinin in chronic antihypertensive actions of ramipril in different hypertension models. J.Cardiovasc.Pharmacol. 1992; 20(-9-):S96-S99. >>> Hoe 140; Saline; SC; rat; 2002; 6 weeks; long-term study, pumps replaced every 2 weeks; hoe 140 is a bradykinin antagonist; concomitant oral administration of ramipril.
P2174 Bao,G., Gohlke,P., Qadri,F., Unger,T. Chronic kinin receptor blockade attenuates the antihypertensive effect of ramipril. Hypertension 1992; 20(--):74-79. >>> Hoe 140; Saline; SC; rat; 2002; 6 weeks; controls received mp w/saline; long-term study, pumps replaced every 2 weeks; oral ace-inhibitor ramipril administered concomitantly.
68. Hirudin
P7249 Lay,A.J., Liang,Z., Rosen,E.D., Castellino,F.J. Mice with a severe deficiency in protein C display prothrombotic and proinflammatory phenotypes and compromised maternal reproductive capabilities. Journal of Clinical Investigation 2005; 115(-6-):1552-1561. >>> Hirudin; IP; Mice (transgenic); 3 days; Controls received mp w/ saline; no stress (see pg. 1555); enzyme inhibitor (thrombin); cardiovascular; immunology.
P7220 Iwaki,T., Cruz,D.T., Martin,J.A., Castellino,F.J. A cardioprotective role for the endothelial protein C receptor in lipopolysaccharide-induced endotoxemia in the mouse. Blood 2005; 105(-6-):2364-2371. >>> Endotoxin, LPS; hirudin; Saline, isotonic; IP; Mice; 1003D; 24-72 hours; Controls received mp w/ vehicle; cardiovascular; "In order to mimic the conditions of endotoxin shock more closely than the usual bolus LPS injection methods, we used a continual intraperitoneal exposure model in mice with t.
P6815 Wang,J., Zheng,H., Ou,X., Albertson,C.M., Fink,L.M., Herbert,J.M., Hauer-Jensen,M. Hirudin ameliorates intestinal radiation toxicity in the rat: support for thrombin inhibition as strategy to minimize side-effects after radiation therapy and as countermeasure against radiation exposure. JOURNAL OF THROMBOSIS AND HAEMOSTASIS 2004; 2(-11-):2027-2035. >>> Hirudin; Saline; IP; Rat; 2ML2; 16 days; Controls received mp w/ vehicle; enzyme inhibitor thrombin; cancer (abdominal, pelvic); toxicology; scrotal hernia created via orchiectomy w/ a loop of ileum sutured to inside of scrotum.
P6789 Mhatre,M., Nguyen,A., Kashani,S., Pham,T., Adesina,A., Grammas,P. Thrombin, a mediator of neurotoxicity and memory impairment. NEUROBIOLOGY OF AGING 2004; 25(-6-):783-793. >>> Thrombin; hirudin; Saline; BSA; CSF/CNS; Rat; 2004; 28 days; Controls received mp w/ vehicle; dose-response (fig 1); no stress (see pg. 784); "Administration of thrombin and hirudin alone or simultaneously was well tolerated by the rats." (p. 784); neurodegenerative (Alzheimer's disease); "hirudin has a relatively short half-life (60-90) minutes, therefore it was administered by continuous ICV infusion." (p. 784.).
P4419 Gerdes,C, Faber-Steinfeld,V, Yalkinoglu,Ö, Wohlfeil,S. Comparison of the effects of the thrombin inhibitor r-hirudin in four animal models of neointima formation after arterial injury. Arterioscler.Thromb.Vasc.Biol. 1996/10; 16(--):1306-1311. >>> Hirudin, r-;; Saline, sterile;; IV (jugular);; rat;; 2ML2; 3, 14 days;; controls received mp w/vehicle; comparision of SC injetions vs. mp; cardiovascular; arterial injury; thrombin inhibitor.
P3662 Hadoke,P.W.F., Wadsworth,R.M., Wainwright,C.L., Butler,K.D., Giddings,M.J. Subcutaneous infusion of r-hirudin does not inhibit neointimal proliferation after angioplasty of the subclavian artery in cholesterol-fed rabbits. Coronary Artery Disease 1996; 7(--):599-608. >>> Hirudin, r-; Mannitol; SC; rabbit; 2ML4; 2001D; 28 days; controls received no drug; cardiovascular; animals received 1-2 pumps each.
P3651 Rodgers,K.E., Girgis,W., Campeau,J.D., diZerega,G.S. Reduction of adhesion formation by intraperitoneal administration of a recombinant hirudin analog. J.Invest.Surgery 1996; 9(--):385-391. >>> Hirudin, recomb. analog; injury site; rabbit; 2ML1; 7 days; controls received mp w/ PBS; tissue perfusion (injury site); immunology; peptides; rabbits were given IM morphine for postoperative pain; wound healing.
P3199 Hampl,V., Archer,S.L., Bach,R., Nelson,D.P., Weir,E.K. Chronic hypoxic pulmonary hypertension: is thrombin involved?. Am.Rev.Respir.Dis. 1993; 148(--):1043-1048. >>> Hirudin, recomb.; Saline; IV (jugular); rat; 2ML4; 24 days; controls received mp with saline; no stress (see pg. 1044) no inflammation; immunology; hirudin is CGP-39393, and it is a thrombin inhibitor.
69. Huperzine
P5528 Lallement,G., Demoncheaux,J.P., Foquin,A., Baubichon,D., Galonnier,M., Clarencon,D., Dorandeu,F. Subchronic administration of pyridostigmine or huperzine to primates: Compared efficacy against soman toxicity. Drug and Chemical Toxicology 2002; 25(-3-):309-320. >>> Pyridostigmine; huperzine; SC; Monkey; 2ML1; 6 days; Enzyme inhibitor (acetylcholinesterase); toxicology.
P5187 Filliat,P., Foquin,A., Lallement,G. Effects of chronic administration of huperzine A on memory in guinea pigs. Drug and Chemical Toxicology 2002; 25(-1-):9-24. >>> Huperzine A; Saline; HCl; SC; Guinea-pig; 2001; 6 days; Toxicology; enzyme inhibitor; huperzine is an alkaloid, reversible Acetylcholinesterase (AChE) inhibitor; neurodegenerative (Alzheimer's disease).
P4806 Lallement,G., Foquin,A., Dorandeu,F., Baubichon,D., Carpentier,P. Subchronic administration of various pretreatments of nerve agent poisoning. II. Compared efficacy against soman toxicity. Drug and Chemical Toxicology 2001; 24(-2-):165-180. >>> Pyridostigmine; Huperzine; Physostigmine; Scopolamine;; SC;; guinea-pig;; 6 days;; Controls received sham operation; enzyme inhibitor; these are poisons known to be acetylcholinesterase inhibitors; doses inhibited 30% of AChE activity; Physostigmine was infused alone or together with Scopolamine; toxicology.
70. IDN 1965
P6808 Engel,D., Peshock,R., Armstong,R.C., Sivasubramanian,N., Mann,D.L. Cardiac myocyte apoptosis provokes adverse cardiac remodeling in transgenic mice with targeted TNF overexpression. American Journal of Physiology-Heart and Circulatory Physiology 2004; 287(-3-):H1303-H1311. >>> IDN 1965; DMSO; IP; Mice; 1002; 28 days; Controls received mp w/ vehicle; pumps replaced at day 14; enzyme inhibitor (caspase); cardiovascular; MRI; 50% DMSO; MRI performed at day 2 and day 28.
P6457 Hayakawa,Y., Chandra,M., Miao,W.F., Shirani,J., Brown,J.H., Dorn,GW II, Armstrong,R.C., Kitsis,R.N. Inhibition of cardiac myocyte apoptosis improves cardiac function and abolishes mortality in the peripartum cardiomyopathy of G alpha q transgenic mice. Circulation 2003; 108(-24-):3036-3041. >>> IDN-1965; DMSO; SC; Mice (pregnant); mice (transgenic); 1002; 25 days; Controls received mp w/ vehicle; pumps replaced after 14 days; enzyme inhibitor (polycaspase); cardiovascular; teratology; 50% DMSO; "Continuous subcutaneous delivery of this potent polycaspase inhibitor is sufficient to suppress effector caspase activity" (p.3037).
P5615 Wencker,D., Chandra,M., Nguyen,K., Miao,W.F., Garantziotis,S., Factor,S.M., Shirani,J., Armstrong,R.C., Kitsis,R.N. A mechanistic role for cardiac myocyte apoptosis in heart failure. Journal of Clinical Investigation 2003; 111(-10-):1497-1504. >>> IDN-1965; DMSO; Water; IP; mice; 4 weeks; controls received mp w/ vehicle; comparison of ip injections vs. mp; vehicle combination was 50% DMSO, 50% water; IDN-1965 is a caspase inhibitor; liver injury; 24 hour recovery period after surgery; "continuous administration of IDN-1965 via an osmotic minipump (a delivery equaling .36 mg/kg/h), however, was extremely effective in reducing liver injury..." p. 817;.
71. Imantinib Mesylate
Q0111 Demestre,M., Herzberg,J., Holtkamp,N., Hagel,C., Reuss,D., Friedrich,R.E., Kluwe,L., Von Deimling,A., Mautner,V.F., Kurtz,A. Imatinib mesylate (Glivec) inhibits Schwann cell viability and reduces the size of human plexiform neurofibroma in a xenograft model. Journal of Neuro-oncology 2010; 98(-1-):11-19. >>> Imatinib mesylate; PBS; SC; Mice (nude); 2004; 28 days; Controls received mp w/ vehicle; cancer (Plexiform neurofibromas); enzyme inhibitor (receptor tyrosine kinase); stress/adverse reaction: (see pg 13) "because of inflammation at the ALZET pump site, four mice of the treatment group had to be discontinued"; animal info (female, athymic nu/nu Balb/c); agent also known as Glivec or Gleevec.
P8330 Raafat,A., Zoltan-Jones,A., Strizzi,L., Bargo,S., Kimura,K., Salomon,D., Callahan,R. Kit and PDGFR-alpha activities are necessary for Notch4/Int3-induced tumorigenesis. ONCOGENE 2007; 26(-5-):662-672. >>> Imatinib mesylate; SC; Mice (transgenic); 2001; 1,3,4,5,7 days; Controls received mp w/ water; dose-response (fig 2); no stress (see pg. 663); cancer (mammary); animal info (female, FVB/N, 10 wks old); antiangiogenic; "Continuous release of Gleevec for a week resulted in 33% inhibition of tumor growth by day 2 and 66% by day 4." (p. 668).
P8159 Bihorel,S., Camenisch,G., Gross,G., Lemaire,M., Scherrmann,J.M. Influence of hydroxyurea on imatinib mesylate (gleevec) transport at the mouse blood-brain barrier. Drug Metabolism and Disposition 2006; 34(-12-):1945-1949. >>> Imatinib mesylate; hydroxyurea; Saline; SC; Rat; 2ML2; 7, 14 days; Half-life (p. 1948) hydroxyurea<1 hour in rats; enzyme inhibitor (ribonucleotide reductase); cancer (glioblastoma); animal info (Hanover Wistar, 270-310 grams); ATP competitive inhibitor; A.K.A, Gleevec or STI571.
P7552 Reeves,P.M., Bommarius,B., Lebeis,S., McNulty,S., Christensen,J., Swimm,A., Chahroudi,A., Chavan,R., Feinberg,M.B., Veach,D., Bornmann,W., Sherman,M., Kalman,D. Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nature Medicine 2005; 11(-7-):731-739. >>> Imatinib mesylate; PBS; SC; Mice; 1007D; 1002; 5, 8-15 days; Controls received mp w/ vehicle; no stress (see pg. 738); enzyme inhibitor (Abl-family kinase); animal info (female, C57/BL, 6 wk. old); agent formerly known as STI571; virology; Gleevec.
P6097 Netzer,W.J., Dou,F., Cai,D.M., Veach,D., Jean,S., Li,Y.M., Bornamann,W.G., Clarkson,B., Xu,H.X., Greengard,P. Gleevec inhibits beta-amyloid production but not Notch cleavage. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2003; 100(-21-):12444-12449. >>> Imatinib mesylate; Inhibitor 2; Saline; DMSO; CSF/CNS (Intrathecal); Guinea-pig (albino); 2001; 7 days; Controls received mp w/ vehicle; enzyme inhibitor (abl kinase); agent formerly known as STI571 (gleevec) is an abl kinase inhibitor (dissolved in saline); inhibitor 2 was dissolved in DMSO; "it has been shown that STI571 does not penetrate the blood-brain barrier efficiently, we therefore delivered (p. 12447) each inhibitor intrathecally over 7 days by means of implanted osmotic minipumps."; neurodegenerative (Alzheimer's disease).
72. Irinotecan
P5136 Morales,C., Zurita,M., Vaquero,J. Antitumoral effect of irinotecan (CPT-11) on an experimental model of malignant neuroectodermal tumor. Journal of Neuro-oncology 2002; 56(--):219-226. >>> Irinotecan (CPT-11); Saline; IP; rat; 2004; 28 days; functionality of mp verified by residual content; comparison of IP and intratumoral injections vs. mp; no stress (see p. 222): animals tolerated the pumps: no infections or peritoneal fibrosis were observed; cancer; enzyme inhibitor (topoisomerase I); animals with pumps showed less toxicity: "schedules of continuous administration of CPT-11 were more efficacious and less toxic..." (p. 223).
73. K252a
Q0880 Zhu,X.H., Yan,H.C., Zhang,J., Qu,H.D., Qiu,X.S., Chen,L.A., Li,S.J., Cao,X.O., Bean,J.C., Chen,L.H., Qin,X.H., Liu,J.H., Bai,X.C., Mei,L., Gao,T.M. Intermittent Hypoxia Promotes Hippocampal Neurogenesis and Produces Antidepressant-Like Effects in Adult Rats. Journal of Neuroscience 2010; 30(-38-):12653-12663. >>> K252a; antibody, chicken anti-BDNF; antibody, chicken IgY; CSF, artificial; DMSO; CSF/CNS; Rat; 2002; 14 days; Controls received mp w/ vehicle; animal info (3 mo old, Sprague Dawley, 180-220 g, male); 50% DMSO used; depression.
Q0538 Kaneko,M., Hanover,J.L., England,P.M., Stryker,M.P. TrkB kinase is required for recovery, but not loss, of cortical responses following monocular deprivation. Nature Neuroscience 2008; 11(-4-):497-504. >>> 1NM-PP1; antibody, anti-TrkB; K252a; DMSO; Tween 20; saline; PBS; CSF, artificial; SC; CSF/CNS (cortex); Mice; 6 days; Controls received mp w/ vehicle; animal info (TrkBF616A, wt); enzyme inhibitor (TrkB kinase); 4% DMSO used; 2% Tween 20 used.
Q0355 Pinnock,S.B., Blake,A.M., Platt,N.J., Herbert,J. The Roles of BDNF, pCREB and Wnt3a in the Latent Period Preceding Activation of Progenitor Cell Mitosis in The Adult Dentate Gyrus by Fluoxetine. PLoS One 2010; 5(-10-):U236-U243. >>> K252a; fluoxetine; Saline; CSF/CNS; SC; Rat; 1002; 2ML2; 7, 14 days; Controls received mp w/ saline; animal info (male, Sprague-Dawley, 8 wks old, 200-250 g); multiple pumps per animal (2); cannula placement verified by examining its track on sections stained with cresyl violet.
P8028 Obata,K., Katsura,H., Sakurai,J., Kobayashi,K., Yamanaka,H., Dai,Y., Fukuoka,T., Noguchi,K. Suppression of the p75 neurotrophin receptor in uninjured sensory neurons reduces neuropathic pain after nerve injury. Journal of Neuroscience 2006; 26(-46-):11974-11986. >>> Antibody, anti-NGF; antibody, anti-P75NTR; K252a; DMSO; saline; CSF/CNS (intrathecal, lumbar); Rat; 2001; ; Controls received mp w/ saline; animal info (male, Sprague-Dawley, 200-250 grams); nerve injury; silastic tubing used; K252a in 50% DMSO; behavioral testing.
P5764 Liang,F.-Q., Allen,G., Earnest,D. Role of brain-derived neurotrophic factor in the circadian regulation of the suprachiasmatic pacemaker by light. J Neurosci 2000; 20(-8-):2978-2987. >>> Brain-derived neurotrophic factor; K252a; CSF, artificial; BSA; DMSO; CSF/CNS (suprachiasmatic nucleus); Rat; 2004; 28 days; Controls received mp w/ vehicle; comparison of acute injections vs. mp p.2979; enzyme inhibitor (tyrosine kinase); BDNF was recombinant human; dissolved in a CSF&0.1% BSA; K252a was dissolved in DMSO; guide cannula used with a stylet; 3-day recovery period before pump implantation.
74. KN-92 And KN-93
P7485 Reeves,S.R., Carter,E.S., Guo,S.Z., Gozal,D. Calcium/calmodulin-dependent kinase II mediates critical components of the hypoxic ventilatory response within the nucleus of the solitary tract in adult rats. American Journal of Physiology-Regulatory Integrative and Comparative Physiology 2005; 289(-3-):R871-R876. >>> KN-93; PBS; CSF/CNS (caudate nucleus solitary tract); Rat; 3 days; Controls received mp w/ vehicle; dose-response (fig. 1); brain tissue distribution; multiple pumps per animal (2); animal info (male, Sprague-Dawley, 275-300 g); CaMKII antagonist; cannula placement verified by fluorescent labeling.
P7196 Ogawa,A., Dai,Y., Yamanaka,H., Iwata,K., Niwa,H., Noguchi,K. Ca2+/calmodulin-protein kinase II alpha in the trigeminal subnucleus caudalis contributes to neuropathic pain following inferior alveolar nerve transection. Experimental Neurology 2005; 192(-2-):310-319. >>> KN-93; KN-92; DMSO; CSF/CNS (medulla); Rat; 2001; 7 days; Controls received mp w/ KN-92; enzyme inhibitor (calcium-calmodulin protein kinase II); peptides; cannula placement confirmed by dissection.
P6396 Benter,I.F., Juggi,J.S., Khan,I., Akhtar,S. Inhibition of Ras-GTPase, but not tyrosine kinases or Ca2+/calmodulin-dependent protein kinase II, improves recovery of cardiac function in the globally ischemic heart. MOLECULAR AND CELLULAR BIOCHEMISTRY 2004; 259(-1-2-):35-42. >>> FPT III; KN-93; Genistein; Saline; IP; Rat; 2ML1; 6 days; Controls received mp w/ vehicle; enzyme inhibitor (tyrosine kinase, CaMKII); cardiovascular; ischemia (cardiac).
P5307 Fang,L., Wu,J., Lin,Q., Willis,W.D. Calcium-calmodulin-dependent protein kinase II contributes to spinal cord central sensitization. J Neurosci. 2002/5/15; 22(-10-):4196-4204. >>> KN-92; KN-93; CSF, artificial; CSF/CNS (intrathecal); Rat; ; Controls received mp w/ vehicle; enzyme inhibitor; KN-93 is a calcium/calmodulin-dependent protein kinase II inhibitor; 5-day recovery period.
75. KT5823
P6277 Leamey,C.A., Ho-Pao,C.L., Sur,M. Disruption of Retinogeniculate Pattern Formation by Inhibition of Soluble Guanylyl Cyclase. The Journal of Neuroscience 2004; 21(-11-):3871-3880. >>> KT5823; Oxadiazolo quinoxzlin-1-one, 1H-[1,2,4], [4,3-a]; DMSO; saline; Eye; Ferret; 1-2 weeks; Controls received mp w/ vehicle; dose-response (p.3875); enzyme inhibitor (guanylyl cyclase; protein Kinase G); DMSO at 50%; OD1; KT5832 added to vehicle control.
76. L-NAME
Q0933 Thaete,L.G., Neerhof,M.G., Silver,R.K. Differential Effects of Endothelin A and B Receptor Antagonism on Fetal Growth in Normal and Nitric Oxide-Deficient Rats. J.Soc.Gynecol.Invest. 2001; 8(-1-):18-23. >>> FR-139317; L-NAME; A-127722; A-182086; Ethyl alcohol; propylene glycol; sodium hydroxide; water; IV (jugular); Rat (pregnant); 7 days; Controls received mp w/ vehicle; animal info (female, Sprague-Dawley); teratology' peptides; multiple pumps per animal (2); 20% ethyl alcohol used.
Q0932 Thaete,L.G., Neerhof,M.G. ENDOTHELIN AND BLOOD PRESSURE REGULATION IN THE FEMALE RAT: STUDIES INNORMAL PREGNANCY AND WITH NITRIC OXIDE SYNTHASE INHIBITION-INDUCEDHYPERTENSION. HYPERTENSION IN PREGNANCY 2011; 19(-2-):233-247. >>> A-127722; A-182086; A-192621; FR-139317; L-NAME; Ethyl alcohol; propylene glycol; NaOH; water; SC; IV (jugular); Rat (pregnant); rat; 7 days; Controls received mp w/ vehicle; animal info (female, Sprague-Dawley); multiple pumps per animal (2); wound clips used; 20% ethyl alcohol used; "It is likely that administration with the pumps resulted in more consistent drug levels..." pg 242.
Q0889 Mihout,F., Shweke,N., Bige,N., Jouanneau,C., Dussaule,J.C., Ronco,P., Chatziantoniou,C., Boffa,J.J. Asymmetric dimethylarginine (ADMA) induces chronic kidney disease through a mechanism involving collagen and TGF-beta 1 synthesis. Journal of Pathology 2011; 223(-1-):37-45. >>> L-NAME; dimethylarginine, asymmetric; SC; Mice; 8 weeks; Controls received mp w/ iso-osmotic saline serum; animal info (23 g, male, SV129, 8 wks old, uninephrectomized); long-term study; enzyme inhibitor (nitric oxide synthase, NOS).
Q0800 Neerhof,M.G., Synowiec,S., Khan,S., Thaete,L.G. Pathophysiology of Chronic Nitric Oxide Synthase Inhibition-Induced Fetal Growth Restriction in the Rat. HYPERTENSION IN PREGNANCY 2011; 30(-1-):28-36. >>> L-NAME; ABT-546; Saline; ethyl alcohol; SC; Rat; 2ML1; 7 days; Controls received mp w/ vehicle; animal info (female, male, Sprague-Dawley, 11-20 wks old, 225-250 g); multiple pumps per animal (2).
Q0029 Santhanam,L., Tuday,E.C., Webb,A.K., Dowzicky,P., Kim,J.H., Oh,Y.J., Sikka,G., Kuo,M., Halushka,M.K., Macgregor,A.M., Dunn,J., Gutbrod,S., Yin,D., Shoukas,A., Nyhan,D., Flavahan,N.A., Belkin,A.M., Berkowitz,D.E. Decreased S-Nitrosylation of Tissue Transglutaminase Contributes to Age-Related Increases in Vascular Stiffness. Circulation Research 2010; 107(-1-):117-U243. >>> L-NAME; Cystamine; Mice; rat; 3 months; 4 weeks; Controls received mp w/vehicle; cardiovascular; enzyme inhibitor (NO synthase; transglutaminase); animal info (male, BL6129S wt, TG2 -/-, 3-5 months old; Fisher 344, 18-19 months old); pumps replaced every 4 weeks.
P9971 Xue,B.J., Singh,M., Guo,F., Hay,M., Johnson,A.K. Protective actions of estrogen on angiotensin II-induced hypertension: role of central nitric oxide. American Journal of Physiology-Heart and Circulatory Physiology 2009; 297(-5-):H1638-H1646. >>> L-NAME; L-VNIO; Angiotensin II; SC; CSF/CNS; Mice; 1002; 7, 14 days; Controls received mp w/ vehicle; peptides; cardiovascular; enzyme ihibitor (NO synthase); animal info (male, female, C57BL/6, 12-16 weeks old); replacement therapy (ovariectomy, gonadectomy); cannula placement confirmed post mortem histologically; N5-(1-imino-3-butenyl)-L-ornithine (L-VNIO).
P8527 Ravishankar,V., Buhimschi,C.S., Booth,C.J., Bhandari,V., Norwitz,E., Copel,J., Buhimschi,I.A. Fetal nucleated red blood cells in a rat model of intrauterine growth restriction induced by hypoxia and nitric oxide synthase inhibition. American Journal of Obstetrics and Gynecology 2007; 196(-5-):U104-U111. >>> L-NAME; Saline, sterile; SC; Rat (pregnant); 2ML1; 4 days; Controls received mp w/ vehicle; enzyme inhibitor (NO synthase); animal info (female, Sprague-Dawley, G-D17, 300-350 g).
P8511 Clarkson,A.N., Liu,H., Schiborra,F., Shaw,O., Sammut,I.A., Jackson,D.M., Appleton,I. Angiogenesis as a predictive marker of neurological outcome following hypoxia-ischemia. Brain Research 2007; 1171(--):111-121. >>> Clomethiazole; L-NAME; SC; Rat; 2ML1; 5 days; Controls received mp w/ vehicle or saline or no treatment; no stress (see pg. 112); enzyme inhibitor (NO synthase); ischemia (cerebral); animal info (male, Wistar, 21 days old).
P8455 Ebose,E.J., Campbell,P.I., Okorodudu,A.O. Electrolytes and pH changes in pre-eclamptic rats. Clinica Chimica Acta 2007; 384(-1-2-):135-140. >>> L-NAME; Saline, sterile, isotonic; SC; Rat (pregnant); 2ML2; 2 days; Controls received mp w/ vehicle; enzyme inhibitor (NOS); animal info (female, Sprague-Dawley, 270-340g, GD15).
P8361 Gangula,P.R.R., Maner,W.L., Micci,M.A., Garfield,R.E., Pasricha,P.J. Diabetes induces sex-dependent changes in neuronal nitric oxide synthase dimerization and function in the rat gastric antrum. American Journal of Physiology-Gastrointestinal and Liver Physiology 2007; 292(-3-):G725-G733. >>> L-NAME; SC; Rat; 2ML1; 4 days; Replacement therapy (STZ-induced diabetes mellitus; enzyme inhibitor (nitric oxide synthase); animal info (male, female, Sprague-Dawley, 7 wks old).
P8327 Schwenke,D.O., Pearson,J.T., Mori,H., Shirai,M. Does central nitric oxide elicit pulmonary hypertension in conscious rats?. RESPIRATORY PHYSIOLOGY&NEUROBIOLOGY 2006; 153(-3-):250-260. >>> L-NAME; SIN-1; CSF, artificial; CSF/CNS; Rat; 2004; 3 weeks; Controls received mp w/ vehicle; enzyme inhibitor (NO synthase); cardiovascular; animal info (male, Sprague-Dawley, 200-320 grams, 8 weeks old); Evans blue dye used to confirm correct cannula placement; SIN-1 is 2-[4-morpholinyl]-sydnonimine-hydrochloride.
P8301 Badn,W., Hegardt,P., Fellert,M.A., Darabi,A., Esbjoernsson,M., Smith,K.E., Janelidze,S., Salford,L.G., Visse,E., Siesjoe,P. Inhibition of inducible nitric oxide synthase enhances anti-tumour immune responses in rats immunized with IFN-gamma-secreting glioma cells. SCANDINAVIAN JOURNAL OF IMMUNOLOGY 2007; 65(-3-):289-297. >>> L-NAME; L-NIL; Saline; IP; Rat; 2001; 1 week; 14, 28 days; Controls received mp w/ vehicle; dose-response (fig. 3); comparison of IP injections vs. mp; enzyme inhibitor (Nitric oxide synthase, iNOS); cancer (glioma); L-NIL is L-N6- (1-iminsethyl) -L-lysine.
P8215 Aikawa,K., Chichester,P., Whitbeck,C., Levin,R.M. Effect of nitric oxide synthase inhibition on changes induced by estradiol in bladders from ovariectomized rabbits. UROLOGIA INTERNATIONALIS 2005; 75(-2-):133-138. >>> L-NAME; Saline; SC; Rabbit; 4 weeks; Controls received sham OVX w/ no mp; enzyme inhibitor (NO synthase); animal info (female, New Zealand White, 3.5-4.0 kg.).
P7889 Coates,B.J., Broderick,T.L., Batia,L.M., Standley,C.A. MgSO4 prevents left ventricular dysfunction in an animal model of preeclampsia. American Journal of Obstetrics and Gynecology 2006; 195(-5-):1398-1403. >>> L-NAME; magnesium sulfate; Saline; SC; Rat (pregnant); 2ML1; 4 days; Controls received mp w/ vehicle; cardiovascular; animal info (female, Sprague-Dawley, 150-175g.); "Infusion of L-NAME in pregnant rats represent an excellent animal model suitable for the study of cardiovascular dysfunction in preeclampsia." (pg. 1401).
P7747 Schwenke,D.O., Pearson,J.T., Kangawa,K., Shirai,M. Does central nitric oxide chronically modulate the acute hypoxic ventilatory response in conscious rats?. ACTA PHYSIOLOGICA 2006; 186(-4-):309-318. >>> L-NAME; sydnonimine-hydrochloride, 3-[4-morpholinyl]-; CSF, artificial; CSF/CNS; Rat; 2004; 3 weeks; Controls received mp w/ vehicle; no stress (see pg. 312); enzyme inhibitor (no synthase); post op. care (viccillin); animal info (male, Sprague-Dawley, 8 wk. old, 200-320g.); correct catheter positioning confirmed post mortem w/ Evans blue dye.
P7299 Takei,H., Yamamoto,M., Kase,Y., Takeda,S. The effect of herbal medicine Toki-shakuyaku-san on blood pressure in an Nw-nitro-L-arginine methyl ester-induced pre-eclampsia rat model during pregnancy and the postpartum period. JOURNAL OF PHARMACOLOGICAL SCIENCES 2005; 98(-3-):255-262. >>> L-NAME; SC; Rat (pregnant); 2ML2; 2 weeks; Controls received mp w/ saline; enzyme inhibitor (NO synthase); cardiovascular.
P7204 Pfosser,A., Thalgott,M., Buettner,K., Brouet,A., Feron,O., Boekstegers,P., Kupatt,C. Liposomal Hsp90 cDNA induces neovascularization via nitric oxide in chronic ischemia. Cardiovascular Research 2005; 65(-3-):728-736. >>> Geldanamycin; L-NAME; SC; Rabbit; 25, 28 days; Enzyme inhibitor (Hsp90, NO synthase).
P7179 Jacobi,J., Sydow,K., von Degenfeld,G., Zhang,Y., Dayoub,H., Wang,B.Y., Patterson,A.J., Kimoto,M., Blau,H.M., Cooke,J.P. Overexpression of dimethylarginine dimethylaminohydrolase reduces tissue asymmetric dimethylarginine levels and enhances angiogenesis. Circulation 2005; 111(-11-):1431-1438. >>> L-NAME; dimethylarginine, asymmetric; PBS; SC; IP; Mice; mice (transgenic); 2002; 2004; 2, 3 weeks; Controls received mp w/ vehicle; enzyme inhibitor (nitric oxide synthase); cardiovascular; ischemia (hindlimb).
P7049 Bourraindeloup,M., Adamy,C., Candiani,G., Cailleret,M., Bourin,M.C., Badoual,T., Su,J.B., Adubeiro,S., Roudot-Thoraval,F., Dubois-Rande,J.L., Hittinger,L., Pecker,F. N-acetylcysteine treatment normalizes serum tumor necrosis factor-alpha level and hinders the progression of cardiac injury in hypertensive rats. Circulation 2004; 110(-14-):2003-2009. >>> L-NAME; SC; Rat; 2ML4; 4,6 weeks; Functionality of mp verified by systolic blood pressure; pumps replaced after 4 weeks; enzyme inhibitor (no synthase); cardiovascular.
P7024 De Seranno,S., Estrella,C., Loyens,A., Cornea,A., Ojeda,S.R., Beauvillain,J.C., Prevot,V. Vascular endothelial cells promote acute plasticity in ependymoglial cells of the neuroendocrine brain. Journal of Neuroscience 2004; 24(-46-):10353-10363. >>> L-NAME; Sodium chloride; CSF/CNS (median eminence); Rat; 2002; 2 weeks; Controls received mp w/ vehicle; functionality of mp verified by determining correct cannula placement and exhaustion of infusion solution; enzyme inhibitor (NOS).
P6953 Thaete,L.G., Kushner,D.M., Dewey,E.R., Neerhof,M.G. Endothelin and the regulation of uteroplacental perfusion in nitric oxide synthase inhibition-induced fetal growth restriction. PLACENTA 2005; 26(-2-3-):242-250. >>> L-NAME; A-127722; Saline; ethyl alcohol; NaOH; water; propylene glycol; SC; Rat (pregnant); 2ML1; 1,4,7 days; Functionality of mp verified by residual volume; stability verified by prior experiment (24 days); multiple pumps per animal (2); drugs infused in separate pumps; A-127722 (ETA receptor antagonist) was dissolved in 20% alcohol, 40% PG and 0.04 M of NaOH.
P6655 Li,X., Simard,J.M. Increase in Cx45 gap junction channels in cerebral smooth muscle cells from SHR. Hypertension 2002; 40(-6-):940-946. >>> Angiotensin II; L-NAME; captopril; SC; Rat; 4 weeks; Enzyme inhibitor (nitric oxide synthase); cardiovascular; antihypertensive.
P6488 Wheeler,M.T., Allikian,M.J., Heydemann,A., Hadhazy,M., Zarnegar,S., McNally,E.M. Smooth muscle cell-extrinsic vascular spasm arises from cardiomyocyte degeneration in sarcoglycan-deficient cardiomyopathy. Journal of Clinical Investigation 2004; 113(-5-):668-675. >>> L-NAME; IP; Mice (transgenic); 6 days; Controls received mp w/ saline; enzyme inhibitor (no synthase); cardiovascular.
P6318 Steudel,W., Ichinose,F., Huang,P.L, Hurford,W.E., Jones,R.C., Bevan,J.A., Fishman,M.C, Zapol,W.M. Pulmonary Vasoconstriction and Hypertension in Mice With Targeted Disruption of the Endothelial Nitric Oxide Synthase (NOS 3) Gene. Circulation Research 1997; 81(-1-):34-41. >>> L-NAME; Saline, normal; IP; Mice; 1007D; 5 days; Controls received no treatment; comparison of acute IV injections vs. mp; enzyme inhibitor (nitric oxide synthase); cardiovascular.
P6271 McDonald,W.S., Lo,TP Jr, Thurmond,M., Jones,C., Cohen,R., Miller,A., Beasley,D. Role of nitric oxide in skin flap delay. PLASTIC AND RECONSTRUCTIVE SURGERY 2004; 113(-3-):927-931. >>> L-NAME; IP; Mice; 1003D; ; Functionality of mp verified by residual volume; dose-response (p. 929); enzyme inhibitor (NOS).
P6257 Elger,W., Beier,S., Pollow,K., Garfield,R., Shi,S.Q., Hillisch,A. Conception and pharmacodynamic profile of drospirenone. Steroids 2003; 68(-10-13-):891-905. >>> L-NAME; SC; Rat (pregnant); 10 days; Teratology; pump model not listed.
P6083 Turban,S., Wang,X.Y., Knepper,M.A. Regulation of NHE3, NKCC2, and NCC abundance in kidney during aldosterone escape phenomenon: role of NO. American Journal of Physiology-Renal Physiology 2003; 285(-5-):F843-F851. >>> Angiotensin II; aldosterone; L-NAME; Acetic acid; DMSO; saline; water; SC; Rat; 2001; 2ML1; 7 days; Controls received mp w/ vehicle; peptides; angiotensin II dissolved in acetic acid; albo dissolved in 30% DMSO/saline; L-NAME dissolved in water.
P5994 Murase,T., Tian,Y., Fang,X.Y., Verbalis,J.G. Synergistic effects of nitric oxide and prostaglandins on renal escape from vasopressin-induced antidiuresis. American Journal of Physiology-Regulatory Integrative and Comparative Physiology 2003; 284(-2-):R354-R362. >>> Vasopressin, 1-desamino-8-D arginine; L-NAME; diclofenac; ranitidine; Saline; DMSO; SC; Rat; 2001; 2002; 5 days; Vasopressin, 1-desamino-8-D arginine was infused in the 2002 pump; L-NAME was dissolved in saline and diclofenac was dissolved in 50% DMSO; both were infused from a 2001 pump.
P5917 Packer,M.A., Stasiv,Y., Benraiss,A., Chmielnicki,E., Grinberg,A., Westphal,H., Goldman,S.A., Enikolopov,G. Nitric oxide negatively regulates mammalian adult neurogenesis. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2003; 100(-16-):9566-9571. >>> L-Name; D-Name; Calcium; Hank's buffered saline; CSF/CNS; Rat; 2002; ; Enzyme inhibitor (nitric oxide synthase).
P5906 Nadeau,S., Rivest,S. Glucocorticoids play a fundamental role in protecting the brain during innate immune response. Journal of Neuroscience 2003; 23(-13-):5536-5544. >>> Tumor necrosis factor-alpha; L-NAME; endotoxin, LPS; Saline; BSA; ascorbic acid; PIPES; DMSO; CSF/CNS (cortex, dorsal basal ganglia); Rat; 2004; 3,7,14,21 days; Controls received mp w/ vehicle; tissue perfusion (cerebral tissue&dorsal ganglia); enzyme inhibitor (nitric oxide); brain tissue distribution; guid cannula used; TNF-a was dissolved in saline + 0.1% BSA + 0.01% ascorbic acid; L-NAME was dissolved in PIPES&10% DMSO&infused into the dorsal basal ganglia.
P5899 Kurisu,S., Ozono,R., Oshima,T., Kambe,M., Ishida,T., Sugino,H., Matsuura,H., Chayama,K., Teranishi,Y., Iba,O., Amano,K., Matsubara,H. Cardiac angiotensin II type 2 receptor activates the kinin/NO system and inhibits fibrosis. Hypertension 2003; 41(-1-):99-107. >>> Angiotensin II; HOE 140; L-NAME; Saline; SC; Mice (transgenic); 2002; 14 days; Controls received mp w/ vehicle; enzyme inhibitor (no); cardiovascular; HOE140 is a bradykinin B2 receptor antagonist; L-NAME is a nitric oxide synthase inhibitor; table on p. 101 for weights, blood pressure, heart rate, etc..
P5846 Nemade,R.V., Carrette,O., Larsen,W.J., Markoff,E. Involvement of nitric oxide and the ovarian blood follicle barrier in murine follicular cyst development. Fertility and Sterility 2002; 78(-6-):1301-1308. >>> L-NAME; D-NAME; Gonadotrophin, human chorionic; Water, sterile; SC; Mice; 1003D; 1007D; 3,4,7 days; Functionality of mp verified by plasma levels taken; enzyme inhibitor (nitric oxide synthase) "L-NAME"; multiple pumps per animal in some groups; human choriogonadotropin is (hCG).
P5730 Buckwalter,J.B., Curtis,V.C., Valic,Z., Ruble,S.B., Clifford,P.S. Endogenous vascular remodeling in ischemic skeletal muscle: a role for nitric oxide. Journal of Applied Physiology 2003; 94(-3-):935-940. >>> L-NAME; D-NAME; Phenylephrine; Saline; heparin; IA (femoral); Rabbit; 2ML2; 6 weeks; Controls received mp w/ phenylephrine or D-NAME; enzyme inhibitor (Nitric oxide synthase); cardiovascular; peptides; L-NAME&D-NAME (no synthase inhibitors) were dissolved in heparinized saline (100 U/ml).
P5611 Witlin,A.G., Gangula,P.R.R., Wimalawansa,S.J., Grafe,M., Grady,J.J., Yallampalli,C. Adrenomedullin requires an intact nitric oxide system to function as a nendogenous vasodilator in rat gestation. HYPERTENSION IN PREGNANCY 2003; 22(-1-):9-24. >>> Adrenomedullin, human; L-NAME; SC; Rat (pregnant); 1003D; 2001D; 2ML1; 2ML2; 1-5 days; Controls received mp/w vehicle; dose-response (table, p. 17); teratology; peptides; antihypertensive; agents infused individually or in combination..
P5371 Tam,S.L., Sims,E., Kaufman,S. Effect of NOS inhibition on central response to atrial distension during pregnancy. American Journal of Physiology-Regulatory Integrative and Comparative Physiology 2002; 283(-4-):R827-R831. >>> L-NAME; D-NAME; SC; Rat (pregnant); 2ML1; ; Enzyme inhibitor.
P5300 Horstman,D.J., Fischer,L.G., Kouretas,P.C., Hannan,R.L., Rich,G.F. Role of nitric oxide in heparin-induced attenuation of hypoxic pulmonary vascular remodeling. J Appl.Physiol 2002/5; 92(-5-):2012-2018. >>> L-NAME; Heparin; Saline; SC; Rat; 2ML4; 3 days or 3 weeks; Controls received mp w/ vehicle; cardiovascular; 24 hour recovery period.
P5241 Murakami,H., Miao,R.Q., Chao,L., Chao,J. Adenovirus-mediated kallikrein gene transfer inhibits neointima formation via increased production of nitric oxide in rat artery. Immunopharmacology 1999/10/15; 44(-1-2-):137-143. >>> L-NAME; IP; Rat; 2ML2; 2 weeks; Cardiovascular.
P5156 Tam,S.L., Kaufman,S. NOS inhibition restores renal responses to atrial distension during pregnancy. American Journal of Physiology-Regulatory Integrative and Comparative Physiology 2002; 282(--):R1364-R1367. >>> L-NAME; D-NAME; SC; rat (pregnant); 2ML1; 6 days; controls received mp w/ inactive agent; cardiovascular; enzyme inhibitor (NOS).
P5107 Murakami,H, Miao,R.Q, Chao,L, Chao,J. Adenovirus-mediated kallikrein gene transfer inhibits neointima formation via increased production of nitric oxide in rat artery. Immunopharmacology 1999; 44(--):137-143. >>> L-NAME; IP; rat; 2ML2; 14 days; cardiovascular; L-Name is an enzyme inhibitor (NO synthase).
P4877 Ikegaki,I., Hattori,T., Yamaguchi,T., Sasaki,Y., Satoh,S., Asano,T., Shimokawa,H. Involvement of Rho-kinase in vascular remodeling caused by long-term inhibition of nitric oxide synthesis in rats. European Journal of Pharmacology 2001; 427(--):69-75. >>> L-NAME; IP; rat; 2ML4; 28 days; controls received no treatment; cardiovascular; L-NAME is a nitric oxide synthesis inhibitor.
P4784 Buhimschi,I.A., Shi,S.Q., Saade,G.R., Garfield,R.E. Marked variation in responses to long-term nitric oxide inhibition during pregnancy in outbred rats from two different colonies.. American Journal of Obstetrics and Gynecology 2001; 184(-4-):686-693. >>> L-NAME; Saline;; SC;; rat (pregnant);; 2ML2; 2ML4;; 14 or 28 days;; Controls received mp w/ vehicle; teratology; enzyme inhibitor; L-NAME is a nitric oxide synthase inhibitor;.
P4673 Paterson,S, Zheng,Y, Smith,P.F., Darlington,C.L. The effects of L-NAME on vestibular compensation and NOS activity in the vestibular nucleus, cerebellum and cortex of the guinea pig.. Brain Research 2000; 879(--):148-155. >>> L-NAME; Saline; SC; Guinea-pig; 1003D; 50 hours; Controls received mp w/ vehicle; functionality of mp verified by nitric oxide synthase activity; dose-response (p. 153); enzyme inhibitor; L-NAME is a nitric oxide synthase inhibitor;.
77. L-NIL
P8698 Badn,W., Visse,E., Darabi,A., Smith,K.E., Salford,L.G., Siesjoe,P. Postimmunization with IFN-gamma-secreting glioma cells combined with the inducible nitric oxide synthase inhibitor mercaptoethylguanidine prolongs survival of rats with intracerebral tumors. Journal of Immunology 2007; 179(-6-):4231-4238. >>> L-NIL; Saline; IP; Rat; 2001; 7, 14 days; Controls received mp w/ PBS; pumps replaced after 7 days and 3 non-delivery days; enzyme inhibitor (iNOS); cancer (glioma); animal info (Fischer 344, 8-10 wks old); L-N6-(1-imminoethyl)-lysine.
P8301 Badn,W., Hegardt,P., Fellert,M.A., Darabi,A., Esbjoernsson,M., Smith,K.E., Janelidze,S., Salford,L.G., Visse,E., Siesjoe,P. Inhibition of inducible nitric oxide synthase enhances anti-tumour immune responses in rats immunized with IFN-gamma-secreting glioma cells. SCANDINAVIAN JOURNAL OF IMMUNOLOGY 2007; 65(-3-):289-297. >>> L-NAME; L-NIL; Saline; IP; Rat; 2001; 1 week; 14, 28 days; Controls received mp w/ vehicle; dose-response (fig. 3); comparison of IP injections vs. mp; enzyme inhibitor (Nitric oxide synthase, iNOS); cancer (glioma); L-NIL is L-N6- (1-iminsethyl) -L-lysine.
78. L-NIO
P5799 Kanno,S., Wu,Y-J.L., Lee,P.C., Billiar,T.R, Ho,C. Angiotensin-converting enzyme inhibitor preserves p21 and endothelial nitric oxide synthase expression in monocrotaline-induced pulmonary arterial hypertension in rats. Circulation 2001; 104(-8-):945-950. >>> L-NIO; IV (jugular); Rat; 35 days; Controls received mp w/ saline; enzyme inhibitor (Nitric oxide synthase); L-NIO is N-iminoethyl-L-ornithine, a potent NOS inhibitor.
79. L-NMMA
R0140 Li,J, Billiar,T.R. Nitric oxide IV. determination of nitric oxide protection and toxicity in liver. Am.J.Physiol. 1999; 276(--):G1069-G1073. >>> L-NMMA; L-NAME; Aminoguanidine; IV (hepatic portal);; rat;; ; nitric oxide synthase inhibitors;.
P7793 Seto,S., Nagao,S., Ozeki,S., Tetsuo,H., Akahoshi,M., Yano,K. Contribution of central nitric oxide to the regulation of blood pressure and sodium balance in DOCA-salt hypertension. Journal of Cardiovascular Pharmacology 2006; 47(-5-):680-685. >>> L-NMMA; IP; CSF/CNS; Rat; 2ML4; 4 weeks; Controls received mp w/ saline; replacement therapy (nephrectomy); dose-response (fig. 1); enzyme inhibitor (no synthase); cardiovascular; animal info (male, Wistar, 7 wk. old, 240g.); cannula location confirmed by methylene blue staining.
P7271 Kashiwagi,S., Izumi,Y., Gohongi,T., Demou,Z.N., Xu,L., Huang,P.L., Buerk,D.G., Munn,L.L., Jain,R.K., Fukumura,D. NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissue-engineered blood vessels. Journal of Clinical Investigation 2005; 115(-7-):1816-1827. >>> L-NMMA; D-NMMA; SC; Mice; mice (SCID); 1002; 8, 21 days; Controls received mp w/ D-NMMA; pumps replaced at day 14; enzyme inhibitor (NO synthase); cancer (melanoma); cardiovascular; eNOS -/- mice; iNOS -/- mice.
P6845 Hagendoorn,J., Padera,T.P., Kashiwagi,S., Isaka,N., Noda,F., Lin,M.I., Huang,P.L., Sessa,W.C., Fukumura,D., Jain,R.K. Endothelial nitric oxide synthase regulates microlymphatic flow via collecting lymphatics. Circulation Research 2004; 95(-2-):204-209. >>> L-NMMA; D-NMMA; SC; Mice; 3 days; Controls received mp w/ D-NMMA; enzyme inhibitor (NO synthase); cardiovascular.
P6754 Momohara,Y., Sakamoto,S., Obayashi,S., Aso,T., Goto,M., Azuma,H. Roles of endogenous nitric oxide synthase inhibitors and endothelin-1 for regulating myometrial contractions during gestation in the rat. MOLECULAR HUMAN REPRODUCTION 2004; 10(-7-):505-512. >>> L-NMMA; IP; Rat; 2 weeks; Controls received mp w/ saline; enzyme inhibitor (no synthase).
P4418 Schaffer,M.R., Tantry,U., Thornton,F.J, Barbul,A. Inhibition of nitric oxide synthesis in wounds: pharmacology and effect on accumulation of collagen in wounds in mice.. Eur.J.Surg. 1999; 165(--):262-267. >>> L-NMMA; Aminoguanidine hemisulphate; MITU;; PBS;; IP;; mice;; 10 days;; control received mp w/vehicle; comparison of IP injections vs. mp; wound healing study; MITU is S-methyl isothiouronium, a competitive NO synthase inhibitor..
P4228 Wada,Y., Matsuoka,H., Okuda,S., Imaizumi,T. Chronic inhibition of nitric oxide in central nervous system does not cause hypertension. Hypertension Res. 1998; 21(--):97-101. >>> L-NMMA; D-NMMA; CSF/CNS (cisterna magna); rat; 2001; 7 days; controls received mp w/D-NMMA; no stress (p. 98); nitric oxide synthase inhibitor; L-NMMA is N6-monomethyl-L-arginine; silastic PE10 tubing connected to PE50 tubing; pump implanted 7 days after cannula implantation; catheter patency verified; cardiovascular.
P3522 Suzuki,Y., Ikari,H., Hayashi,T., Iguchi,A. Central administration of a nitric oxide synthase inhibitor impairs spatial memory in spontaneous hypertensive rats. Neuroscience Letters 1996; 207(--):105-108. >>> L-NMMA; Saline; Trypan blue; CSF/CNS (dorsal third ventricle); rat; 2001; no duration posted; agent is N-monomethyl-L-arginine; enzyme inhibitor: nitric oxide synthase.
P3473 Cohen,T.I., Weinberg,R.J., Blight,A.R. Intrathecal infusion of the Nitric Oxide Synthase Inhibitor N-methyl L-arginine after experimental spinal cord injury in guinea pigs. J.Neurotrauma 1996; 13(-7-):361-369. >>> L-NMMA; D-NMMA; CSF/CNS (spinal cord, intrathecal); guinea-pig; 2001; no duration posted; no comment posted.
80. LY294002
Q0762 Bruel-Jungerman,E., Veyrac,A., Dufour,F., Horwood,J., Laroche,S., Davis,S. Inhibition of PI3K-Akt Signaling Blocks Exercise-Mediated Enhancement of Adult Neurogenesis and Synaptic Plasticity in the Dentate Gyrus. PLoS One 2009; 4(-11-):U52-U61. >>> LY294002; DMSO; CSF, artificial; CSF/CNS; Rat; 2004; ; Controls received mp w/ vehicle; animal info (young, male, adult, Sprague-Dawley, 10-12 wks old); enzyme inhibitor (Phosphoinositide 3-kinase, PI3K); post op. care (topical antiseptic, exocptoplix); behavioral testing (running wheel); 30% DMSO used; aCSF recipe.
P8062 Gelling,R.W., Morton,G.J., Morrison,C.D., Niswender,K.D., Myers,MG Jr, Rhodes,C.J., Schwartz,M.W. Insulin action in the brain contributes to glucose lowering during insulin treatment of diabetes. Cell Metabolism 2006; 3(-1-):67-73. >>> LY294002; CSF/CNS (third ventricle); Rat; 2002; 9 days; Controls received mp w/ vehicle; comparison of icv injections vs. mp; enzyme inhibitor (phosphatidylinositol 3-kinase); animal info (male, Sprague-Dawley, 250-350g); cannula placement confirmed; tissue perfusion (ventricle).
P7818 Dell,S., Peters,S., Muether,P., Kociok,N., Joussen,A.M. The role of PDGF receptor inhibitors and PI3-kinase signaling in the pathogenesis of corneal neovascularization. INVESTIGATIVE OPHTHALMOLOGY&VISUAL SCIENCE 2006; 47(-5-):1928-1937. >>> AG-1296; wortmannin; LY294002; PBS; IP; Mice; 2001; 1 week; Controls received mp w/ vehicle; dose-response (fig. 6); enzyme inhibitor (PDGF receptor kinase, phosphatidylinositol 3-kinase); animal info (male, C57BL/6,7-10wk old 20g.).
P6915 Poulaki,V., Joussen,A.M., Mitsiades,N., Mitsiades,C.S., Iliaki,E.F., Adamis,A.P. Insulin-like growth factor-I plays a pathogenetic role in diabetic retinopathy. American Journal of Pathology 2004; 165(-2-):457-469. >>> Wortmannin; ly294002; antibody, monoclonal aLR-3; SP600125; SN50; geldanamycin; IP; Rat; 2002; 7 days; Enzyme inhibitor (P1-3K, JNK); diabetes.
P5277 Nakanishi,K., Sakamoto,M., Yasuda,J., Takamura,M., Fujita,N., Tsuruo,T., Todo,S., Hirohashi,S. Critical involvement of the phosphatidylinositol 3-kinase/Akt pathway in anchorage-independent growth and hematogeneous intrahepatic metastasis of liver cancer. Cancer Res 2002/5/15; 62(-10-):2971-2975. >>> LY294002; DMSO; IP; Mice; 1002; 4 weeks; Controls received mp w/ vehicle; pumps replaced after 2 weeks; cancer; enzyme inhibitor; 35% DMSO used; LY4294002 is a phosphatidylinositol 3-kinase inhibitor.
81. Lepirudin
P8342 Castellino,F.J., Ganopolsky,J.G., Noria,F., Sandoval-Cooper,M.J., Ploplis,V.A. Focal arterial inflammation is augmented in mice with a deficiency of the protein C gene. THROMBOSIS AND HAEMOSTASIS 2006; 96(-6-):794-801. >>> Lepirudin; IP; Mice; 2001; 7 days; Controls received no treatment; enzyme inhibitor (thrombin); cardiovascular; copper/silicone cuff on left carotid artery.
82. Letrozole
Q0830 Zhu,W., Wang,L., Zhang,L., Palmateer,J.M., Libal,N.L., Hurn,P.D., Herson,P.S., Murphy,S.J. ISOFLURANE PRECONDITIONING NEUROPROTECTION IN EXPERIMENTAL FOCAL STROKE IS ANDROGEN-DEPENDENT IN MALE MICE. Neuroscience 2010; 169(-2-):758-769. >>> Letrozole; Propylene glycol; SC; Mice; 1002; 13 days; Controls received mp w/ vehicle; animal info (male, C57BL/6, ArKO, ArWT); enzyme inhibitor (aromatase).
Q0821 Zhu,S., Zhang,Y., Bai,G., Li,H. Necrostatin-1 ameliorates symptoms in R6/2 transgenic mouse model of Huntington's disease. Cell Death&Disease 2011; 2(-;-):U38-U41. >>> Letrozole; Propylene glycol; SC; Mice; 1002; 13 days; Controls received mp w/ vehicle; animal info (male, C57BL/6, ArKO, ArWT); enzyme inhibitor (aromatase).
83. Leupeptin
Q0252 Shinohara,M., Sato,N., Kurinami,H., Takeuchi,D., Takeda,S., Shimamura,M., Yamashita,T., Uchiyama,Y., Rakugi,H., Morishita,R. Reduction of Brain beta-Amyloid (A-beta) by Fluvastatin, a Hydroxymethylglutaryl-CoA Reductase Inhibitor, through Increase in Degradation of Amyloid Precursor Protein C-terminal Fragments (APP-CTFs) and A-beta Clearance. Journal of Biological Chemistry 2010; 285(-29-):22091-22102. >>> Leupeptin; E-64a; CSF, artificial; CSF/CNS; Mice (transgenic); 2002; 1 week; Controls received mp w/ vehicle; peptides; ALZET brain infusion kit 3 used; no stress (see pg 22092); neurodegenerative (Alzheimer's Disease); animal info (male, C57BL/6, APP23 Tg, 8 wks old); Lysosomal inhibitor.
P9059 Yang,D.S., Kumar,A., Stavrides,P., Peterson,J., Peterhoff,C.M., Pawlik,M., Levy,E., Cataldo,A.M., Nixon,R.A. Neuronal apoptosis and autophagy cross talk in aging PS/APP mice, a model of Alzheimer's disease. American Journal of Pathology 2008; 173(-3-):665-681. >>> Leupeptin; HEPES, buffer; CSF/CNS; Mice (transgenic); 2004; 2 weeks; Enzyme inhibitor (cysteine protease); cyanoacrylate adhesive; animal info (6 months old, PS/APP, or wt); neurodegenerative (Alzheimer's Disease); pumps primed in sterile saline at 37 degree Celsius for 48 hours.
P7214 Nakajima,T., Takauchi,S., Ohara,K., Kokai,M., Nishii,R., Maeda,S., Takanaga,A., Tanaka,T., Takeda,M., Seki,M., Morita,Y. Alpha-Synuclein-positive structures induced in leupeptin-infused rats. Brain Research 2005; 1040(-1-2-):73-80. >>> Leupeptin; PBS; CSF/CNS; Rat; 2002; 14 days; Controls received mp w/ vehicle; enzyme inhibitor (protease); peptides; "The leupeptin infusion rat model is thought to be a useful material for studying several neuronal changes resembling the aging or degeneration of the central nervous tissue." (p. 79).
P7091 yala-Grosso,C., Tam,J., Xanthoudakis,S., Bureau,Y., Roy,S., Nicholson,D.W., Robertson,G.S. Effects of fimbria-fornix transection on calpain and choline acetyl transferase activities in the septohippocampal pathway. Neuroscience 2004; 126(-4-):927-940. >>> Leupeptin; MDL 28170; Saline, sterile; DMSO; cyclodextrin; CSF/CNS; Rat; 5 days; Controls received mp w/ vehicle; replacement therapy (axotomy); enzyme inhibitor (calpain); 2% DMSO; mp primed overnight at 37 degree Celsius; 10% cyclodextrin used.
P4742 Tang,W, Seidman,M.D, Henig,J.P, Shulman,A, Stracher,A. The effects of leupeptin on cochlear blood flow, auditory sensitivity, and histology.. International Tinnitus Journal 2001; 7(-1-):4-12. >>> Leupeptin;; Hank's solution;; ear (round window);; guinea-pig;; 2002;; 8 weeks;; Controls received mp w/ vehicle; tissue perfusion (bulla); long-term study, pumps replaced every 13 days; IntraEAR catheter used; Leupeptin is a potent calpain inhibitor; neuroprotection; buprenorphine given as postoperative analgesic; chloramphenicol given as prophlactic antibiotic;.
P4270 Frautschy,S.A., Horn,D.L., Sigel,J.J., Harris-White,M.E., Mendoza,J.J., Yang,F., Saido,T.C., Cole,G.M. Protease inhibitor coinfusion with amyloid beta-protein results in enhanced deposition and toxicity in rat brain. Journal of Neuroscience 1998/10/15; 18(-20-):8311-8321. >>> Amyloid protein, beta; Aprotinin; Leupeptin;; HEPES;; CSF/CNS;; rat; 2004;; 4 weeks; controls received mp w/ vehicle; peptides; ALZET brain infusion kit used; beta-amyloid protein infused alone, or concomitantly with aprotinin or leupeptin; enzyme inhibitors.
P3822 Arai,T., Ikarashi,Y., Okamoto,K., Kuribara,H., Maruyama,Y. Memory disturbance and hippocampal degeneration induced by continuous intraventricular infusion of a protease inhibitor, leupeptin. Brain Research 1997; 754(--):157-162. >>> Leupeptin; CSF, artificial;; CSF/CNS; rat; 2002; 14 days; controls received mp w/aCSF; ALZET brain infusion kit used.
P3762 Porta,E.A., Monserrat,A.J., Berra,A., Rubio,M.C. Effects of lovastatin and leupeptin on ceroidogenesis of vitamin E-deficient and-supplemented young rats. In 'Lipofuscin and ceroid pigments', E.A.Porta (ed.), Plenum Press, N.Y. 1990; (--):169-190. >>> Leupeptin; Saline; IP; rat; 2002; 45 days; long-term study, pumps replaced every 15 days; no stress (see pgs. 178, 180).
P3263 Karran,E.H., Dodgson,K., Harris,S.J., Markwell,R.E., Harper,G.P. A simple in vivo model of collagen degradation using collagen-gelled cotton buds: the effects of collagenase inhibitors and other agents. Inflamm.Res. 1995; 44(--):36-46. >>> Collagenase inhibitor A; Collagenase inhibitor B; Collagenase inhibitor C; tempol; Superoxide dismutase-PEG; Cytochalasin B; Pepstatin; APMSF; TLCK; SBTI; Leupeptin; E-64; Methylamine; SC; Rat; 2001; 2ML1; 7 days; controls received mp w/vehicle; no stress (see pg. 39); immunology; pumps connected with catheter tubing to 14C-collagen-gelled cotton buds.
P2002 Kitani,K., Nagy,I.Zs., Ohta,M., Kanai,S., Sato,Y., Ivy,G.O. Effect of leupeptin on the lateral mobility of proteins in the plasma membrane of hepatocytes of C57BL/6 mice: FRAP studies on liver smears. Arch.Gerontol.Geriatr. 1992; 14(--):27-45. >>> Leupeptin; IP; mice; 2,5,8,11,14 days; stress/adverse reaction: states IP mp may have had adverse effect on results, however, mp size used was too large for animal/implant site per manufacturer; thiol-protease inhibitor.
P1987 Ivy,G.O. Protease inhibitors as a model for NCL disease, with special emphasis on the infantile and adult forms. Am.J.Med.Genet. 1992; 42(--):555-560. >>> E-64C; Aprotinin; Chloroquine; Leupeptin; CSF/CNS; rat; 2002; 2 weeks; no comment posted.
P1916 Lee,K.S., Frank,S., Vanderklish,P., Arai,A., Lynch,G. Inhibition of proteolysis protects hippocampal neurons from ischemia. Proc.Natl.Acad.Sci. 1991; 88(--):7233-7237. >>> Leupeptin; CSF/CNS; gerbil; 3 days; Ischemia (cerebral); peptides.
P1897 Ivy,G.O., Kanai,S., Ohta,M., Sato,Y., Otsubo,K., Kitani,K. Leupeptin causes an accumulation of lipofuscin-like substances in liver cells of young rats. Mech.Ageing Dev. 1991; 57(--):213-231. >>> Leupeptin; Saline; IP; rat; 2 weeks; peptides; thiol protease inhibitor.
P1243 Staubli,U., Larson,J., Thibault,O., Baudry,M., Lynch,G. Chronic administration of a thiol-proteinase inhibitor blocks long-term potentiation of synaptic responses. Brain Research 1988; 444(-1-):153-158. >>> Leupeptin; Saline; CSF/CNS; rat; 2002; 3 days; controls received mp w/ saline; mp connected to cannula in left ventricle; peptides.
P1100 Morris,R.G.M., Hagan,J.J., Nadel,L., Jensen,J., Baudry,M., Lynch,G.S. Spatial learning in the rat: Impairment induced by the thiol-proteinase inhibitor, leupeptin, and an analysis of [3H] glutamate receptor binding in relation to learning. Behav.Neural.Biol. 1987; 47(--):333-345. >>> Leupeptin; Saline; CSF/CNS; rat; 2002; 5 days; controls received mp w/saline; mp connected to catheter in lateral ventricle; 2 experiments were conducted, only 1 used the mp; peptides.
P0935 Siman,R., Ahdoot,M., Lynch,G. Ontogeny, compartmentation, and turnover of spectrin isoforms in rat central neurons. J.Neurosci. 1987; 7(-1-):55-64. >>> Leupeptin; Saline; CSF/CNS; rat; 10 days; mp model not stated; controls received mp w/saline; peptides; see p.534 for methods.
P0884 Ostrowski,L.E., Ahsan,A., Suthar,B.P., Pagast,P., Bain,D.L., Wong,C., Patel,A., Schultz,R.M. Selective inhibition of proteolytic enzymes in an in vivo mouse model for experimental metastasis. Cancer Res. 1986; 46(--):4121-4128. >>> Arginal, H-D-Phe-Pro-; EP-453; Leupeptin; DMSO; PBS; Propylene glycol; SC; mice; 2001; 5-7 days; controls received mp w/vehicle; mice injected w/melanoma cells; comparison of ip injections vs. mp infusion; cancer; no stress (see p. 4123); peptides.
P0633 Staubli,U., Baudry,M., Lynch,G. Olfactory discrimination learning is blocked by leupeptin, a thiol protease inhibitor. Brain Research 1985; 337(--):333-336. >>> Leupeptin; Saline; CSF/CNS; rat; 2002; 2 weeks; 2 doses leupeptin given; dose-response data; infusion into lateral ventricle; peptides.
P0534 Ivy,G.O., Schottler,F., Wenzel,J., Baudry,M., Lynch,G. Inhibitors of lysosomal enzymes: accumulation of lipofuscin-like dense bodies in the brain. Science 1984; 226(-4677-):985-987. >>> Chloroquine; Leupeptin; Saline; CSF/CNS; rat; about 2 weeks; mp model not stated; comparison of icv injection vs. mp infusion; comparison of agents effects; 3 doses of leupeptin used; peptides.
P0456 Lynch,G., Baudry,M. The biochemistry of memory: a new and specific hypothesis. Science 1984; 224(-4653-):1057-1063. >>> Leupeptin; Aprotinin; Saline; CSF/CNS; rat; 2002; 2 weeks; comparison of agents effects; 3 different drug concentrations used in mp: 4 mg Leu./ml saline, 8 mg/ml, 20 mg/ml; aprotinin and saline used separately as controls; peptides.
P0362 Kuranda,M.J., Aronson Jr,N.N. Tissue locations for the turnover of radioactively labeled rat orosomucoid in vivo. Arch.Biochem.Biophys. 1983; 224(-2-):526-533. >>> Leupeptin; Saline; SC; rat; 2ML1; 1 1/2 days; 125I-orosomucoid admin. 12 hours after pump implant; peptides.
84. Lovastatin
P2086 Joles,J., Willekes-Koolschijn,N., Koomans,H., Van Tol,A., Geelhoed-Mieras,T., Crommelin,D., Van Bloois,L., Krajnc-Franken,M., Cohen,L., Griffioen,M., Erkelens,W. Subcutaneous administration of HMG-CoA reductase inhibitors in hyperlipidaemic and normal rats. Lab.Anim. 1992; 26(--):269-280. >>> Lovastatin; Pravastatin; Liposomes; Simvastatin; Propylene glycol; rat; 2ML4; no duration posted; comparison of injections and oral administration vs. mp; stress/adverse reaction: local cystic reaction to simvastatin and lovastatin (p. 271, 275); enzyme inhibitor (HMG-CoA reductase), sc injections of simvastatin also caused subcutaneous toxicity.
85. Lysine Chloromethyl Ketone, N-a-tosyl-L-
P4854 Zhang,J.L., Yamaguchi,Y., Mori,K., Okabe,K., Hidaka,H., Ohshiro,H., Uchino,S., Ishihara,K., Furuhashi,T., Yamada,S., Ogawa,M. A serine protease inhibitor, N-alpha-tosyl-L-lysine chloromethyl ketone, prolongs rat hepatic allograft survival. Journal of Surgical Research 2001; 96(--):296-303. >>> Lysine chloromethyl ketone, N-a-tosyl-L-; Saline; SC; rat; up to 7 days; controls received mp w/ vehicle; immunology; enzyme inhibitor; TLCK is a serine protease inhibitor; immunosuppression..
P1673 Pakzad,R. Influence of the trypsin inhibitors aprotinin (Trasylol) and TLCK, administered locally by osmotic minipumps, on the gelatinolytic activity of acrosin and the transport of spermatozoa in the female reproductive tract of rabbits. Z.Mikrosk.-Anat.Forsch. 1989; 103(-6-):957-966. >>> Lysine chloromethyl ketone, N-a-tosyl-L-; Aprotinin; intrauterine; rabbit; 6 days; German with English summary (p. 957); trypsin inhibitors; tissue perfusion (uterus).
86. MDL 28170
P8724 Hori,R., Nakagawa,T., Sakamoto,T., Matsuoka,Y., Takebayashi,S., Ito,J. Pharmacological inhibition of Notch signaling in the mature guinea pig cochlea. NeuroReport 2007; 18(-18-):1911-1914. >>> MDL 28170; DMSO; PBS; Ear (cochlea); Guinea-pig; 1002; 14 days; Tissue perfusion (cochlea); enzyme inhibitor (gamma secretase); peptides; animal info (Hartley strain, 350-400g); MDL 28170 is a gamma-secretase inhibitor; 0.3% DMSO used; "a silicon tube (180 micron OD) connected to a micro-osmotic minipump...".
P7091 yala-Grosso,C., Tam,J., Xanthoudakis,S., Bureau,Y., Roy,S., Nicholson,D.W., Robertson,G.S. Effects of fimbria-fornix transection on calpain and choline acetyl transferase activities in the septohippocampal pathway. Neuroscience 2004; 126(-4-):927-940. >>> Leupeptin; MDL 28170; Saline, sterile; DMSO; cyclodextrin; CSF/CNS; Rat; 5 days; Controls received mp w/ vehicle; replacement therapy (axotomy); enzyme inhibitor (calpain); 2% DMSO; mp primed overnight at 37 degree Celsius.
P5598 Crocker,S.J., Smith,P.D., Jackson-Lewis,V., Lamba,W.R., Hayley,S.P., Grimm,E., Callaghan,S.M., Slack,R.S., Melloni,E., Przedborski,S., Robertson,G.S., Anisman,H., Merali,Z., Park,D.S. Inhibition of calpains prevents neuronal and behavioral deficits in an MPTP mouse model of Parkinson's disease. Journal of Neuroscience 2003; 23(-10-):4081-4091. >>> MDL 28170; Ringer's solution; cyclodextrins; DMSO; CSF/CNS; Mice; 1007D; ; Neurodegenerative (Parkinson's disease); MDL-28170 is a calpain inhibitor.
87. MDL 28842
P2493 Zhang,C., Bowlin,T., Mirkin,B.L. Suppression of C-1300 murine neuroblastoma cell proliferation in tissue culture and tumor growth in vivo by (Z) 5'-fluoro-4', -5'-didehydro-5'-deoxyadenosine (MDL 28,842), an irreversible inhibitor of s-adenosyl-l-homocysteine hydrolase. Oncology Res. 1993; 5(-10/11-):433-439. >>> MDL 28842; DMSO; Ethanol; Saline; SC; mice; 2001; 10, 30 days; dose-response (table p. 435, graph p. 436); pumps replaced every 10 days; cancer; enzyme inhibitor.
88. MDL 73811
P5355 Marasco,CJ Jr, Kramer,D.L., Miller,J., Porter,C.W., Bacchi,C.J., Rattendi,D., Kucera,L., Iyer,N., Bernacki,R., Pera,P., Sufrin,J.R. Synthesis and evaluation of analogues of 5 '-([(Z)-4-amino-2-butenyl]m ethylamino)-5 '-deoxyadenosine as inhibitors of tumor cell growth, trypanosomal growth, and HIV-1 infectivity. Journal of Medicinal Chemistry 2002; 45(-23-):5112-5122. >>> MDL 73811; MDL 73811 analogue; Water; Mice; 3, 7 days; Dose-response; immunology.
P2171 Bacchi,C.J., Nathan,H.C., Yarlett,N., Goldberg,B., McCann,P.P., Bitonti,A.J., Sjoerdsma,A. Cure of murine trypanosoma brucei rhodesiense infections with an S-adenosylmethionine decarboxylase inhibitor. Antimicrob.Agents Chemother. 1992; 36(-12-):2736-2740. >>> MDL 73811; mice; 2001; 2002; 7 days; comparison of oral admin vs mp; enzyme inhibitor.
89. MI-1, 2
P4025 Karran,E.H., Young,T.J., Markwell,R.E., Harper,G.P. In vivo model of cartilage degradation - effects of a matrix metalloproteinase inhibitor. Annals of the Rheumatic Diseases 1995; 54(--):662-669. >>> MI-1; MI-2; Propylene glycol; cartilage, femoral head; rat; 2ML2; 14 days; tissue perfusion (femoral head cartilage); good methods (p. 663); MI-1 and MI-2 are matrix metalloproteinase inhibitors; enzyme inhibitors.
90. ML-7
P9149 Han,Y.J., Hu,W.Y., Piano,M., de Lanerolle,P. Regulation of myosin by angiotensin II in light chain kinase expression hypertension. American Journal of Hypertension 2008; 21(-8-):860-865. >>> U0126; ML-7; DMSO; SC; Rat; 2ML4; 3 weeks; Controls received mp w/ vehicle; enzyme inhibitor (smMLCK or MEK or MAP kinase); animal info (male, SHR, WKY, 16 wks old); 50% DMSO used.
P9137 Barkan,D., Kleinman,H., Simmons,J.L., Asmussen,H., Kamaraju,A.K., Hoenorhoff,M.J., Liu,Z.Y., Costes,S.V., Cho,E.H., Lockett,S., Khanna,C., Chambers,A.F., Green,J.E. Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. Cancer Research 2008; 68(-15-):6241-6250. >>> ML-7; DMSO; Mice; 2004; 1 week; Controls received mp w/ vehicle; enzyme inhibitor (myosin light chain kinase, MLCK); cancer (breast); animal info (4-6 wks old, female, BALB/c, nu/nu).
P8127 Han,Y.J., Hu,W.Y., Chernaya,O., Antic,N., Gu,L.Z., Gupta,M., Piano,M., de Lanerolle,P. Increased myosin light chain kinase expression in hypertension: Regulation by serum response factor via an insertion mutation in the promoterD. MOLECULAR BIOLOGY OF THE CELL 2006; 17(-9-):4039-4050. >>> U0126; ML-7; DMSO; SC; Rat; 2ML4; 3 weeks; Controls received mp w/ vehicle; enzyme inhibitor (myosin light chain kinase); cardiovascular; animal info (SHR, Wistar-Kyoto, 1, 16 wks old); 50% DMSO.
P8116 Goldman,J., Zhong,L., Liu,S.Q. Negative regulation of vascular smooth muscle cell migration by blood shear stress. American Journal of Physiology-Heart and Circulatory Physiology 2007; 292(-2-):H928-H938. >>> PD-98059; ML-7; IV (vena cava); Rat; 2ML1; 5, 7 days; Enzyme inhibitor (MAP kinase-ERK kinase 1/2, myosin light chain kinase); animal info (male, Sprague-Dawley, 30. old, vein grafts).
P7780 Gu,L.Z., Hu,W.Y., Antic,N., Mehta,R., Turner,J.R., de Lanerolle,P. Inhibiting myosin light chain kinase retards the growth of mammary and prostate cancer cells. European Journal of Cancer 2006; 42(-7-):948-957. >>> ML-7; DMSO; SC; Mice; 2004; 4 weeks; Controls received mp w/ vehicle; no stress (see pg. 952, 955); enzyme inhibitor (myosin light chain kinase); cancer (mammary adenocarcinoma); toxicology; animal info (female, 14-20 wk. old, MMTV-free, C3H/Hen); 50% DMSO.
P7380 Fazal,F., Gu,L.Z., Ihnatovych,I., Han,Y., Hu,W., Antic,N., Carreira,F., Blomquist,J.F., Hope,T.J., Ucker,D.S., de Lanerolle,P. Inhibiting myosin light chain kinase induces apoptosis in vitro and in vivo. MOLECULAR AND CELLULAR BIOLOGY 2005; 25(-14-):6259-6266. >>> ML-7; DMSO; Mice; 1002; 28 days; Pumps replaced at 14 days; controls received mp w/ vehicle; animal info (female, 14-20 weeks old).
91. MLN-4760
P9973 Trask,A.J., Groban,L., Westwood,B.M., Varagic,J., Ganten,D., Gallagher,P.E., Chappell,M.C., Ferrario,C.M. Inhibition of Angiotensin-Converting Enzyme 2 Exacerbates Cardiac Hypertrophy and Fibrosis in Ren-2 Hypertensive Rats. American Journal of Hypertension 2010; 23(-6-):687-693. >>> MLN-4760; Saline, physiological; SC; Rat (transgenic); 2ML4; 28 days; Controls received mp w/ vehicle; cardiovascular; enzyme inhibitor (ACE2); no stress (see pg. 689); animal info (male, (mRen2)27 Tg, hypertensive, 12 weeks old).
92. MS-PPOH
P8742 Zhang,W.R., Koerner,I.P., Noppens,R., Grafe,M., Tsai,H.J., Morisseau,C., Luria,A., Hammock,B.D., Falck,J.R., Alkayed,N.J. Soluble epoxide hydrolase: a novel therapeutic target in stroke. Journal of Cerebral Blood Flow and Metabolism 2007; 27(-12-):1931-1940. >>> MS-PPOH; SC; Mice; 2001D; 24 hours; Enzyme inhibitor (p45D epoxygenase; ischemia (cerebral); animal info (C57BL/6, 20-26g, MCAO); N-methylsultonyl-6-(2-propargyloxyphenyl) hexanamide.
P7845 Pokreisz,P., Fleming,I., Kiss,L., Barbosa-Sicard,E., Fisslthaler,B., Falck,J.R., Hammock,B.D., Kim,I.H., Szelid,Z., Vermeersch,P., Gillijns,H., Pellens,M., Grimminger,F., van Zonneveld,A.J., Collen,D., Busse,R., Janssens,S. Cytochrome P450 epoxygenase gene function in hypoxic pulmonary vasoconstriction and pulmonary vascular remodeling. Hypertension 2006; 47(-4-):762-770. >>> MS-PPOH; Cyclodextrin, 2-hydroxypropyl-beta; SC; Mice; 2001; 7 days; Controls received mp w/ vehicle; enzyme inhibitor (epoxygenase); cardiovascular; animal info (Swiss Webster, 30-35g., 7% hypoxia); N-methylsulfonyl-6-(2-propargyloxyphenyl) hexanamide.
93. Marimastat
P9727 Skipper,J.B., McNally,L.R., Rosenthal,E.L., Wang,W.Q., Buchsbaum,D.J. In vivo Efficacy of Marimastat and Chemoradiation in Head and Neck Cancer Xenografts. ORL-JOURNAL FOR OTO-RHINO-LARYNGOLOGY AND ITS RELATED SPECIALTIES 2009; 71(-1-):1-5. >>> Marimastat; DMSO; SC; Mice (nude); 2002; 14 days; Controls received mp w/vehicle; cancer; animal info (3 mo old, female).
P8016 Fridman,J.S., Caulder,E., Hansbury,M., Liu,X.D., Yang,G.J., Wang,Q., Lo,Y., Zhou,B.B., Pan,M., Thomas,S.M., Grandis,J.R., Zhuo,J.C., Yao,W.Q., Newton,R.C., Friedman,S.M., Scherle,P.A., Vaddi,K. Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer. Clinical Cancer Research 2007; 13(-6-):1892-1902. >>> Marimastat; INCB3619; SC; Mice; mice (nude); 7, 14 days; Controls received mp w/ vehicle; enzyme inhibitor (metalloprotease); cancer (squamous cell carcinoma, breast, lung carcinoma); toxicology; animal info (BALB/c, CD-1 nu/nu); ErbB ligand shedding inhibitor; half-life (pg 1894) "<2h in the mouse" 6.1h in larger animals.
P5943 Wada,N., Otani,Y., Kubota,T., Kimata,M., Minagawa,A., Yoshimizu,N., Kameyama,K., Saikawa,Y., Yoshida,M., Furukawa,T., Fujii,M., Kumai,K., Okada,Y., Kitajima,M. Reduced angiogenesis in peritoneal dissemination of gastric cancer through gelatinase inhibition. CLINICAL&EXPERIMENTAL METASTASIS 2003; 20(-5-):431-435. >>> Marimastat; DMSO; water; SC; Mice (SCID); 2002; 2 weeks; controls received mp w/ vehicle; enzyme inhibitor (matrix metalloprotease); marimastat, the broad-spectrum matrix metalloproteinase inhibitor was dissolved in 50% DMSO; angiogenesis inhibitor.
P5454 Charoenrat,P., Rhys-Evans,P., Eccles,S. A synthetic matrix metalloproteinase inhibitor prevents squamous carcinoma cell proliferation by interfering with epidermal growth factor receptor autocrine loops. International Journal of Cancer 2002; 100(-5-):527-533. >>> Marimastat; DMSO; Water, sterile; SC; Mice; 2002; 17 days; Controls received mp w/ vehicle; cancer; enzyme inhibitor (matrix metalloproteinase).
P5338 Kimata,M., Otani,Y., Kubota,T., Igarashi,N., Yokoyama,T., Wada,N., Yoshimizu,N., Fujii,M., Kameyama,K., Okada,Y., Kumai,K., Kitajima,M. Matrix metalloproteinase inhibitor, marimastat, decreases peritoneal spread of gastric carcinoma in nude mice. Japanese Journal of Cancer Research 2002; 93(-7-):834-841. >>> Marimastat; DMSO; SC; Mice (nude); 28 days; Controls received mp w/ vehicle; pumps replaced after 14 days; gastric cancer; enzyme inhibitor; matrix metalloproteinase inhibitor; 50% DMSO vehicle.
94. Mepacrine HCl
P2767 Nakamura,S. Effects of phospholipase a2 inhibitors on the antidepressant-induced axonal regeneration of noradrengeric locus coeruleus neurons. Microscopy Res.and Tech. 1994; 29(--):204-210. >>> Desipramine HCl; Mepacrine HCl; Bromphenacyl bromide, 4-; Saline; DMSO; CSF/CNS (cortex); rat; 2002; >2 weeks; antidepressant; mepacrine and 4-bromphenacyl bromide are phospholipase a2 inhibitors; 2 pumps implanted: one delivered just desipramine to one hemisphere, while the other infused desipramine and pla2 inhibitors to the other hemisphere.
95. Methazolamide
P1552 Linser,P.J., Plunkett,J.A. A role for carbonic anhydrase in early eye morphogenesis. Invest.Ophthalmol.Vis.Sci. 1989; 30(-4-):783-785. >>> Methazolamide; Tyrode's solution; Eye; in vitro; bird (chicken embryo); 2001; 3 days; comparison of topical dosing vs. mp infusion; tissue perfusion.
96. Metyrapone
Q0228 Yamana,R., Shirai,M., Suzuki,T., Tanaka,K., Yamamoto,M., Arishima,K., Takizawa,T. Corticosterone Synthesis Inhibitor-Induced Decrease in the Age-Dependant Expression of Nitric Oxide Synthase 3 in the Preterm Ductus Arteriosus of Rats. JOURNAL OF VETERINARY MEDICAL SCIENCE 2010; 72(-5-):555-560. >>> Metyrapone; DMSO; PEG 400; SC; Rat; 2001D; 6, 12, 24 hours; Controls received mp w/ vehicle; enzyme inhibitor (11-beta-hydroxylase); animal info (female, Wistar, 10-12 wks old); 50% DMSO used; 50% PEG 400 used.
97. Mevalonate
P7005 Duncan,R.E., El-Sohemy,A., Archer,M.C. Mevalonate promotes the growth of tumors derived from human cancer cells in vivo and stimulates proliferation in vitro with enhanced cyclin-dependent kinase-2 activity. Journal of Biological Chemistry 2004; 279(-32-):33079-33084. >>> Mevalonate; SC; Mice (nude); 2004; 13 weeks; Controls received mp w/ vehicle, or isotonic saline; long-term study; pumps replaced every 28 days; cancer (MDA-MB-435); MDA-MB-435 is a highly malignant human cancer of either breast adenocarcinoma or occult melanoma (origin uncertain); cancer (breast, melanoma, adenocarcinoma).
P6735 Duncan,R.E, El-Sohemy,A, Archer,M.C. Delivery of mevalonate to murine extrahepatic tissues via mini-osmotic pumps. Journal of Pharmalogical and Toxicological Methods 2004; 50(--):139-143. >>> Mevalonate; Water, distilled; saline; SC; Mice; 1002; 2 weeks; Controls received mp w/ saline; "...delivery from pumps without the use of an outflow direction device was effective for delivering mevalonate to mammary glands and colons of mice." p. 141.
P6040 Ohashi,K., Osuga,J., Tozawa,R., Kitamine,T., Yagyu,H., Sekiya,M., Tomita,S., Okazaki,H., Tamura,Y., Yahagi,N., Iizuka,Y., Harada,K., Gotoda,T., Shimano,H., Yamada,N., Ishibashi,S. Early embryonic lethality caused by targeted disruption of the 3-hydroxy-3-methylglutaryl-CoA reductase gene. Journal of Biological Chemistry 2003; 278(-44-):42936-42941. >>> Mevalonate; SC; Mice (pregnant); 2004; 4 weeks; Teratology.
P3457 Soma,M.R., Parolini,C., Donetti,E., Fumagalli,R., Paoletti,R. Inhibition of isoprenoid biosynthesis and arterial smooth-muscle cell proliferation. J.Cardiovasc.Pharmacol. 1995; 25(-S 4-):S20-S24. >>> Mevalonate; Fluvastatin; IP; perivascular (arterial collar); rabbit; no duration posted; controls received mp w/ saline; tissue perfusion (carotid artery collar); cardiovascular; enzyme inhibitor (HMG-CoA reductase).
P3443 Corsini,A., Bernini,F., Quarato,P., Donetti,E., Bellosta,S., Fumagalli,R., Paoletti,R., Soma,V.M.R. Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Cardiology 1996; 87(--):458-468. >>> Mevalonate; Fluvastatin; Saline, physiological; IP; perivascular (arterial collar); 5 days; tissue perfusion (lesion site-carotid collar); enzyme inhibitor (HMG-CoA reductase).
98. Miglustat
P8343 Bone,W., Walden,C.M., Fritsch,M., Voigtmann,U., Leifke,E., Gottwald,U., Boomkamp,S., Platt,F.M., van der Spoel,A.C. The sensitivity of murine spermiogenesis to miglustat is a quantitative trait: a pharmacogenetic study. Reproductive Biology and Endocrinology 2007; 5(--):U1-U13. >>> Miglustat; SC; Mice; 2004; 7 weeks; Functionality of mp verified by serum agent levels; comparison of oral vs. mp; long-term study; enzyme inhibitor (ceramide glucosyltransferase); animal info (male, C57BL/6J, BALB/C, FVB/N, 6 weeks old); reproductive endocrinology.
99. Nitropropionic Acid, 3-
Q0495 Cleren,C., Calingasan,N.Y., Starkov,A., Jacquard,C., Chen,J.Y., Brouillet,E., Beal,M.F. Promethazine protects against 3-nitropropionic acid-induced neurotoxicity. NEUROCHEMISTRY INTERNATIONAL 2010; 56(-2-):208-212. >>> Nitropropionic acid, 3-; Water, distilled; SC; Rat; 2ML1; 6 days; Animal info (male, Lewis, 12 wks old).
Q0499 Puerta,E., Hervias,I., Barros-Minones,L., Jordan,J., Ricobaraza,A., Cuadrado-Tejedor,M., Garcia-Osta,A., Aguirre,N. Sildenafil protects against 3-nitropropionic acid neurotoxicity through the modulation of calpain, CREB, and BDNF. NEUROBIOLOGY OF DISEASE 2010; 38(-2-):237-245. >>> Nitropropionic acid, 3-; SC; Rat; 2ML1; 5 days; Animal info (male, Lewis, 290-340 g.); neurodegenerative (Huntington's Disease).
P9752 Kraft,J.C., Osterhaus,G.L., Ortiz,A.N., Garris,P.A., Johnson,M.A. IN VIVO DOPAMINE RELEASE AND UPTAKE IMPAIRMENTS IN RATS TREATED WITH 3-NITROPROPIONIC ACID. Neuroscience 2009; 161(-3-):940-949. >>> Nitropropionic acid-3; Water; SC; Rat; 2ML1; 5 days; Controls received sham surgery; animal info (male, Lewis, 12 wks old, 300-350 g); behavioral testing (force plate actometer).
P9556 Yang,L.C., Calingasan,N.Y., Wille,E.J., Cormier,K., Smith,K., Ferrante,R.J., Beal,M.F. Combination therapy with Coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's Diseases. Journal of Neurochemistry 2009; 109(-5-):1427-1439. >>> MPTP; nitropropionic acid, 2-; PBS; SC; Rat; mice; 2004; 2ML1; ; Animal info (male, C57BL/6, 25-30g, Lewis 260-300g); neurodegenerative (Parkinson's, Hungtington's disease).
P9837 Yang,L.C., Calingasan,N.Y., Thomas,B., Chaturvedi,R.K., Kiaei,M., Wille,E.J., Liby,K.T., Williams,C., Royce,D., Risingsong,R., Musiek,E.S., Morrow,J.D., Sporn,M., Beal,M.F. Neuroprotective Effects of the Triterpenoid, CDDO Methyl Amide, a Potent Inducer of Nrf2-Mediated Transcription. PLoS One 2009; 4(-6-):U87-U99. >>> MPTP; nitropropionic acid, 3-; PBS; SC; Rat; mice; 2004; 2ML1; 7, 28 days; Animal info (male, C57BL/6, 3 months old, 25-30 g., male, Lewis, 3 months old, 250-300 g.); neurodegenerative (Parkinson's, Huntington's Disease).
Q0650 Yang,L.C., Shi,Q.L., Ho,D.J., Starkov,A.A., Wille,E.J., Xu,H., Chen,H.L., Zhang,S., Stack,C.M., Calingasan,N.Y., Gibson,G.E., Beal,M.F. Mice deficient in dihydrolipoyl succinyl transferase show increased vulnerability to mitochondrial toxins. NEUROBIOLOGY OF DISEASE 2009; 36(-2-):320-330. >>> Nitropropionic acid, 3-; SC; Mice; 5 days; WT controls received mp; animal info (8 mo old, male, DLST+/-, wt); enzyme inhibitor (mitochondrial succinate dehydrogenase).
P8801 Lee,S.T., Park,J.E., Kim,D.H., Kim,S., Im,W.S., Kang,L., Jung,S.H., Kim,M.W., Chu,K., Kim,M. Granulocyte-colony stimulating factor attenuates striatal degeneration with activating survival pathways in 3-nitropropionic acid model of Huntington's disease. Brain Research 2008; 1194(-;-):130-137. >>> Nitropropionic acid, 3-; PBS; NaOH; SC; Rat; 2ML1; 5 days; Animal info (male, Lewis, 300-320g., 12 wks. old); neurodegenerative (Huntington's disease).
P9305 Park,J.E., Lee,S.T., Im,W.S., Chu,K., Kim,M. Galantamine reduces striatal degeneration in 3-nitropropionic acid model of Huntington's disease. Neuroscience Letters 2008; 448(-1-):143-147. >>> Nitropropionic acid, 3-; PBS; SC; Rat; 2ML1; 5 days; Animal info (male, Lewis, 12 wks old, 300-320 g.); neurodegenerative (Huntington's Disease).
P9266 Puchowicz,M.A., Zechel,J.L., Valerio,J., Emancipator,D.S., Xu,K., Pundik,S., LaManna,J.C., Lust,W.D. Neuroprotection in diet-induced ketotic rat brain after focal ischemia. Journal of Cerebral Blood Flow and Metabolism 2008; 28(-12-):1907-1916. >>> Butyrate, sodium-B-hydroxy-; propionate; nitropropionic acid, 3-; Saline, normal; CSF/CNS; Rat; 2001; 4 days; Controls received mp w/ vehicle; ALZET brain infusion kit used; ischemia (cerebral); animal info (male Wistar, 28 days old, 110 g., MCAO); neurodegenerative (Alzheimer's, Parkinson's, Freidereich's ataxia, ALS, stroke).
P8922 Escartin,C., Boyer,F., Bemelmans,A.P., Hantraye,P., Brouillet,E. IGF-1 exacerbates the neurotoxicity of the mitochondrial inhibitor 3NP in rats. Neuroscience Letters 2007; 425(-3-):167-172. >>> Insulin-like growth factor I; nitropropionic acid, 3-; Acetic acid; BSA; SC; Rat; 2001; 2ML1; 5 days; Controls received mp w/ vehicle; functionality of mp verified by plasma glucose; dose-response (fig. 1, pg. 169); ALZET brain infusion kit used; animal info (Lewis, 400 g.); neurodegenerative (Huntington's Disease).
P8899 Jacquard,C., Trioulier,Y., Cosker,F., Escartin,C., Bizat,N., Hantraye,P., Cancela,J.M., Bonvento,G., Brouillet,E. Brain mitochondrial defects amplify intracellular [Ca2+] rise and neurodegeneration but not Ca2+ entry during NMDA receptor activation. FASEB Journal 2006; 20(-7-):U322-U336. >>> Nitropropionic acid, 3-; Water, deionized; NaOH; Phosphate buffer; SC; Rat; 2ML1; 6 days; Controls received empty mp; dose-response (fig.2); animal info (male, Lewis, 320-350 g., 12 wks old); neurodegenerative (Huntington's Disease).
P8115 Lee,S.T., Chu,K., Park,J.E., Kang,L., Ko,S.Y., Jung,K.H., Kim,M. Memantine reduces striatal cell death with decreasing calpain level in 3-nitropropionic model of Huntington's disease. Brain Research 2006; 1118(-;-):199-207. >>> Nitropropionic acid, 3-; PBS; NaOH; SC; Rat; 2ML1; 4, 5 days; Animal Info (male, Sprague-Dawley, 220-240g.); neurodegenerative (Huntington's disease).
P7909 Picconi,B., Passino,E., Sgobio,C., Bonsi,P., Barone,I., Ghiglieri,V., Pisani,A., Bernardi,G., mmassari-Teule,M., Calabresi,P. Plastic and behavioral abnormalities in experimental Huntington's disease: A crucial role for cholinergic interneurons. NEUROBIOLOGY OF DISEASE 2006; 22(-1-):143-152. >>> Nitropropionic acid, 3-; Water, distilled; NaOH; SC; Rat; 2ML4; 5 days; Controls received emtpy mp; neurodegenerative (Huntington's disease); animal info (male, Lewis, 340-370 g, 12 weeks old).
P8039 Woodruff,T.M., Crane,J.W., Proctor,L.M., Buller,K.M., Shek,A.B., de Vos,K., Pollitt,S., Williams,H.M., Shiels,I.A., Monk,P.N., Taylor,S.M. Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration. FASEB Journal 2006; 20(-9-):1407-1417. >>> Nitropropionic acid, 3-; PBS; sodium hydroxide; SC; Rat; 2ML1; 7 days; Animal info (male, Lewis); neurodegenerative (Huntington's disease).
P7174 Bizat,N., Galas,M.C., Jacquard,C., Boyer,F., Hermel,J.M., Schiffmann,S.N., Hantraye,P., Blum,D., Brouillet,E. Neuroprotective effect of zVAD against the neurotoxin 3-nitropropionic acid involves inhibition of calpain. Neuropharmacology 2005; 49(-5-):695-702. >>> Nitropropionic acid, 3-; zVAD; Saline; DMSO; SC; CSF/CNS; Rat; 2001; 2ML1; 5 days; Controls received mp w/ vehicle sham operation; enzyme inhibitor (caspase, calpain), multiple pumps per animal (2); 40% DMSO.
R0232 Brouillet,E., Jacquard,C., Bizat,N., Blum,D. 3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. Journal of Neurochemistry 2005; 95(-6-):1521-1540. >>> Nitropropionic acid, 3-; SC; IP; Rat; mice; 2002; 2ML1; 2ML4; 4 weeks; 5,14 days; Neurodegenerative (Huntington's disease); dose-response (table 1); toxicology; animal info (C57BL/6, Sprague-Dawley, Lewis); "an improved 3NP model using osmotic minipumps in Lewis rats." (p. 1526).
P7294 Cleren,C., Calingasan,N.Y., Chen,J., Beal,M.F. Celastrol protects against MPTP- and 3-nitropropionic acid-induced neurotoxicity. Journal of Neurochemistry 2005; 94(-4-):995-1004. >>> Nitropropionic acid, 3-; Water, distilled; SC; Rat; 2ML1; 5 days; Enzyme inhibitor (succinate dehydrogenase).
P8098 Newcomb,J.D., Brown,W.D., Rodriguez,A.I., Garbuzova-Davis,S., Saporta,S., Sanberg,P.R., Willing,A.E. Behavioral alterations in Lewis rats following two-day continuous 3-nitropropionic acid administration. NEUROTOXICITY RESEARCH 2005; 8(-3-4-):259-265. >>> Nitropropionic acid, 3-; Saline; SC; Rat; 2ML4; 2 days; Controls received mp w/ vehicle; toxicology; animal info (male, Lewis, 12 wks old, 250-300g.).
P6441 Blum,D., Galas,M.G., Cuvelier,L., Schiffmann,S.N. Chronic intoxication with 3-nitropropionic acid in rats induces the loss of striatal dopamine terminals without affecting nigral cell viability. Neuroscience Letters 2004; 354(-3-):234-238. >>> Nitropropionic acid, 3-; PBS; NAOH; SC; Rat; 2ML1; 5 days; Enzyme inhibitor (succinate dehydrogenase); neurodegenerative (Huntington's disease); 3NP pH was adjusted to 7.4; "chronic intoxication with 3NP leads to alterations in striatal dopamine terminals similar to those found in HD patients and transgenic models." p.237.
P6873 Blum,D., Hemming,F.J., Galas,M.C., Torch,S., Cuvelier,L., Schiffmann,S.N., Sadoul,R. Increased Alix (apoptosis-linked gene-2 interacting protein X) immunoreactivity in the degenerating striatum of rats chronically treated by 3-nitropropionic acid. Neurosci.Lett. 2004/9/30; 368(-3-):309-313. >>> Nitropropionic acid, 3-; PBS; NaOH; SC; Rat; 2ML1; 5 days; Controls received sham operation with no mp.
P6934 Lastres-Becker,I., Bizat,N., Boyer,F., Hantraye,P., Fernandez-Ruiz,J., Brouillet,E. Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo. NeuroReport 2004; 15(-15-):2375-2379. >>> Nitropropionic acid, 3-; SC; Rat; 2ML1; 5 days; Neurodegenerative (Huntington's disease).
P7083 Yang,L.C., Sugama,S., Mischak,R.P., Kiaei,M., Bizat,N., Brouillet,E., Joh,T.H., Beal,M.F. A novel systemically active caspase inhibitor attenuates the toxicities of MPTP, malonate, and 3NP in vivo. NEUROBIOLOGY OF DISEASE 2004; 17(-2-):250-259. >>> Nitropropionic acid, 3-; NaOH; SC; Rat; 2ML1; 7 days; Controls received mp w/ agent, but no Q-VD-OPH treatment; enzyme inhibitor (succinate dehydrogenase).
P6893 Bizat,N, Hermel,J.M., Humbert,S, Jacquard,C., Creminon,C., Escartin,C., Saudou,F, Krajewski,S., Hantraye,P., Brouillet,E. In Vivo Calpain/Caspase Cross-talk during 3-Nitropropionic Acid-induced Striatal Degeneration. Journal of Biological Chemistry 2003; 278(-44-):43245-43253. >>> Nitropropionic acid, 3-; calpain inhibitor I; DMSO; PBS; SC; CSF/CNS; Rat; 2001; 2ML1; 1-5 days; Controls received mp w/ vehicle or sham operation; enzyme inhibitor (succinate dehydrogenase); ALZET brain infusion kit used; multiple pumps per animal (2); 40% DMSO used for calpain inhibitor I; neurodegenerative (Huntington's disease).
P5908 Bizat,N., Hermel,J.M., Boyer,F., Jacquard,C., Creminon,C., Ouary,S., Escartin,C., Hantraye,P., Krajewski,S., Brouillet,E. Calpain is a major cell death effector in selective striatal degeneration induced in vivo by 3-nitropropionate: Implications for Huntington's disease. Journal of Neuroscience 2003; 23(-12-):5020-5030. >>> Nitropropionic acid, 3-; calpain inhibitor-1; PBS; DMSO; SC; CSF/CNS; Rat; 2001; 2ML1; 5 days; ALZET brain infusion kit 1 used; neurodegenerative (Huntington's disease); 3-NP was infused using the 2ML1,&the CI-1 was delievered ICV using the 2001; CI-1 was dissolved in PBS&40% DMSO; pumps implanted simultaneously.
P5907 Blum,D., Galas,M.C., Pintor,A., Brouillet,E., Ledent,C., Muller,C.E., Bantubungi,K., Galluzzo,M., Gall,D., Cuvelier,L., Rolland,A.S., Popoli,P., Schiffmann,S.N. A dual role of adenosine A2A receptors in 3-nitropropionic acid-induced striatal lesions: Implications for the neuroprotective potential of A2A antagonists. Journal of Neuroscience 2003; 23(-12-):5361-5369. >>> Nitropropionic acid, 3-; PBS; sodium hydroxide; SC; Rat; 2ML1; 5 days.
P7106 McBride,J.L, During,M.J, Wuu,J, Chen,E.Y, Leurgans,S.E., Kordower,J.H. Structural and functional neuroprotection in a rat model of Huntington's disease by viral gene transfer of GDNF. Experimental Neurology 2003; 181(--):213-223. >>> Nitropropionic acid, 3-; SC; Rat; 2ML4; 6 days; Neurodegenerative (huntington's disease).
P6114 Tieu,K., Perier,C., Caspersen,C., Teismann,P., Wu,D.C., Yan,S.D., Naini,A., Vila,M., Jackson-Lewis,V., Ramasamy,R., Przedborski,S. D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease. Journal of Clinical Investigation 2003; 112(-6-):892-901. >>> Hydroxybutyrate, D-B; hydroxybutyrate, L; nitropropionic acid, 3-; Saline; SC; Mice; 2001; 7 days; Controls received mp w/ vehicle; neurodegenerative (Parkinson's disease).
P5504 Blum,D., Galas,M.C., Gall,D., Cuvelier,L., Schiffmann,S.N. Striatal and cortical neurochemical changes induced by chronic metabolic compromise in the 3-nitropropionic model of Huntington's disease. NEUROBIOLOGY OF DISEASE 2002; 10(-3-):410-426. >>> Nitropropionic acid, 3-; PBS; SC; Rat; 2ML1; 1, 2, 3, 4, 5 days; Neurodegenerative (Huntington's disease); neurotoxicity.
P5325 Blum,D., Gall,D., Galas,M.C., d'Alcantara,P., Bantubungi,K., Schiffmann,S.N. The adenosine A1 receptor agonist adenosine amine congener exerts a neuroprotective effect against the development of striatal lesions and motor impairments in the 3-nitropropionic acid model of neurotoxicity. Journal of Neuroscience 2002; 22(-20-):9122-9133. >>> Nitropropionic acid, 3-; SC; Rat; 5 days; Neurodegenerative (Huntington's disease).
P6937 Blum,D., Gall,D, Cuvelier,L., Schiffmann,S.N. Topological analysis of striatal lesions induced by 3-nitropropionic acid in the Lewis rat. Neuropharmacology and Neurotoxicology 2001; 12(-8-):1769-1772. >>> Nitropropionic acid, 3-; PBS; SC; Rat; 2ML1; 5 days; Neurodegenerative (Huntington's Disease).
P6892 El Massioui,N, Quary,S, Cheruel,F, Hantraye,P., Brouillet,E. Perseverative Behavior Underlying Attentional Set-Shifting Deficits in Rats Chronically Treated With the Neurotoxin 3-Nitropropionic Acid. Experimental Neurology 2001; 172(--):172-181. >>> Nitropropionic acid, 3-; SC; Rat; 2ML4; 5 days; Controls received empty mp.
P4813 Vis,J.C., Verbeek,M.M., de Waal,R.M.W., ten Donkelaar,H.J., Kremer,B. The mitochondrial toxin 3-nitropropionic acid induces differential expression patterns of apoptosis-related markers in rat striatum.. Neuropathology and Applied Neurobiology 2001; 27(--):68-76. >>> Nitropropionic acid, 3-;; Water;; SC;; rat;; 4 weeks;; Controls received mp w/ saline; neurodegenerative (Huntington's disease).
P6936 Dautry,C, Vaufrey,F, Brouillet,E., Bizat,N, Henry,P.G, Conde,F., Bloch,G., Hantraye,P. Early N-Acetylaspartate Depletion is a Marker of Neuronal Dysfunction in Rats and Primates Chronically Treated With the Mitochondrial Toxin 3-Nitropropionic Acid. Journal of Cerebral Blood Flow and Metabolism 2000; 20(--):789-799. >>> Nitropropionic acid, 3-; SC; Rat; 2ML4; 3,5 days; Controls received empty mp; neurodegenerative (Huntington's Disease).
P4756 Leventhal,L, Sortwell,C.E, Hanbury,R, Collier,T.J., Korkower,J.H, Palfi,S. Cyclosporin A protects striatal neurons in vitro and in vivo from 3-nitropropionic acid toxicity.. The Journal of Comparative Neurology 2000; 425(--):471-478. >>> Nitropropionic acid, 3-; PBS;; SC;; rat;; 2004;; 7 days;; Controls received mp w/ vehicle; toxicology; 3-nitro-propionate also called 3-nitropropionic acid (3NP); 3NP is a mitochondrial toxin; neurodegenerative (Huntington's disease).
P4670 Ouary,S, Bizat,N, Altairac,S., Menetrat,H, Mittoux,V., Conde,F., Hantraye,P., Brouillet,E. Major strain differences in response to chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid in rats: Implications for neuroprotection studies.. Neuroscience 2000; 97(-3-):521-530. >>> Nitropropionic acid, 3-;; Saline;; SC; rat; 2ML4;; 5 days;; Controls received empty pumps; comparison of IP injections vs. mp; neurodegenerative (Huntington's disease); mitochondrial toxin; neuroprotection..
100. OKY-046
P1646 Ruiz,P., Coffman,T.M., Klotman,P.E., Sanfilippo,F. Association of chronic thromboxane inhibition with reduced in situ cytotoxic T cell activity in rejecting rat renal allografts. Transplantation 1989; 48(-4-):660-666. >>> OKY-046; Saline; IA (renal); rat; 4 days; tissue perfusion; OKY-046 is a thromboxane synthetase inhibitor.
P1431 Coffman,T.M., Ruiz,P., Sanfilippo,F., Klotman,P.E. Chronic thromboxane inhibition preserves function of rejecting rat renal allografts. Kidney Int. 1989; 35(--):24-30. >>> OKY-046; Saline; IA (renal); rat; 4 days; schematic of OP ligated to aortic cuff of allograft; tissue perfusion; cancer/immunology.
101. ONO-1714
P6069 Kato,Y., Miura,Y., Yamamoto,N., Ozaki,N., Oiso,Y. Suppressive effects of a selective inducible nitric oxide synthase (iNOS) inhibitor on pancreatic beta-cell dysfunction. Diabetologia 2003; 46(-9-):1228-1233. >>> ONO-1714; Saline; SC; Mice; 2004; 4 weeks; Controls received mp w/ vehicle; ONO-1714 plasma levels taken; ONO-1714 is a novel cyclic amidine analog (an iNOS inhibitor); low an high dose used.
P5824 Ogawa,D., Shikata,K., Matsuda,M., Okada,S., Usui,H., Wada,J., Taniguchi,N., Makino,H. Protective effect of a novel and selective inhibitor of inducible nitric oxide synthase on experimental crescentic glomerulonephritis in WKY rats. NEPHROLOGY DIALYSIS TRANSPLANTATION 2002; 17(-12-):2117-2121. >>> ONO-1714; Saline; IP; Rat; 14 days; Controls received mp w/ vehicle; enzyme inhibitor (inducible Nitric oxide synthase); ONO-1714 is a novel cyclic amidine analog (an iNOS inhibitor).
102. Olprinone
Q0833 Yamanaka,K., Hatano,E., Narita,M., Kitamura,K., Yanagida,A., Asechi,H., Nagata,H., Taura,K., Nitta,T., Uemoto,S. Olprinone Attenuates Excessive Shear Stress Through Up-Regulation of Endothelial Nitric Oxide Synthase in a Rat Excessive Hepatectomy Model. LIVER TRANSPLANTATION 2011; 17(-1-):60-69. >>> Olprinone; IP; Rat; 2001; ; Controls received equal amounts of saline; animal info (male, Lewis, inbred, 9-10 wks old, 240-280 g, hepatectomy); enzyme inhibitor (phosphodiesterase III); "We used Alzet peritoneal pump placement instead of intravenous access for continuous administration in this study because the peritoneal pump could more steadily and easily administer OLP continuously." pg 67.
Q0335 Narita,M., Hatano,E., Ikai,I., Miyagawa-Hayashino,A., Yanagida,A., Nagata,H., Asechi,H., Taura,K., Uemoto,S. A Phosphodiesterase III Inhibitor Protects Rat Liver From Sinusoidal Obstruction Syndrome Through Heme Oxygenase-1 Induction. Annals of Surgery 2009; 249(-5-):806-813. >>> Olprinone; Water, distilled; IP; Rat; 2001; 60 hours; Animal info (male, Sprague-Dawley, 7-8 wks old, 250 g); enzyme inhibitor (phosphodiesterase III).
103. Ozagrel Natrium
P8880 Yokoyama,Y., Kawai,T., Kawai,S., Kitagawa,T., Watanabe,K., Kawai,K., Nagino,M. Up-regulated thromboxane production in the rat liver with biliary obstruction does not contribute to promote hepatic injury. SHOCK 2008; 29(-6-):688-691. >>> Ozagrel natrium; SQ29548; PBS; IP; Rat; 2001; 4 days; Controls received sham operation; enzyme inhibitor (TXA2 synthase); animal info (male, Wistar, 250-300g.); SQ29548 is a TXA2 receptor antagonist.
104. PD-98059
Q0832 Kobayashi,A., Shinoda,M., Sessle,B.J., Honda,K., Imamura,Y., Hitomi,S., Tsuboi,Y., Okada-Ogawa,A., Iwata,K. Mechanisms involved in extraterritorial facial pain following cervical spinal nerve injury in rats. Molecular Pain 2011; 7(-;-):U1-U11. >>> PD98059; fluoroacetate; DMSO; CSF/CNS (spinal cord, intrathecal); Rat; 2001; 7 days; Controls received mp w/ vehicle; animal info (adult, male, Sprague Dawley, 200-300 g); enzyme inhibitor (mitogen-activated protein kinase, MEK 1/2); 10% DMSO used.
Q0395 Adachi,K., Shimizu,K., Hu,J.W., Suzuki,I., Sakagami,H., Koshikawa,N., Sessle,B.J., Shinoda,M., Miyamoto,M., Honda,K., Iwata,K. Purinergic receptors are involved in tooth-pulp evoked nocifensive behavior and brainstem neuronal activity. Molecular Pain 2010; 6(-;-):U1-U11. >>> PD 98059; DMSO; CSF/CNS (intrathecal); Rat; 1 week; Animal info (male, Sprague Dawley, adult, 300-360 g); enzyme inhibitor (mitogen-activated extracellular signal-regulated kinase, MEK); 10% DMSO used.
P9757 Tsujimura,T., Kondo,M., Kitagawa,J., Tsuboi,Y., Saito,K., Tohara,H., Ueda,K., Sessle,B.J., Iwata,K. Involvement of ERK phosphorylation in brainstem neurons in modulation of swallowing reflex in rats. JOURNAL OF PHYSIOLOGY-LONDON 2009; 587(-4-):805-817. >>> PD 98059; DMSO; saline; CSF/CNS (intrathecal); Rat; 2001; ; Controls received mp w/vehicle; animal info (Sprague Dawley, male, 250-350 g); 10% DMSO used.
P9599 Creson,T.K., Hao,Y.L., Engel,S., Shen,Y., Hamidi,A., Zhuo,M., Manji,H.K., Chen,G. The anterior cingulate ERK pathway contributes to regulation of behavioral excitement and hedonic activity. BIPOLAR DISORDERS 2009; 11(-4-):339-350. >>> PD98059; CSF/CNS (anterior cingulate, cortex); Rat; 1002; ; Enzyme inhibitor (ERK); ALZET brain infusion kit 1 used; animal info (male, Sprague Dawley, 250-200g); behavioral testing (open-field, elevated-plus-maze, forced-swim, saccharin preference, amphetamine induced hyperactivity); brain tissue distribution; tissue perfusion (cortex).
P9459 Wei,S.G., Yu,Y., Zhang,Z.H., Felder,R.B. Angiotensin II upregulates hypothalamic AT1 receptor expression in rats via the mitogen-activated protein kinase pathway. American Journal of Physiology-Heart and Circulatory Physiology 2009; 296(-5-):H1425-H1433. >>> Angiotensin II; losartan; PD-98059; SP-600125; SB-203580; Saline; DMSO; CSF, artificial; SC; CSF/CNS; Rat; 2002; 2004; 4 weeks; Controls received mp w/ vehicle; pumps replaced after 2 weeks; enzyme inhibitor (MAP kinase, Jun N-terminal kinase); cardiovascular; peptides; multiple pumps per animal (2); animal info (male, Sprague Dawley, 275-300 g.); cannula placement confirmed at end of study; 0.1%-0.5% DMSO used.
P9265 Zhang,M., Hallows,J.L., Wang,X.Z., Bu,B.T., Wang,W., Vincent,I. Mitogen-activated protein kinase activity may not be necessary for the neuropathology of Niemann-Pick type C mice. Journal of Neurochemistry 2008; 107(-3-):814-822. >>> PD-98059; DMSO; saline; dye, Evan's blue; CSF/CNS; Mice; 1002; 2 weeks; Controls received mp w/ vehicle; functionality of mp verified by dye infusion; dose-response (fig. 1); enzyme inhibitor (MAPK/ERK 1); brain tissue distribution; animal info (female, BALB/c, Nctr-Npc, 5 wks old); 50% DMSO used; behavioral testing (limb motor activity/coat hanger test).
P8116 Goldman,J., Zhong,L., Liu,S.Q. Negative regulation of vascular smooth muscle cell migration by blood shear stress. American Journal of Physiology-Heart and Circulatory Physiology 2007; 292(-2-):H928-H938. >>> PD-98059; ML-7; IV (vena cava); Rat; 2ML1; 5, 7 days; Enzyme inhibitor (MAP kinase-ERK kinase 1/2, myosin light chain kinase); animal info (male, Sprague-Dawley, 30. old, vein grafts).
P7956 Di,Cristo G., Berardi,N., Cancedda,L., Pizzorusso,T., Putignano,E., Ratto,G.M., Maffei,L. Requirement of ERK activation for visual cortical plasticity. Science 2001/6/22; 292(-5525-):2337-2340. >>> U0126; PD-98059; SB203580; CSF/CNS (visual cortex); Rat; 1 week; Controls received mp w/ vehicle; stability verified by inhibition of ERK activation by picrotoxin; enzyme inhibitor (p38 MAP kinase); animal info (Dark-reared, P28); tissue perfusion (visual cortex).
P6519 Haddad,F., Adams,G.R. Inhibition of MAP/ERK kinase prevents IGF-I-induced hypertrophy in rat muscles. Journal of Applied Physiology 2004; 96(-1-):203-210. >>> PD-98059; insulin-like growth factor I; IM (plantaris); Rat; 2002; 14 days; Controls received no treatment to the contralateral muscle; functionality of mp verified by residual volume aspiration&measurement; no stress (see pg.205); good methods p. 203; enzyme inhibitor (MAPK/ERK kinase); mp primed in sterile saline @ 37 degrees Celsius.
P4759 Muthalif,M.M, Benter,I.F., Khandekar,Z, Gaber,L, Estes,A, Malik,S, Parmentier,J.-H, Manne,V, Malik,K.U. Contribution of Ras GPase/MAP kinase and cytochrome P450 metabolites to deoxycorticosterone-salt-induced hypertension.. Hypertension 2000; 35(-part 2-):457-463. >>> FPT III; BMS-191563; PD-98059; IP; Rat; 2ML1; 5 days; Controls received mp w/ vehicle; replacement therapy (uninephrectomy); cardiovascular; antihypertensive; enzyme inhibitor; FPT III and BMS-191563 are Ras farnesyl transferase enzyme inhibitors; PD-98059 is an MEK enzyme inhibitor; MEK is MAP (mean arterial pressure) kinase kinase inhibitor.
105. PF-956980
P8843 Changelian,P.S., Moshinsky,D., Kuhn,C.F., Flanagan,M.E., Munchhof,M.J., Harris,T.M., Doty,J.L., Sun,J.M., Kent,C.R., Magnuson,K.S., Perregaux,D.G., Sawyer,P.S., Kudlacz,E.M. The specificity of JAK3 kinase inhibitors. Blood 2008; 111(-4-):2155-2157. >>> PF-956980; PEG 300; SC; Mice; 2004; 14 days; Dose-response (Fig. 1); enzyme inhibitor (JAK3); immunology.
106. PF-3758309
P9917 Murray,B.W., Guo,C.X., Piraino,J., Westwick,J.K., Zhang,C., Lamerdin,J., Dagostino,E., Knighton,D., Loi,C.M., Zager,M., Kraynov,E., Popoff,I., Christensen,J.G., Martinez,R., Kephart,S.E., Marakovits,J., Karlicek,S., Bergqvist,S., Smeal,T. Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2010; 107(-20-):9446-9451. >>> PF-3758309; Mice (nude); 9 days; Dose response; enzyme inhibitor (P21-activated kinsase); animal info (athymic, CRL breed, 6-8 weeks); cancer.
107. PI-88
P9508 Parish,C.R. Identification of Sulfated Oligosaccharide-based Inhibitors of Tumor Growth and Metastasis Using Novel in Vitro Assays for Angiogenesis and Heparanase Activity. Cancer Research 1999; (-59-):3433-3441. >>> PI-88; Saline; IP; Rat; 2ML1; 2ML2; 3, 7 days; Controls received mp w/ vehicle; animal info (female, Fisher, 10-13 wks old); PI-88 is a phosphomannopentaose sulfate.
P5637 Francis,D.J., Parish,C.R., McGarry,M., Santiago,F.S., Lowe,H.C., Brown,K.J., Bingley,J.A., Hayward,I.P., Cowden,W.B., Campbell,J.H., Campbell,G.R., Chesterman,C.N., Khachigian,L.M. Blockade of vascular smooth muscle cell proliferation and intimal thickening after balloon injury by the sulfated oligosaccharide PI-88 - Phosphomannopentaose sulfate directly binds FGF-2, blocks cellular signaling, and inhibits proliferation. Circulation Research 2003; 92(-8-):E70-E77. >>> PI-88; Saline; SC; IP; Rat; rabbit; 2ML2; 2 weeks; Controls received mp w/ vehicle; enzyme inhibitor (heparanase); cardiovascular; PI-88 is a synthetic polysulfated oligosaccharide (also called phosphomannopentaose sulfate); potent inhibitor of tumor metastasis and angiogenesis; pumps implanted SC in rats and IP in rabbits..
P5039 Iversen,P.O., Iversen,P.O., Sorensen,D.R., Benestad,H.B. Inhibitors of angiogenesis selectively reduce the malignant cell load in rodent models of human myeloid leukemias. LEUKEMIA 2002; 16(--):376-381. >>> Endostatin, LPS; PI-88; IP; mice; 2004; 4 weeks; cancer; recombinant human endostatin used; PI-88 is an anticoagulant mannopentaose phosphate sulfate; angiogenesis inhibitors. Agents given singly or concomitantly in same pump.
108. Parecoxib
P9044 Bivol,L.M., Hultstroem,M., Gudbrandsen,O.A., Berge,R.K., Iversen,B.M. Tetradecylthioacetic acid downregulates cyclooxygenase 2 in the renal cortex of two-kidney, one-clip hypertensive rats. American Journal of Physiology-Regulatory Integrative and Comparative Physiology 2008; 295(-6-):R1866-R1873. >>> Parecoxib; SC; Rat; 2ML4; 4 weeks; Enzyme inhibitor (COX-2); animal info (male, Wistar, 180-200 g.).
P8603 Norregaard,R., Jensen,B.L., Topcu,S.O., Diget,M., Schweer,H., Knepper,M.A., Nielsen,S., Frokiaer,J. COX-2 activity transiently contributes to increased water and NaCl excretion in the polyuric phase after release of ureteral obstruction. American Journal of Physiology- Renal Physiology 2007; 292(-5-):F1322-F1333. >>> Parecoxib; Saline; SC; Rat; 3,4 days; Controls received mp w/ vehicle; enzyme inhibitor (cyclooxygenase-2); animal info (male, munich-wistar, 250 grams, bilateral ureteral obstruction and release).
P8269 Norregaard,R., Jensen,B.L., Topcu,S.O., Nielsen,S.S., Walter,S., Djurhuus,J.C., Frokiaer,J. Cyclooxygenase type 2 is increased in obstructed rat and human ureter and contributes to pelvic pressure increase after obstruction. Kidney International 2006; 70(-5-):872-881. >>> Parecoxib; Saline, isotonic; SC; Rat; 2 days; Controls received mp w/ vehicle; enzyme inhibitor (cyclooxygenase-2); animal info (male, Munich-Wistar, 220-250g., Bilateral ureter obstruction).
P7149 Norregaard,R., Jensen,B.L., Li,C.L., Wang,W.D., Knepper,M.A., Nielsen,S., Frokiaer,J. COX-2 inhibition prevents downregulation of key renal water and sodium transport proteins in response to bilateral ureteral obstruction. American Journal of Physiology-Renal Physiology 2005; 289(-2-):F322-F333. >>> Parecoxib; Saline; SC; Rat; 24 hours; Controls received mp w/ vehicle.
109. Physostigmine
Q0425 Mauck,B., Lucot,J.B., Paton,S., Grubbs,R.D. Cholinesterase inhibitors and stress: Effects on brain muscarinic receptor density in mice. Neurotoxicology 2010; 31(-5-):461-467. >>> Pyridostigmine bromide; physostigmine; SC; Mice; 30 days; Controls received mp w/saline; animal info (male, C57BL6, 25 g); enzyme inhibitor (cholinesterase).
Q0242 Van Kampen,J.M., Eckman,C.B. Agonist-induced restoration of hippocampal neurogenesis and cognitive improvement in a model of cholinergic denervation. Neuropharmacology 2010; 58(-6-):921-929. >>> Physostigmine; carbachol; nicotine; pirenzepine; oxotremorine; mecamylamine; Saline; CSF/CNS; Rat; 2002; 2004; ; Controls received mp w/ vehicle; animal info (female, Sprague Dawley, 250 g.); neurodegenerative (Alzheimer's Disease).
P7570 Philippens,I.H.C.H., Joosen,M.J.A., Vanwersch,R.A.P. Stress adversely affects efficacy of physostigmine-scopolamine pretreatment against soman in guinea pigs. Pharmacology Biochemistry and Behavior 2005; 82(-1-):125-132. >>> Physostigmine; scopolamine bromide; Water, distilled; propylene glycol; acetic acid, glacial; ethanol; SC; Guinea-pig; 2002; 2 weeks; Controls received mp w/ vehicle; post op. care (nobecutane); animal info (male, dunkin-hartley albino, 400-450 g); 10% ETOH; wound clips used.
P6802 Choi,E.K., Park,D., Yon,J.M., Hur,G.H., Ha,Y.C., Che,J.H., Kim,J., Shin,S., Jang,J.Y., Hwang,S.Y., Seong,Y.H., Kim,D.J., Kim,J.C., Kim,Y.B. Protection by sustained release of physostigmine and procyclidine of soman poisoning in rats. European Journal of Pharmacology 2004; 505(-1-3-):83-91. >>> Physostigmine salicytate; procyclidine hydrochloride; Propylene glycol; acetic acid, glacial; ethanol; water; SC; Rat; 2001; 3 days; Functionality of mp verified by plasma levels; dose-response (table 1); enzyme inhibitor (cholinesterase); procyclidine is an NMDA antagonist.
P6417 Langley,R.J., Kalra,R., Mishra,N.C., Sopori,M.L. Central but not the peripheral action of cholinergic compounds suppresses the immune system. Journal of Neuroimmunology 2004; 148(-1-2-):140-145. >>> Physostigmine; pyridostigmine bromide; edrophonium; Saline; CSF, artificial; SC; CSF/CNS; Rat; 2ML4; 3 weeks; Controls received mp w/ vehicle; enzyme inhibitor (acetylcholinesterase); immunology; ALZET brain infusion kit.
P5707 Muggleton,N.G., Bowditch,A.P., Crofts,H.S., Scott,E.A.M., Pearce,P.C. Assessment of a combination of physostigmine and scopolamine as pretreatment against the behavioral effects of organophosphates in the common marmoset (Callithrix jacchus). Psychopharmacology 2003; 166(-3-):212-220. >>> Physostigmine salicylate; scopolamine hydrobromide; Saline; SC; Monkey (marmoset); 2002; 14 days; Controls received mp w/ vehicle; behavioral testing; agents infused via same pumps; toxicology.
P5352 Wetherell,J., Hall,T., Passingham,S. Physostigmine and hyoscine improves protection against the lethal and incapacitating effects of nerve agent poisoning in the guinea-pig. Neurotoxicology 2002; 23(-3-):341-349. >>> Physostigmine salicylate; Hyoscine hydrobromide; Pyridostigmine; Saline; SC; Guinea-pig; 2001; 7 days; Physostigmine and hyoscine infused together; toxicology.
P5145 Meshulam,Y., Cohen,G., Chapman,S., Alkalai,D., Levy,A. Prophylaxis against organophosphate poisoning by sustained release of scopolamine and physostigmine. Journal of Applied Toxicology 2001; 21(--):S75-S78. >>> Scopolamine; Physostigmine; Propylene glycol; Ethanol; Water; Acetic acid, glacial; SC; Dog; 2001; 24 or 48 hours; functionality of mp verified by plasma scopolamine&physostigmine levels; dose-response (table, p. S77); toxicology; vehicle was 10% ethanol, 20% PG, 70% water, 0.0035% AA; mentions benefits of infusion via pump (p. S77).
P4935 Beach,T.G., Kuo,Y.M., Schwab,C., Walker,D.G., Roher,A.E. Reduction of cortical amyloid beta levels in guinea pig brain after systemic administration of physostigmine. Neuroscience Letters 2001; 310(--):21-24. >>> Physostigmine salicylate; Saline, sterile; SC; guinea-pig; 2ML2; 10 days; controls received mp w/ vehicle; peptides; neurodegenerative (Alzheimer's disease); peptide amyloid beta; physostigmine is an acetylcholesterase enzyme inhibitor;.
P4925 Daniel,J.M., Dohanich,G.P. Acetylcholine mediates the estrogen-induced increase in NMDA receptor binding in CA1 of the hippocampus and the associated improvement in working memory. Journal of Neuroscience 2001; 21(-17-):6949-6956. >>> Pyridostigmine; Huperzine; Physostigmine; Scopolamine;; SC;; guinea-pig;; 3 days; Controls received sham operation; enzyme inhibitor; these are poisons known to be acetylcholinesterase inhibitors; doses inhibited 30% of AChE activity; Physostigmine was infused alone or together with Scopolamine; toxicology.
P4427 Meshulam,Y, Davidovici,R, Wengier,A, Levy,A. Prophylactic transdermal treatment with Physostigmine and Scopolamine against soman intoxication in guinea-pigs.. Journal of Applied Toxicology 1995; 15(--):263-266. >>> Physostigmine;; SC;; guinea-pig;; 2001;; ; comparison of acute injections vs. mp; half-life (p. 263); "Physostigmine concentrations needed for protection under continuous delivery were significantly smaller...than those needed following acute injection" (p. 265); Physostigmine has half life of 15 min. in rats and 30 min. in humans..
P4230 Philippens,I.H.C.H.M., Busker,R.W., Wolthuis,O.L., Olivier,B., Bruijnzeel,P.L.B., Melchers,B.P.C. Subchronic physostigmine pretreatment in guinea pigs: effective against soman and without side effects. Pharmacol.Biochem.Behav. 1998; 59(-4-):1061-1067. >>> Physostigmine; Scopolamine; Propylene glycol; Ethanol; Water; SC; guinea-pig; 2002; 2 weeks; controls received mp w/vehicle; functionality of mp verified by scopolamine plasma levels; agents infused alone or combined in same pump; "because a bolus injection of physostigmine is not a very realistic pretreatment procedure, a more chronic application was considered and evaluated" (p. 1062).
P2872 Wetherell,J.R. Continuous administration of low dose rates of physostigmine and hyoscine to guinea-pigs prevents the toxicity and reduces the incapacitation produced by soman poisoning. J.Pharm.Pharmacol. 1994; 46(--):1023-1028. >>> Physostigmine; Hyoscine; Saline, sterile; SC; guinea-pig; 2001; 2002; 1, 6 or 13 days; controls received sham surgery.
P2613 Meshulam,Y., Davidovici,R., Levy,A. Protection against soman and sarin exposure by transdermal physostigmine and scopolamine. Proc.Med.Def.Biosci.Rev. 1993; 2(--):812-819. >>> Physostigmine; SC; guinea-pig; 2001; 24 hours; comparison of transdermal administration vs. mp; toxicology; physostigmine administered w/ and w/out scopolamine.
P2593 Anderson,D.R., Harris,L.W., Lennox,W.J., Solana,R.P. Effects of subacute pretreatment with carbamate together with acute adjunct pretreatment against nerve agent exposure. Drug Chem.Toxicol. 1991; 14(-1&2-):1-19. >>> Physostigmine salicylate; Pyridostigmine bromide; Acetic acid, glacial; Water; guinea-pig; 2ML2; 14 days; controls received mp w/ vehicle; functionality of mp verified by AChE assay; comparison of acute injections vs. mp; acute scopolamine administered concomitantly; toxicology.
P2363 Miller,S.A., Blick,D.W., Kerenyi,S.Z., Murphy,M.R. Efficacy of physostigmine as a pretreatment for organophosphate poisoning. Pharmacol.Biochem.Behav. 1993; 44(--):343-347. >>> Physostigmine salicylate; Propylene glycol; Acetic acid, glacial; Ethanol, absolute; Water; SC; rat; 2001; 3,4,5,6,7 days; controls received mp w/ vehicle solution; functionality of mp verified by ChE inhibition (graph, p. 345).
P1891 Alberch,J., Carman-Krzan,M., Fabrazzo,M., Wise,B.C. Chronic treatment with scopolamine and physostigmine changes nerve growth factor (NGF) receptor density and NGF content in rat brain. Brain Research 1991; 542(--):233-240. >>> Physostigmine; SC; rat; 2001; 3, 7 days; no comment posted.
P1615 Mandel,R.J., Chen,A.D., Connor,D.J., Thal,L.J. Continuous physostigmine infusion in rats with excitotoxic lesions of the nucleus basalis magnocellularis: effects on performance in the water maze task and cortical cholinergic markers. J.Pharmacol.Exp.Ther. 1989; 251(-2-):612-619. >>> Physostigmine hemisulfate; Ethanol; Propylene glycol; Water; SC; rat; 1 week, 16 days; pump replaced at 12 days.
P1509 Lim,D.K., Ito,Y., Yu,Z.J., Hoskins,B., Ho,I.K. Prevention of soman toxicity after the continuous administration of physostigmine. Pharmacol.Biochem.Behav. 1989; 31(--):633-639. >>> Physostigmine salicylate; Ethanol; Acetic acid, glacial; Propylene glycol; Water; SC; guinea-pig; 2001; 4, 7 days; no comment posted.
P1508 Lim,D.K., Ito,Y., Stewart,T., Hoskins,B., Ho,I.K. Toxicity study of continuous administration of physostigmine salicylate. Pharmacol.Biochem.Behav. 1989; 31(--):627-631. >>> Physostigmine salicylate; Alcohol; Propylene glycol; Water; SC; guinea-pig; 2001; 7 days; stability of agent in vehicle tested.
P1483 Harris,L.W., Anderson,D.R., Lennox,W.J., Solana,R.P. Effects of subacute administration of physostigmine on blood acetylcholinesterase activity, motor performance, and soman intoxication. Toxicol.Appl.Pharmacol. 1989; 97(--):267-271. >>> Physostigmine salicylate; Acetic acid, glacial; Ethanol; Propylene glycol; Water; SC; rat; 2ML4; 28 days; functionality of mp verified in vitro.
P1408 Miyamoto,M., Narumi,S., Nagaoka,A., Coyle,J.T. Effects of continuous infusion of cholinergic drugs on memory impairment in rats with basal forebrain lesions. J.Pharmacol.Exp.Ther. 1989; 248(-2-):825-835. >>> Oxotremorine; Physostigmine sulfate; Saline; SC; rat; 2002; 3 weeks; no comment posted.
P0978 James,M.K., Cubeddu,L.X. Pharmacologic characterization and functional role of muscarinic autoreceptors in the rabbit striatum. J.Pharmacol.Exp.Ther. 1987; 240(-1-):203-215. >>> Physostigmine; SC; rabbit; 2ML2; 14 days; controls received sham surgery; 2 doses of agent infused.
P0663 Fernando,J.C.R., Hoskins,B., Ho,I.K. Rapid induction of supersensitivity to muscarinic antagonists-induced motor excitation by continuous stimulation of cholinergic receptors. Life Sci. 1985; 37(-9-):883-892. >>> Oxotremorine; Physostigmine sulfate; Saline; SC; rat; 2002; 2 weeks; comparison of single sc injec vs. daily injec vs. mp infusion of agents effects.
P0429 Girgis,M. A combined histochemical-neurophysiological technique for investigating the extent of diffusion of intracerebrally injected drugs. Acta Anat. 1983; 117(--):248-256. >>> Physostigmine; Reserpine; CSF/CNS (limbic system); cat; guinea-pig; monkey; rabbit; 3, 5, and 7 days; comparison of injec by microsyringe vs. mp infusion, infused hippocampus, septum, hypothalamus, caudate-putamen; chemitrode, mp advant. for icv admin; antihypertensive.
P0365 Loullis,C.C., Dean,R.L., Lippa,A.S., Meyerson,L.R., Beer,B., Bartus,R.T. Chronic administration of cholinergic agents: effects on behavior and calmodulin. Pharmacol.Biochem.Behav. 1983; 18(-4-):601-604. >>> Physostigmine; Scopolamine; Saline; SC; rat; 15 days; comparison of agents effects.
110. Plasminogen Activator Inhibitor-1
P8411 Kozai,T., Yamanaka,H., Dai,Y., Obata,K., Kobayashi,K., Mashimo,T., Noguchi,K. Tissue type plasminogen activator induced in rat dorsal horn astrocytes contributes to mechanical hypersensitivity following dorsal root injury. Glia 2007; 55(-6-):595-603. >>> Tissue plasminogen activator inhibitor; Saline; CSF/CNS (intrathecal, subarachnoid space); Rat; 2002; 5,11,15 days; Controls received mp w/ vehicle; dose-response (fig. 5); animal info (male, Sprague-Dawley, 250-300g.); tPA-STOP; Radiculopathy pain model.
P7945 Parathath,S.R., Parathath,S., Tsirka,S.E. Nitric oxide mediates neurodegeneration and breakdown of the blood-brain barrier in tPA-dependent excitotoxic injury in mice. Journal of Cell Science 2006; 119(-2-):339-349. >>> Tissue plasminogen activator; tissue plasminogen activator, S 481A; TmPyP; NMMA; TMPyP, Fe-; PTIO; TPPS, Fe-; SC; Mice; 7 days; Controls received mp w/ vehicle; dose-response (fig 3); enzyme inhibitor (tPA; NO synthase); neurodegenerative; animal info (C57BL/6).
P6562 Yamanaka,H., Obata,K., Fukuoka,T., Dai,Y., Kobayashi,K., Tokunaga,A., Noguchi,K. Tissue plasminogen activator in primary afferents induces dorsal horn excitability and pain response after peripheral nerve injury. European Journal of Neuroscience 2004; 19(-1-):93-102. >>> Tissue plasminogen activator inhibitor; CSF/CNS (intrathecal); Rat; 2001; 2002; 1,2 weeks; Controls received mp w/ saline; dose-response (p.100); inhibitor is a tPA-STOP {2,7-bis-(4-amidinobenzylidene)-cycloheptan-1-one dihydrochloride salt}.
P6178 Swiercz,R, Keck,R.W, Skrzypcak-Jankun,E, Selman,S.H, Jankun,J. Recombinant PAI-1 inhibits angiogenesis and reduces size of LNCaP prostate cancer xenografts in SCID mice. Oncology Reports 2001; 8(--):463-470. >>> Plasminogen activator inhibitor-1; Saline; SC; Mice (SCID); 2004; 28 days; Controls received mp w/ saline; dose-response (fig. 4 and 5); cancer (prostate); angiogenesis inhibitor.
P6129 Seeds,N.W., Basham,M.E., Ferguson,J.E. Absence of tissue plasminogen activator gene or activity impairs mouse cerebellar motor learning. Journal of Neuroscience 2003; 23(-19-):7368-7375. >>> Plasminogen activator inhibitor-1; tissue plasminogen activator, STOP; CSF, artificial; CSF/CNS (cerebellum); Mice; 1007D; 7 days; Controls received mp w/ vehicle; stability verified by amidolytic assays (tpa-STOP); good methods (p. 7369); half-life (p. 7369, 145 hours); ALZET brain infusion kit 1 used; recovery period; PAI-1 was recomb. mutant; "pump implantation and subsequent infusion of either aCSF or PAI-1 did not impair the mice's ability to perform a previously learned motor task." p. 7372; behavioral study.
P5823 Liberatore,G.T., Samson,A., Bladin,C., Schleuning,W.D., Medcalf,R.L. Vampire bat salivary plasminogen activator (desmoteplase) - A unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke 2003; 34(-2-):537-543. >>> Tissue-type plasminogen activator; Desmoteplase; PBS; CSF/CNS; Mice (knockout); 1007D; 7 days; Controls received mp w/ vehicle; peptides; Desmoteplase is a vampire bat salivary plasminogen activator (a fibrinolytic enzyme); neurodegeneration; tissue plasminogen activator is also known as alteplase.
P5322 Pawlak,R., Nagai,N., Urano,T., Napiorkowska-Pawlak,D., Ihara,H., Takada,Y., Collen,D., Takada,A. Rapid, specific and active site-catalyzed effect of tissue-plasminogen activator on hippocampus-dependent learning in mice. Neuroscience 2002; 113(-4-):995-1001. >>> Tissue plasminogen activator; tissue plaminogen activator inhibitor; urokinase plasminogen activator; CSF, artificial; CSF/CNS (hippocampus); Mice; 2 hours.
P4029 Tsirka,S.E., Rogove,A.D., Strickland,S. Neuronal cell death and tPA. Nature 1996; 384(--):123-124. >>> Tissue plasminogen activator, recomb. human; Plasminogen activator inhibitor type-1; PBS; CSF/CNS (hippocampus); mice; 1007D; 2 days; controls received mp w/vehicle; tissue plasminogen activator is a serine-protease; plasminogen activator inhibitor is a serine-protease inhibitor (enzyme inhibitor).
P3956 Ito,T., Matsuno,H., Kozawa,O., Niwa,M., Sakai,N., Uematsu,T. Comparison of the antithrombotic effects and bleeding risk of fractionated aurin tricarboxylic acid and the GPIIb/IIIa antagonist GR144053 in a hamster model of stenosis. Thrombosis Research 1999; 95(--):49-61. >>> Aurintricarboxylic acid; GR144053; Tissue plasminogen activator; IV (jugular); hamster; 2ML1; 7 days; cardiovascular; GR144053 is a GPIIb/IIIa antagonist; ATA&GR144053 infused together w/tPA.
P3447 Mataga,N., Imamura,K., Shiomitsu,T., Yoshimura,Y., Fukamauchi,F., Watanabe,Y. Enhancement of mRNA expression of tissue-type plasminogen activator by L-threo-3,4-dihydroxyphenylserine in association with ocular dominance plasticity. Neurosci.Lett. 1996; 218(--):149-152. >>> Plasminogen activator inhibitor-1; CSF/CNS (visual cortex); cat (kitten); 2001; no duration posted; no comment posted.
P2085 Orita,H., Fukasawa,M., Girgis,W., diZerega. Inhibition of postsurgical adhesions in a standardized rabbit model: intraperitoneal treatment with tissue plasminogen activator. Int.J.Fertil. 1991; 36(-3-):172-177. >>> Tissue plasminogen activator; Saline; IP; rabbit; 2ML1; 7 days; dose-response (table p.174); wound healing.
P1840 Dunn,R.C., Steinleitner,A.J., Lambert,H. Synergistic effect of intraperitoneally administered calcium channel blockade and recombinant tissue plasminogen activator to prevent adhesion formation in an animal model. Am.J.Obstet.Gynecol. 1991; 164(--):1327-1330. >>> Tissue plasminogen activator; Verapamil HCl; IP; rabbit; 2001; 200 hours; TPA.
111. Pravastatin
P9274 Zaher,H., Schwabedissen,H.E.M.Z., Tirona,R.G., Cox,M.L., Obert,L.A., Agrawal,N., Palandra,J., Stock,J.L., Kim,R.B., Ware,J.A. Targeted disruption of murine organic anion-transporting polypeptide 1b2 (oatp1b2/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin. MOLECULAR PHARMACOLOGY 2008; 74(-2-):320-329. >>> Rifampin; pravastatin; Water; DMSO; SC; Mice; 2001D; 24 hours; Functionality of mp verified by plasma concentrations; dose-response (fig. 5); comparison of IV injections vs. mp; animal info (male, DBA1/lacJ, wt, Slco1b2 -/-, 9-14 wks old); 0.5% DMSO used.
P2086 Joles,J., Willekes-Koolschijn,N., Koomans,H., Van Tol,A., Geelhoed-Mieras,T., Crommelin,D., Van Bloois,L., Krajnc-Franken,M., Cohen,L., Griffioen,M., Erkelens,W. Subcutaneous administration of HMG-CoA reductase inhibitors in hyperlipidaemic and normal rats. Lab.Anim. 1992; 26(--):269-280. >>> Lovastatin; Pravastatin; Liposomes; Simvastatin; Propylene glycol; rat; 2ML4; no duration posted; comparison of injections and oral administration vs. mp; stress/adverse reaction: local cystic reaction to simvastatin and lovastatin (p. 271, 275); enzyme inhibitor (HMG-CoA reductase), sc injections of simvastatin also caused subcutaneous toxicity.
112. Pyridostigmine
Q0425 Mauck,B., Lucot,J.B., Paton,S., Grubbs,R.D. Cholinesterase inhibitors and stress: Effects on brain muscarinic receptor density in mice. Neurotoxicology 2010; 31(-5-):461-467. >>> Pyridostigmine bromide; physostigmine; SC; Mice; 30 days; Controls received mp w/saline; animal info (male, C57BL6, 25 g); enzyme inhibitor (cholinesterase).
P8345 Bernatova,I., Babal,P., Grubbs,R.D., Morris,M. Acetylcholinesterase inhibition affects cardiovascular structure in mice. PHYSIOLOGICAL RESEARCH 2006; 55(--):S89-S97. >>> Pyridostigmine bromide; SC; Mice; 1007D; 7 days; Controls received mp w/ isotonic saline; enzyme inhibitor (acetylcholinesterase); cardiovascular; animal info (male, C57BL/6J, 10-12 weeks old, 25 grams).
P8259 Dubovicky,M., Paton,S., Morris,M., Mach,M., Lucot,J.B. Effects of combined exposure to pyridostigmine bromide and shaker stress on acoustic startle response, pre-pulse inhibition and open field behavior in mice. Journal of Applied Toxicology 2007; 27(-3-):276-283. >>> Pyridostigmine bromide; SC; Mice; 1007D; 7 days; Controls received mp w/ vehicle, or isotonic saline; no stress (see pg. 278, 280); enzyme inhibitor (acetylcholinesterase); animal info (male, C57BL/6J, 24-26g., 2 months old).
P8143 Griffiths,G.D., Hornby,R.J., Jagger,C.P., Brown,A.P., Stoten,A., Pearce,P.C., Scott,L., Pritchard,D.I. Development of methods to measure humoral immune responses against selected antigens in the common marmoset (Callithrix jacchus) and the effect of pyridostigmine bromide administration. INTERNATIONAL IMMUNOPHARMACOLOGY 2006; 6(-12-):1755-1764. >>> Pyridostigmine bromide; Saline, sterile isotonic; SC; Marmoset; 28 days; Controls received mp w/ vehicle; no stress (see p.1759,1762); immunology; animal info (male, female, 300-500g.); mp primed 40 hours; "delivery by pump ensured the animals would receive an appropriate dose of the drug over the desired time period.", oral delivery "would introduce unacceptable stress into the experiment and presentation in food was discounted because of difficulties in estimating the dose administered." (p.1757).
P8082 Hornby,R.J., Pearce,P.C., Bowditch,A.P., Scott,L., Griffiths,G.D. Multiple vaccine and pyridostigmine bromide interactions in the common marmoset Callithrix jacchus: Immunological and endocrinological effects. INTERNATIONAL IMMUNOPHARMACOLOGY 2006; 6(-12-):1765-1779. >>> Pyridostigmine bromide; Saline, sterile isotonic; SC; Marmoset; 2004; 28 days; Controls received mp w/ vehicle; no stress (see p.1776); immunology; animal info (female, vasectomized male, 331-565g. 2-5.5 yrs. old); mp primed 40 hours.
P7217 Griffiths,G.D., Telford,G., Hooi,D.S.W., Cook,D.L., Wilkinson,L.J., Green,C.A., Pritchard,D.I. A T-cell-dependent humoral immune response is preserved during the administration of the nerve agent pre-treatment pyridostigmine bromide in a murine model. INTERNATIONAL IMMUNOPHARMACOLOGY 2005; 5(-3-):525-540. >>> Pyridostigmine bromide; Saline, sterile isotonic; SC; Mice; 2004; 28 days; Controls received mp w/ vehicle; enzyme inhibitor (cholinesterase); immunology; mp primed in saline at 37 degrees celsius for 48 hours; "PB administration was achieved by 28-day mini-osmotic pumps thus removing the requirement for multiple oral dosing and the associated stress this may have caused." (p. 536).
P7030 Joaquim,L.F., Farah,V.M., Bernatova,I., Fazan,R.Jr, Grubbs,R., Morris,M. Enhanced heart rate variability and baroreflex index after stress and cholinesterase inhibition in mice. American Journal of Physiology-Heart and Circulatory Physiology 2004; 287(-1-):H251-H257. >>> Pyridostigmine; SC; Mice; 1007D; 3 days; Controls received mp w/ saline; enzyme inhibitor (acetylcholinesterase); cardiovascular.
P6741 Van Helden,H.P.M., Vanwersch,R.A.P., Kuijpers,W.C., Trap,H.C., Philippens,I.H.C., Benschop,H.P. Low levels of Sarin affect the EEG in marmoset monkeys: a pilot study. Journal of Applied Toxicology 2004; 24(-6-):475-483. >>> Pyridostigmine bromide; Propylene glycol: ethanol; acidic acid, glacial; water, distilled; SC; Marmoset; 2002; ; Controls received mp w/ vehicle; toxicology; sarin vapor.
P6551 Van Helden,H.P.M., Trap,H.C., Kuijpers,W.C., Oostdijk,J.P., Benschop,H.P., Langenberg,J.P. Low-level exposure of guinea pigs and marmosets to sarin vapour in air: Lowest-observable-adverse-effect level (LOAEL) for miosis. Journal of Applied Toxicology 2004; 24(-1-):59-68. >>> Pyridostigmine bromide; Propylene glycol; ethanol; water; acetic acid, glacial; SC; Guinea-pig; marmoset; 2002; 4 days; Controls received mp w/ vehicle; toxicology.
P6417 Langley,R.J., Kalra,R., Mishra,N.C., Sopori,M.L. Central but not the peripheral action of cholinergic compounds suppresses the immune system. Journal of Neuroimmunology 2004; 148(-1-2-):140-145. >>> Physostigmine; pyridostigmine bromide; edrophonium; Saline; CSF, artificial; SC; CSF/CNS; Rat; 2ML4; 3 weeks; Controls received mp w/ vehicle; enzyme inhibitor (acetylcholinesterase); immunology; ALZET brain infusion kit.
P5638 Bernatova,I., Dubovicky,M., Price,W.A., Grubbs,R.D., Lucot,J.B., Morris,M. Effect of chronic pyridostigmine bromide treatment on cardiovascular and behavioral parameters in mice. Pharmacology Biochemistry and Behavior 2003; 74(-4-):901-907. >>> Pyridostigmine bromide; Saline; SC; Mice; 1007D; 7 days; Controls received mp w/ vehicle; pyridostigmine blood levels checked; enzyme inhibitor (acetylcholinesterase)..
P5528 Lallement,G., Demoncheaux,J.P., Foquin,A., Baubichon,D., Galonnier,M., Clarencon,D., Dorandeu,F. Subchronic administration of pyridostigmine or huperzine to primates: Compared efficacy against soman toxicity. Drug and Chemical Toxicology 2002; 25(-3-):309-320. >>> Pyridostigmine; huperzine; SC; Monkey; 2ML1; 6 days; Enzyme inhibitor (acetylcholinesterase); toxicology.
P5352 Wetherell,J., Hall,T., Passingham,S. Physostigmine and hyoscine improves protection against the lethal and incapacitating effects of nerve agent poisoning in the guinea-pig. Neurotoxicology 2002; 23(-3-):341-349. >>> Physostigmine salicylate; Hyoscine hydrobromide; Pyridostigmine; Saline; SC; Guinea-pig; 2001; 7 days; Physostigmine and hyoscine infused together; toxicology.
P4817 Griffiths,G.D., Hornby,R.J., Stevens,D.J., Scott,L.A.M., Upshall,D.G. Biological consequences of multiple vaccine and pyridostigmine pretreatment in the guinea pig.. Journal of Applied Toxicology 2001; 21(--):59-68. >>> Pyridostigmine bromide;; Saline;; SC;; guinea-pig;; 28 days;; Controls received mp w/ vehicle; functionality of mp verified by AChE levels via assay p. 60; immunology; enzyme inhibitor; PB is an acetylcholinesterase inhibitor; toxicology.
P4806 Lallement,G., Foquin,A., Dorandeu,F., Baubichon,D., Carpentier,P. Subchronic administration of various pretreatments of nerve agent poisoning. II. Compared efficacy against soman toxicity. Drug and Chemical Toxicology 2001; 24(-2-):165-180. >>> Pyridostigmine; Huperzine; Physostigmine; Scopolamine;; SC;; guinea-pig;; 6 days;; Controls received sham operation; enzyme inhibitor; these are poisons known to be acetylcholinesterase inhibitors; doses inhibited 30% of AChE activity; Physostigmine was infused alone or together with Scopolamine; toxicology.
P3276 Matthew,C.B., Glenn,J.F., Bowers Jr,W.D., Navara,D.K. Cholinergic drug interactions and heat tolerance. Life Sci. 1994; 54(-17-):1237-1245. >>> Pyridostigmine bromide; SC; rat; 2ML2; 2 weeks; controls received mp w/saline; comparison of iv injection vs. mp; toxicology.
P3020 Walday,P., Aas,P., Haider,T., Fonnum,F. Effect of pyridostigmine pretreatment, HI-6 and toxogonin treatment on rat tracheal smooth muscle response to cholinergic stimulation after organophosphorus inhalation exposure. Arch.Toxicol. 1993; 67(--):212-219. >>> Pyridostigmine; SC; rat; 2001; 18 days; toxicology.
P2593 Anderson,D.R., Harris,L.W., Lennox,W.J., Solana,R.P. Effects of subacute pretreatment with carbamate together with acute adjunct pretreatment against nerve agent exposure. Drug Chem.Toxicol. 1991; 14(-1&2-):1-19. >>> Physostigmine salicylate; Pyridostigmine bromide; Acetic acid, glacial; Water; guinea-pig; 2ML2; 14 days; controls received mp w/ vehicle; functionality of mp verified by AChE assay; comparison of acute injections vs. mp; acute scopolamine administered concomitantly; toxicology.
P2573 Kerenyi,S.Z., Murphy,M.R., Hartgraves,S.L. Toxic interactions between repeated soman and chronic pyridostigmine in rodents. Pharmacol.Biochem.Behav. 1990; 37(-2-):267-271. >>> Pyridostigmine bromide; Acetic acid; Sodium hydroxide; SC; rat; 2001; 7 days; controls received mp w/ vehicle; dose-response (p.268); toxicology.
P2331 Koplovitz,I., Gresham,V.C., Dochterman,L.W., Kaminskis,A., Stewart,J.R. Evaluation of the toxicity, pathology, and treatment of cyclohexylmethylphosphonofluoridate (CMPF) poisoning in rhesus monkeys. Arch.Toxicol. 1992; 66(-9-):622-628. >>> Pyridostigmine; Saline; monkey; 2ML2; 3-12 days; no comment posted.
P2303 Blick,D.W., Kerenyi,S.Z., Miller,S., Murphy,M.R., Brown,G.C., Hartgraves,S.L. Behavioral toxicity of anticholinesterases in primates: chronic pyridostigmine and soman interactions. Pharmacol.Biochem.Behav. 1991; 38(--):527-532. >>> Pyridostigmine bromide; Acetic acid; Sodium hydroxide; SC; monkey; 2ML1; 5 days; controls received mp w/ vehicle.
P1982 Adler,M., Deshpande,S.S., Foster,R.E., Maxwell,D.M., Albuquerque,E.X. Effects of subacute pyridostigmine administration on mammalian skeletal muscle function. J.Applied Toxicol. 1992; 12(-1-):25-33. >>> Pyridostigmine bromide; Citric acid; Sodium hydroxide; Parabens; Sodium citrate; SC; rat; 2ML2; 14 days; cholinesterase inhibitor.
P1109 Kerenyi,S.Z., Hartgraves,S.L. Premature excess release from the alzet osmotic pump. Pharmacol.Biochem.Behav. 1987; 27(-1-):199-201. >>> Dye, FD&C Red No. 40; Pyridostigmine; Acetate, sodium; Acetic acid; SC; rat; 2001; no duration posted; dose-response; mp malfunction; pyridostigmine used in vivo, dye in vitro; excessive early release of mp attributed to temp. change after implant.; stress/adverse reaction (cholinesterase poisoning due to mp malf.).
P1085 Anderson,R.J., Chamberlain,W.L., Roesner,M., Dacko,C., Robertson,D.G. Decreased tetanic contracture of rat skeletal muscle induced by pyridostigmine. J.Toxicol.Environ.Health 1986; 18(--):221-230. >>> Pyridostigmine; Saline; rat; 1, 4, 10, 20 days; mp model not stated; controls received mp w/vehicle; 2 doses of agent infused; comparison of ip inject. vs. mp infusion; mp malfunction - residual drug in exiting tube gave equivalent of bolus injection but was corrected in later exp..
P0984 Shiloff,J.D., Clement,J.G. Effects of subchronic pyridostigmine pretreatment on the toxicity of soman. Can.J.Physiol.Pharmacol. 1986; 64(--):1047-1049. >>> Pyridostigmine; SC; rat; 2001; 5 days; 2001, 5 days; toxicology; teratology.
P0847 Hudson,C.S., Foster,R.E., Kahng,M.W. Ultrastructural effects of pyridostigmine on neuromuscular junctions in rat diaphragm. Neurotoxicology 1987; 7(-1-):167-186. >>> Pyridostigmine bromide; Citric acid monohydrate; Methyl paraben; Propyl paraben; Saline; Sodium citrate dihydrate; Water; SC; rat; 2ML2; 2, 7, 14 days; controls received mp w/vehicle; toxicology; various doses of agent infused; possible malfunction of one mp; comparison of sc injections vs. mp infusion; functionality of mp verified via assay.
P0822 Hudson,C.S., Foster,R.E., Kahng,M.W. Neuromuscular toxicity of pyridostigmine bromide in the diaphragm, extensor digitorum longus, and soleus muscles of the rat. Fundam.Appl.Toxicol. 1985; 5(-6 pt. 2-):S260-S26S. >>> Pyridostigmine bromide; Citric acid monohydrate; Methyl paraben; Propyl paraben; Saline; Sodium citrate dihydrate; Water; SC; rat; 2ML2; 2 days; comparison of single injection vs. mp infusion; controls received mp w/ vehicle; study to determine neuromuscular effects of agent on different types of muscle fibers; toxicology.
113. R03201195
P7815 Goldstein,D.M., Alfredson,T., Bertrand,J., Browner,M.F., Clifford,K., Dalrymple,S.A., Dunn,J., Freire-Moar,J., Harris,S., Labadie,S.S., La Fargue,J., Lapierre,J.M., Larrabee,S., Li,F.J., Papp,E., McWeeney,D., Ramesha,C., Roberts,R., Rotstein,D., San Pablo,B., Sjogren,E.B., So,O.Y., Talamas,F.X., Tao,W., Trejo,A., Villasenor,A., Welch,M., Welch,T., Weller,P., Whiteley,P.E., Young,K., Zipfel,S. Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3- dihydroxypropoxy)phenyl]methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 map kinase. Journal of Medicinal Chemistry 2006; 49(-5-):1562-1575. >>> R03201195; PEG 400; SC; Rat; 14 days; Controls received mp w/ vehicle; functionality of mp verified by plasma concentrations; pumps replaced on day 8; enzyme inhibitor (p38 map kinase); multiple pumps per animal (2); animal info (female, Lewis, 120-150g., rat adjuvant arthritis).
114. Ro3303544
P8645 Adachi,K., Mirzadeh,Z., Sakaguchi,M., Yamashita,T., Nikolcheva,T., Gotoh,Y., Peltz,G., Gong,L., Kawase,T., varez-Buylla,A., Okano,H., Sawamoto,K. beta-Catenin signaling promotes proliferation of progenitor cells in the adult mouse subventricular zone. Stem Cells 2007; 25(-11-):2827-2836. >>> Ro3303544; Saline; CSF/CNS; Mice; 1007D; 7 days; Controls received mp w/ vehicle; enzyme inhibitor (protein kinase); animal info (adult, male, C57BL/6, 9 wks); GSK3-beta is a protein kinase.
115. Rolipram
Q0670 Nout,Y.S., Culp,E., Schmidt,M.H., Tovar,C.A., Proeschel,C., Mayer-Proeschel,M., Noble,M.D., Beattie,M.S., Bresnahan,J.C. Glial restricted precursor cell transplant with cyclic adenosine monophosphate improved some autonomic functions but resulted in a reduced graft size after spinal cord contusion injury in rats. Experimental Neurology 2011; 227(-1-):159-171. >>> Rolipram; DMSO; SC; Rat; 2ML2; 14 days; Controls received mp w/ vehicle; animal info (male, 71 days old); stress/adverse reaction: (increased body-weight loss, increased micturition peak frequencies) see pg. 167; spinal cord injury.
Q0470 Dai,H.N., Macarthur,L., McAtee,M., Hockenbury,N., Tidwell,J.L., McHugh,B., Mansfield,K., Finn,T., Hamers,F.P.T., Bregman,B.S. Activity-Based Therapies To Promote Forelimb Use after a Cervical Spinal Cord Injury. Journal of Neurotrauma 2009; 26(-10-):1719-1732. >>> Rolipram; Saline; DMSO; SC; Rat; 2ML1; 5, 10 days; Controls received mp w/ vehicle; animal info (adult, female, Sprague-Dawley, 6 wks old); 15% DMSO used; behavioral testing (Skilled target reaching, Gridwalk, Vertical exploration, CatWalk gait analysis).
Q0459 Beaumont,E., Whitaker,C.M., Burke,D.A., Hetman,M., Onifer,S.M. EFFECTS OF ROLIPRAM ON ADULT RAT OLIGODENDROCYTES AND FUNCTIONAL RECOVERY AFTER CONTUSIVE CERVICAL SPINAL CORD INJURY. Neuroscience 2009; 163(-4-):985-990. >>> Rolipram; DMSO; SC; Rat; 2002; ; Spinal cord injury; animal info (female, adult, Sprague Dawley, 228-267 g); multiple pumps per animal (2); stress/adverse reaction: (see pg. 966) "the data of one rat in the rolipram-treated group was removed from the study because of its morbidity".
Q0071 Udina,E., Ladak,A., Furey,M., Brushart,T., Tyreman,N., Gordon,T. Rolipram-induced elevation of cAMP or chondroitinase ABC breakdown of inhibitory proteoglycans in the extracellular matrix promotes peripheral nerve regeneration. Experimental Neurology 2010; 223(-1-):143-152. >>> Rolipram; Saline; SC; Rat; 2ML2; 2 weeks; Controls received mp w/ vehicle; enzyme inhibitor (phosphodiesterase IV); animal info (female, Sprague Dawley, 200-220 g.).
P9461 Whitaker,C.M., Beaumont,E., Wells,M.J., Magnuson,D.S.K., Hetman,M., Onifer,S.M. Rolipram attenuates acute oligodendrocyte death in the adult rat ventrolateral funiculus following contusive cervical spinal cord injury. Neuroscience Letters 2008; 438(-2-):200-204. >>> Rolipram; DMSO; SC; Rat; 2002; 12, 24, 72 hours; Controls received mp w/ vehicle; enzyme inhibitor (phosphodiesterase 4); multiple pumps per animal (2); post op. care (Gentozen, bacitracin zinc); animal info (female, Sprague Dawley, 228-267 g., SCI).
P7915 Monti,B., Berteotti,C., Contestabile,A. Subchronic Rolipram delivery activates hippocampal CREB and arc, enhances retention and slows down extinction of conditioned fear. Neuropsychopharmacology 2006; 31(-2-):278-286. >>> Rolipram; DMSO; saline; SC; Rat; 2001; 7 days; Controls received mp w/ vehicle or sham operated; comparison of IP injections vs. mp; no stress (see pg. 281); enzyme inhibitor (phosphodiesterase); animal info (male, Wistar, 10 weeks old); 50% DMSO used; "These concomitant effects were only observed in rats treated subchronically through osmotic minipumps, indicating that attainment of an increased steady level of expression and activity was essential in the enhancement of the behavioral response." (P. 283).
P7769 Hinkle,R.T., Dolan,E., Cody,D.B., Bauer,M.B., Isfort,R.J. Phosphodiesterase 4 inhibition reduces skeletal muscle atrophy. Muscle&Nerve 2005; 32(-6-):775-781. >>> Pentoxifylline; clenbuterol; ariflo; rolipram; Saline, physiological; SC; Mice; 10 days; Controls received mp w/ vehicle; comparison of SC injections vs. mp; enzyme inhibitor (cAMP phosphodiesterases); animal info (male, C57B16, 20-30g.); ariflo also known as cilomilast or SB-207499.
P7471 Monti,B., Berteotti,C., Contestabile,A. Subchronic Rolipram delivery activates hippocampal CREB and arc, enhances retention and slows down extinction of conditioned fear. Neuropsychopharmacology 2005; 31(-2-):1-9. >>> Rolipram; DMSO; saline; SC; Rat; 2001; 5, 7 days; Controls received mp w/ vehicle or sham operation; comparison of IP injection vs. mp; no stress (see pg. 4); enzyme inhibitor (phosphodiesterase); animal info (male, Wistar, 10 wk old); 50% DMSO; "effects were only observed in rats treated subchronically through osmotic minipumps, indicating that attainment of an increased steady level of expression and activity was essential in the enhancement of the behavioral response.".
P6824 Day,Y.J., Huang,L., McDuffie,M.J., Rosin,D.L., Ye,H., Chen,J.F., Schwarzschild,M.A., Fink,J.S., Linden,J., Okusa,M.D. Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow-derived cells. J.Clin.Invest 2003/9; 112(-6-):883-891. >>> ATL146e; rolipram; DMSO; PBS; SC; Mice; 1003D; 29 hours; Controls received mp w/ vehicle; enzyme inhibitor (phospodiesterase IV); cardiovascular; ischemia; 0.01% DMSO; chimeric mice obtained via bone marrow transplantation.
P6579 Pearse,D.D., Pereira,F.C., Marcillo,A.E., Bates,M.L., Berrocal,Y.A., Filbin,M.T., Bunge,M.B. cAMP and Schwann cells promote axonal growth and functional recovery after spinal cord injury. Nature Medicine 2004; 10(-6-):610-616. >>> Rolipram; DMSO; SC; Rat; 2001; 2 weeks; Controls received mp w/ vehicle; both pumps replaced after 1 week; enzyme inhibitor (phosphodiesterase IV); multiple pumps per animal (2).
P6261 Nikulina,E., Tidwell,J.L., Dai,H.N., Bregman,B.S., Filbin,M.T. The phosphodiesterase inhibitor rolipram delivered after a spinal cord lesion promotes axonal regeneration and functional recovery. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2004; 101(-23-):8786-8790. >>> Rolipram; Saline; DMSO; SC; Rat; 1,2,3,10 days; Controls received mp w/ vehicle; dose-response (p. 8788, Fig 2A); 50% DMSO used in the 1,2,&3 day study; 16% used in the 10 day study; no pump model listed; transplantation.
P5880 Wang,W.D., Li,C.L., Kwon,T.H., Knepper,M.A., Frokiaer,J., Nielsen,S. AQP3, p-AQP2, and AQP2 expression is reduced in polyuric rats with hypercalcemia: prevention by cAMP-PDE inhibitors. American Journal of Physiology-Renal Physiology 2002; 283(-6-):F1313-F1325. >>> Rolipram; milrinone; DMSO; Lactic acid; SC; IP; Rat; 2001; 8 days; Controls received mp w/ vehicle; functionality of mp verified by plasma levels; enzyme inhibitor (cAMP-phosphodiesterase); Rolipram (implanted SC) was dissolved in 50% DMSO&milrinone was dissolved in 30% lactic acid implanted IP; multiple pumps per animal (2).
116. Roscovitine
Q0755 Crews,L., Patrick,C., Adame,A., Rockenstein,E., Masliah,E. Modulation of aberrant CDK5 signaling rescues impaired neurogenesis in models of Alzheimer's disease. Cell Death&Disease 2011; 2(-;-):U24-U36. >>> Roscovitine; CSF/CNS; Mice; 1007D; 2 weeks; Controls received mp w/ vehicle; animal info (8 mo old, non tg, APP tg); cyanoacrylate adhesive.
Q0356 Menn,B., Bach,S., Blevins,T.L., Campbell,M., Meijer,L., Timsit,S. Delayed Treatment with Systemic (S)-Roscovitine Provides Neuroprotection and Inhibits In Vivo CDK5 Activity Increase in Animal Stroke Models. PLoS One 2010; 5(-8-):U113-U123. >>> Roscovitine, S-; DMSO; Krebs-Ringer's solution; CSF/CNS; SC; Rat; mice; 1003D; 48, 72 hours; Controls received mp w/ vehicle; animal info (P60, male, C57B/6, 20-25 g; P60, male, Sprague Dawley, 280-320 g); ischemia (cerebral).
P9767 Zhang,Q., Chen,C., Lue,J.G., Xie,M.J., Pan,D.J., Luo,X., Yu,Z.Y., Dong,Q., Wang,W. Cell Cycle Inhibition Attenuates Microglial Proliferation and Production of IL-1-beta, MIP-1-alpha, and NO After Focal Cerebral Ischemia in the Rat. Glia 2009; 57(-8-):908-920. >>> Roscovitine; DMSO; saline; CSF/CNS; Rat; 2001; ; Controls received mp w/vehicle; functionality of mp verified by "weighing the cassette before placement and after the experiment" pg. 909; enzyme inhibitor (cyclin dependant kinase); ALZET brain infusion kit used; ischemia (cerebral); animal info (adult, male, Sprague Dawley, 220-270 g); 0.2% DMSO used; MCAO.
P7615 Kitazawa,M., Oddo,S., Yamasaki,T.R., Green,K.N., LaFerla,F.M. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. Journal of Neuroscience 2005; 25(-39-):8843-8853. >>> Roscovitine; DMSO; CSF/CNS; Mice; mice (transgenic); 1002; 2 weeks; Controls received mp w/ vehicle; enzyme inhibitor (cdK5); ALZET Brain Infusion Kit 3 used; neurodegenerative (Alzheimer's disease); animal info (3xTg-AD, WT, 4 month old, female); 50% DMSO.
P7011 Wang,C.H., Lee,T.H., Tsai,Y.J., Liu,J.K., Chen,Y.J., Yang,L.C., Lu,C.Y. Intrathecal cdk5 inhibitor, roscovitine, attenuates morphine antinociceptive tolerance in rats1. Acta Pharmacologica Sinica 2004; 25(-8-):1027-1030. >>> Roscovitine; morphine; DMSO; CSF/CNS (intrathecal); Rat; 2001; 5 days; Enzyme inhibitor (cyclin dependent kinase 5); tolerance.
P6916 Zhang,M., Li,J., Chakrabarty,P., Bu,B.T., Vincent,I. Cyclin-dependent kinase inhibitors attenuate protein hyperphosphorylation, cytoskeletal lesion formation, and motor defects in Niemann-Pick type C mice. American Journal of Pathology 2004; 165(-3-):843-853. >>> Roscovitine; olomoucine; iso-olomoucine; DMSO; CSF/CNS; Mice; 1002; 2, 4 weeks; Pumps replaced every 2 weeks for 4 week infusions; enzyme inhibitor (CDK); neurodegenerative (Alzheimer's disease, Amyotrophic Lateral Sclerosis, Niemann-Pick Type C disease); lynch coil used to accomodate 75% DMSO.
P5649 Norrholm,S.D., Bibb,J.A., Nestler,E.J., Ouimet,C.C., Taylor,J.R., Greengard,P. Cocaine-induced proliferation of dendritic spines in nucleus accumbens is dependent on the activity of cyclin-dependent kinase-5. Neuroscience 2003; 116(-1-):19-22. >>> Roscovitine; Sodium phosphate; sodium chloride; DMSO; CSF/CNS (nucleus accumbens); Rat; 2004; 28 days; Controls received mp w/ vehicle; tissue perfusion (nucleus accumbens); enzyme inhibitor (cyclin dependent kinase-5); roscovitine is a potent Cdk5 inhibitor; bilateral cannula used; 50% DMSO used.
117. SB203580
Q0604 Gee,E., Milkiewicz,M., Haas,T.L. p38 MAPK Activity Is Stimulated by Vascular Endothelial Growth Factor Receptor 2 Activation and Is Essential for Shear Stress-Induced Angiogenesis. Journal of Cellular Physiology 2010; 222(-1-):120-126. >>> SB203580; Saline; IP; Rat; 7 days; Controls received mp w/ SB202474; animal info (male, Sprague Dawley, 150-200 g).
Q0559 Brades,S., Svensson,C.I., Steinauer,J., Pothoulakis,C., Yaksh,T.L., Mayer,E.A. Role of Spinal Microglia in Visceral Hyperalgesia and NK1R Up-Regulation in a Rat Model of Chronic Stress. Gastroenterology 2009; 136(-4-):1339-1348. >>> SB203580; minocycline; Saline; CSF/CNS (intrathecal); Rat; 2002; 10 days; Controls received mp w/ vehicle; animal info (adult, male, Wistar, 250-275 g); enzyme inhibitor (MAPK, mitogen-activated protein kinase); PE5 connected to PE10 tubing used; catheter position verified postmortem.
Q0178 Obata,K., Katsura,H., Mizushima,T., Yamanaka,H., Kobayashi,K., Dai,Y., Fukuoka,T., Tokunaga,A., Tominaga,M., Noguchi,K. TRPA1 induced in sensory neurons contributes to cold hyperalgesia after inflammation and nerve injury (vol 115, pg 2393, 2005). Journal of Clinical Investigation 2010; 120(-1-):394-394. >>> SB203580; antibody, anti-NGF; oligodeoxynucleotide, antisense; oligodeoxynucleotide, missense; oligodeoxynucleotide, FITC-, antisense; Saline; DMSO; CSF/CNS (intrathecal); Rat; 2001; 7 days; Controls received mp w/ missense oligo; animal info (male, Sprague-Dawley, 200-250 g, SNL); antisense (TRPA1); enzyme inhibitor (p38 MAP kinase); 50% DMSO; behavioral testing (basal pain hypersensitivity, paw withdrawal latency, mechanical withdrawal threshold).
Q0155 Cheng,H.T., Dauch,J.R., Oh,S.S., Hayes,J.M., Hong,Y., Feldman,E.L. p38 mediates mechanical allodynia in a mouse model of type 2 diabetes. Molecular Pain 2010; 6(-;-):U1-U14. >>> SB203580; CSF, artificial; DMSO; CSF/CNS (intrathecal); Mice; 1007D; 1 week; Animal info (db+, db/db, 8 wks old); 10% DMSO used; diabetes; PE cannula used to target the L5 region.
P9949 Okubo,M., Yamanaka,H., Kobayashi,K., Noguchi,K. Leukotriene Synthases and the Receptors Induced by Peripheral Nerve Injury in the Spinal Cord Contribute to the Generation of Neuropathic Pain. Glia 2010; 58(-5-):599-610. >>> AA-861; U-75302; SB203580; pranlukast; U0126; Ethanol; saline; DMSO; CSF/CNS (intrathecal, subarachnoid space); Rat; 2001; ; Controls received mp w/ saline; enzyme inhibitor (5-lipoxygenase); animal info (male, Sprague Dawley, 200-250 g); 0.02-0.2% ethanol used; 50% DMSO used; spinal nerve injury; behavioral testing (mechanical allodynia).
P9459 Wei,S.G., Yu,Y., Zhang,Z.H., Felder,R.B. Angiotensin II upregulates hypothalamic AT1 receptor expression in rats via the mitogen-activated protein kinase pathway. American Journal of Physiology-Heart and Circulatory Physiology 2009; 296(-5-):H1425-H1433. >>> Angiotensin II; losartan; PD-98059; SP-600125; SB-203580; Saline; DMSO; CSF, artificial; SC; CSF/CNS; Rat; 2002; 2004; 4 weeks; Controls received mp w/ vehicle; pumps replaced after 2 weeks; enzyme inhibitor (MAP kinase, Jun N-terminal kinase); cardiovascular; peptides; multiple pumps per animal (2); animal info (male, Sprague Dawley, 275-300 g.); cannula placement confirmed at end of study; 0.1%-0.5% DMSO used.
P9299 Stirling,D.P., Liu,J., Plunet,W., Steeves,J.D., Tetzlaff,W. SB203580, a p38 mitogen-activated protein kinase inhibitor, fails to improve functional outcome following a moderate spinal cord injury in rat. Neuroscience 2008; 155(-1-):128-137. >>> SB203580; DMSO; streptomycin; penicillin; CSF/CNS (subarachnoid space); Rat; 2001; 7 days; Controls received mp w/ vehicle; dose-response (fig 5); enzyme inhibitor (p38 MAP Kinase); animal info (male, Wistar, adult, SCI); behavioral testing (locomotor activity).
P8958 Li,J.H., Deane,J.A., Campanale,N.V., Bertram,J.F., Ricardo,S.D. Blockade of p38 mitogen-activated protein kinase and TGF-beta1/Smad signaling pathways rescues bone marrow-derived peritubular capillary endothelial cells in adriamycin-induced nephrosis. Journal of the American Society of Nephrology 2006; 17(-10-):2799-2811. >>> SB203580; ALK5; DMSO; water; Mice; 2 weeks; Controls received mp w/ vehicle; dose-response (p. 2801); enzyme inhibitor (p38 MAP Kinase); multiple pumps per animal (2); animal info (male, BALB/C, 6 wks old, 20-25 g.); TGF-B receptor I inhibitor.
P8873 Terayama,R., Omura,S., Fujisawa,N., Yamaai,T., Ichikawa,H., Sugimoto,T. Activation of microglia and p38 mitogen-activated protein kinase in the dorsal column nucleus contributes to tactile allodynia following peripheral nerve injury. Neuroscience 2008; 153(-4-):1245-1255. >>> SB203580; Saline; CSF/CNS (intrathecal, cisterna magna); Rat; 2002; 14 days; Controls received mp w/ vehicle; enzyme inhibitor (p38 MAP kinase); animal info (male, Sprague Dawley, 250-300g., spinal cord injury); PE10 tubing used; pump infusion schematic pg. 1246, Fig. 1.
P8255 Li,J.H., Deane,J.A., Campanale,N.V., Bertram,J.F., Ricardo,S.D. The contribution of bone marrow-derived cells to the development of renal interstitial fibrosis. Stem Cells 2007; 25(-3-):697-706. >>> SB203580; alk5; Saline; Mice; 2, 4 weeks; Controls received mp w/ vehicle; replacement therapy (ADR-induced nephropathy); dose-response (pg. 698); enzyme inhibitor (p38 MAP kinase); animal info (male, BALB/C, bone marrow transplant, 20 wks old); ADR is adriamycin, TGF-B receptor I (ALK5) inhib.
P7977 Yamanaka,H., Obata,K., Kobayashi,K., Dai,Y., Fukuoka,T., Noguchi,K. Alteration of the cell adhesion molecule L1 expression in a specific subset of primary afferent neurons contributes to neuropathic pain. European Journal of Neuroscience 2007; 25(-4-):1097-1111. >>> Immunoglobulin G, non-immune mouse; antibody, anti-L1-CAM; SB203580; Saline; CSF/CNS (intrathecal); Rat; 2001; 2002; ; Animal info (Male, Sprague-Dawley, 200-250 grams); silicone tubing, 0.64 mm O.D filled with 5.0 ul's of saline; inserted ~ 0.5 cm's into the intrathecal space; enzyme inhibitor (p38 MAP kinase).
P7956 Di,Cristo G., Berardi,N., Cancedda,L., Pizzorusso,T., Putignano,E., Ratto,G.M., Maffei,L. Requirement of ERK activation for visual cortical plasticity. Science 2001/6/22; 292(-5525-):2337-2340. >>> U0126; PD-98059; SB203580; CSF/CNS (visual cortex); Rat; 1 week; Controls received mp w/ vehicle; stability verified by inhibition of ERK activation by picrotoxin; enzyme inhibitor (p38 MAP kinase); animal info (Dark-reared, P28); tissue perfusion (visual cortex).
P7885 Li,J.H., Campanale,N.V., Liang,R.J., Deane,J.A., Bertram,J.F., Ricardo,S.D. Inhibition of p38 mitogen-activated protein kinase and transforming growth factor-beta 1/Smad signaling pathways modulates the development of fibrosis in adriamycin-induced nephropathy. American Journal of Pathology 2006; 169(-5-):1527-1540. >>> SB203580; ALK5 Inhibitor; DMSO; Mice; 2 weeks; Controls received mp w/ vehicle; dose-response (pg. 1528); enzyme inhibitor (p38 MAP kinase, ALK5); animal info (male, BALB/C, 8 wk old, 25-30g.).
P7244 Obata,K., Katsura,H., Mizushima,T., Yamanaka,H., Kobayashi,K., Dai,Y., Fukuoka,T., Tokunaga,A., Tominaga,M., Noguchi,K. TRPA1 induced in sensory neurons contributes to cold hyperalgesia after inflammation and nerve injury. Journal of Clinical Investigation 2005; 115(-9-):2393-2401. >>> SB203580; antibody, anti-nerve growth factor; oligodeoxynucleotide, antisense; oligodeoxynucleotide, FITC antisense; oligodeoxynucleotide, missense; DMSO; saline; CSF/CNS (intrathecal); Rat; 2001; 7 days; Controls received mp w/ vehicle, or sham surgery or mismatch ODN or contralateral no treatment; antisense (TRPA1); brain tissue distribution; 50% DMSO.
P7023 Obata,K., Yamanaka,H., Kobayashi,K., Dai,Y., Mizushima,T., Katsura,H., Fukuoka,T., Tokunaga,A., Noguchi,K. Role of mitogen-activated protein kinase activation in injured and intact primary afferent neurons for mechanical and heat hypersensitivity after spinal nerve ligation. Journal of Neuroscience 2004; 24(-45-):10211-10222. >>> U0126; SB203580; FR167653; SP 600125; antibody, anti-NGF, sheep; DMSO, saline; CSF/CNS (intrathecal); Rat; 2001; 7 days; Controls received mp w/ vehicle; enzyme inhibitors (MAPK kinase, p38, JNK); 50% DMSO used.
P6780 Obata,K., Yamanaka,H., Dai,Y., Mizushima,T., Fukuoka,T., Tokunaga,A., Noguchi,K. Differential activation of MAPK in injured and uninjured DRG neurons following chronic constriction injury of the sciatic nerve in rats. European Journal of Neuroscience 2004; 20(-11-):2881-2895. >>> U0126; SB203580; DMSO; CSF/CNS (intrathecal); Rat; 1003D; 2001; 7 days; Controls received mp w/ vehicle; enzyme inhibitor (p38 MAP kinase); 50% DMSO used.
P6294 Schafers,M., Svensson,C.I., Sommer,C., Sorkin,L.S. Tumor Necrosis Factor-alpha Induces Mechanical Allodynia after Spinal Nerve Ligation by Activation of p38 MAPK in Primary Sensory Neurons. The Journal of Neuroscience 2003; 23(-7-):2517-2521. >>> SB203580; CSF/CNS (intrathecal); Rat; 2002; 14 days; Controls received mp w/ saline; enzyme inhibitor (p38 MAP kinase).
P6063 Horiuchi,D., Ogata,T., Morino,T., Chuai,M., Yamamoto,H. Continuous intrathecal infusion of SB203580, a selective inhibitor of p38 mitogen-activated protein kinase, reduces the damage of hindlimb function after thoracic spinal cord injury in rat. NEUROSCIENCE RESEARCH 2003; 47(-2-):209-217. >>> SB203580; Saline; CSF/CNS (intrathecal); Rat; 1 week; Controls received mp w/ vehicle; enzyme inhibitor (p38 MAP kinase); pump infusion schematic (p. 210).
P5746 Ji,Ru-Rong, Samad,Tarek A., Jin,Shan-Xue, Schmoll,Raymond, Woolf,Clifford J. MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia.. Neuron 2002; 36(-1-):57-68. >>> SB203580; Saline; CSF/CNS (intrathecal); Rat; 1007D; ; Controls received mp w/ vehicle; Comparison of intrathecal injections vs. mp; SB203580 is an enzyme inhibitor (p38 MAP kinase).
118. SC-37698
P2082 Ye,C., Rabinovitch,M. Inhibition of elastolysis by SC-37698 reduces development and progression of monocrotaline pulmonary hypertension. Am.J.Physiol. 1991; 261(-30-):H1255-H1267. >>> SC-37698; Ethanol; PEG 400; IV (jugular); rat; 2ML2; 2 weeks; enzyme inhibitor (elastase); silastic 20 'melded' to PE 60.
119. SK&F 86002
P3003 Fann,P.C., Hartman,D.F., Goode,R.L. Pharmacologic and surgical enhancement of composite graft survival. Arch Otolaryngol.Head Neck Surg. 1993; 119(--):313-319. >>> SK&F 86002; IM; rabbit; 2ML2; 14 days; functionality of mp verified by explanting pump; stress/adverse reaction: (pg. 318) some scarring noted in area of implantation w/ small deposits of yellow crystals around catheter; enzyme inhibitor; SK&F 86002 is a dual cyclooxygenase (COX)/lipooxygenase inhibitor; "implantation of osmotic (Alzet) pumps prolonged anesthesia time by approximately 50%, possibly increasing the ischemic insult."; mp implanted beneath the superficial layer of the deep cervical fascia at time of ear surgery.
120. SP600125
P9675 Li,X.P., Du,Y.L., Fan,X.L., Yang,D.H., Luo,G.R., Le,W.D. c-Jun N-terminal kinase mediates lactacystin-induced dopamine neuron degeneration. Journal of Neuropathology and Experimental Neurology 2008; 67(-10-):933-944. >>> SP600125; CSF, artificial; DMSO; CSF/CNS; Rat; 2004; 4 weeks; Enzyme inhibitor (JNK, C-Jun-N-terminal); ALZET brain infusion kit 2 used; animal info (male, Sprague Dawley, 200-250 g.); 3% DMSO used; neurodegenerative (Parkinson's Disease); brain tissue distribution.
P9475 Suga,H., Eto,H., Shigeura,T., Inoue,K., Aoi,N., Kato,H., Nishimura,S., Manabe,I., Gonda,K., Yoshimura,K. IFATS Collection: Fibroblast Growth Factor-2-Induced Hepatocyte Growth Factor Secretion by Adipose-Derived Stromal Cells Inhibits Postinjury Fibrogenesis Through a c-Jun N-Terminal Kinase-Dependent Mechanism. Stem Cells 2009; 27(-1-):238-249. >>> SP 600125; antibody, anti-FGF-L, goat; antibody, anti-mouse HGF, goat; SC; Mice; 1007D; 7 days; Controls received mp w/ PBS; enzyme inhibitor (JNK); animal info (6 wks old, ICR).
P9459 Wei,S.G., Yu,Y., Zhang,Z.H., Felder,R.B. Angiotensin II upregulates hypothalamic AT1 receptor expression in rats via the mitogen-activated protein kinase pathway. American Journal of Physiology-Heart and Circulatory Physiology 2009; 296(-5-):H1425-H1433. >>> Angiotensin II; losartan; PD-98059; SP-600125; SB-203580; Saline; DMSO; CSF, artificial; SC; CSF/CNS; Rat; 2002; 2004; 4 weeks; Controls received mp w/ vehicle; pumps replaced after 2 weeks; enzyme inhibitor (MAP kinase, Jun N-terminal kinase); cardiovascular; peptides; multiple pumps per animal (2); animal info (male, Sprague Dawley, 275-300 g.); cannula placement confirmed at end of study; 0.1%-0.5% DMSO used.
P8412 Milkiewicz,M., Mohammadzadeh,F., Ispanovic,E., Gee,E., Haas,T.L. Static strain stimulates expression of matrix metal loproteinase-2 and VEGF in microvascular endothelium via JNK- and ERK-dependent pathways. Journal of Cellular Biochemistry 2007; 100(-3-):750-761. >>> SP600125; PEG 400; saline; cremophor EL; polypropylene glycol; IM (Extensor digitorum longus); Rat; 1003D; 4 days; Controls received mp w/ vehicle; enzyme inhibitor (JNK); animal info (male, Sprague-Dawley, 300g., sustained EDL stretch); 5% EtOH; Fenestrated catheter provided drug delivery along the length of the EDL muscle.
P7023 Obata,K., Yamanaka,H., Kobayashi,K., Dai,Y., Mizushima,T., Katsura,H., Fukuoka,T., Tokunaga,A., Noguchi,K. Role of mitogen-activated protein kinase activation in injured and intact primary afferent neurons for mechanical and heat hypersensitivity after spinal nerve ligation. Journal of Neuroscience 2004; 24(-45-):10211-10222. >>> U0126; SB203580; FR167653; SP 600125; antibody, anti-NGF, sheep; DMSO, saline; CSF/CNS (intrathecal); Rat; 2001; 7 days; Controls received mp w/ vehicle; enzyme inhibitors (MAPK kinase, p38, JNK); 50% DMSO used.
P6915 Poulaki,V., Joussen,A.M., Mitsiades,N., Mitsiades,C.S., Iliaki,E.F., Adamis,A.P. Insulin-like growth factor-I plays a pathogenetic role in diabetic retinopathy. American Journal of Pathology 2004; 165(-2-):457-469. >>> Wortmannin; ly294002; antibody, monoclonal aLR-3; SP600125; SN50; geldanamycin; IP; Rat; 2002; 7 days; Enzyme inhibitor (P1-3K, JNK); diabetes.
121. Simvastatin
Q0763 Wei,P., Grimm,P.R., Settles,D.C., Balwanz,C.R., Padanilam,B.J., Sansom,S.C. Simvastatin Reverses Podocyte Injury but not Mesangial Expansion in Early Stage Type 2 Diabetes Mellitus. RENAL FAILURE 2009; 31(-6-):503-513. >>> Simvastatin; Ethanol; SC; Mice; 4 weeks; Controls received mp w/ vehicle; animal info (C57BL/6, male, 26 wks old); 60% ethanol used.
P9177 Holmberg,E., Zhang,S.X., Sarmiere,P.D., Kluge,B.R., White,J.T., Doolen,S. Statins decrease chondroitin sulfate proteoglycan expression and acute astrocyte activation in central nervous system injury. Experimental Neurology 2008; 214(-1-):78-86. >>> Simvastatin; CSF/CNS; Rat; 2004; 4 weeks; Comparison of PO gavage vs. mp; ALZET brain infusion kit used; post op. care (buprenorphine); animal info (female, Long Evans, adult, 200-22 g.); cannula placement confirmed by preparing cryosections of the brain at the lateral ventricle and verifying the presence of a cavity created by the cannula; spinal cord injury.
P9024 Skoglund,B., Aspenberg,P. Locally applied Simvastatin improves fracture healing in mice. BMC MUSCULOSKELETAL DISORDERS 2007; 8(-;-):U1-U6. >>> Simvastatin; PEG 400; SC; bone (femur); Mice; 1002; 14 days; Comparison of SC injections vs. SC mp vs. localized delivery; half-life (p. 2 of 6) "about 2 hours in humans"; animal info (mature, male, Balb-C); tissue perfusion (femur); compound passed through sterile filter before filling in pumps; silcone tube used; "continuous systemic delivery resulted in a 160% larger force at failure."; "Continuous local delivery... resulted in a 170% larger force at failure as well as a twofold larger energy uptake.".
P7913 Banes-Berceli,A.K., Shaw,S., Ma,G.C., Brands,M., Eaton,D.C., Stern,D.M., Fulton,D., Caldwell,R.W., Marrero,M.B. Effect of simvastatin on high glucose- and angiotensin II-induced activation of the JAK/STAT pathway in mesangial cells. American Journal of Physiology-Renal Physiology 2006; 291(-1-):F116-F121. >>> Simvastatin; Water, distilled; SC; Rat; ; Controls received no treatment; animal info (male, Sprague-Dawley, 225-250 g).
P2086 Joles,J., Willekes-Koolschijn,N., Koomans,H., Van Tol,A., Geelhoed-Mieras,T., Crommelin,D., Van Bloois,L., Krajnc-Franken,M., Cohen,L., Griffioen,M., Erkelens,W. Subcutaneous administration of HMG-CoA reductase inhibitors in hyperlipidaemic and normal rats. Lab.Anim. 1992; 26(--):269-280. >>> Lovastatin; Pravastatin; Liposomes; Simvastatin; Propylene glycol; rat; 2ML4; no duration posted; comparison of injections and oral administration vs. mp; stress/adverse reaction: local cystic reaction to simvastatin and lovastatin (p. 271, 275); enzyme inhibitor (HMG-CoA reductase), sc injections of simvastatin also caused subcutaneous toxicity.
122. Sorbinil
P6190 Dobretsov,M., Hastings,S.L., Romanovsky,D., Stimers,J.R., Zhang,J.M. Mechanical hyperalgesia in rat models of systemic and local hyperglycemia. Brain Research 2003; 960(-1-2-):174-183. >>> Glucose; sorbinil; HEPES, buffered saline; CSF/CNS (sciatic nerve); Rat; 2002; 14 days; Enzyme inhibitor (aldose reductase); post op. care (amoxicillin/clavulanate potassium 3 days).
P1722 Lerman,S. Test models to determine potential ocular drug induced side effects. Lens Eye Toxic.Res. 1989; 6(-1/2-):1-36. >>> 8-MOP; Chromophore; Sorbinil; Liposomes; Radio-isotopes; Eye (lens); rabbit; 2ML1; 7 days; tissue perfusion (ocular lens); liposome-encapsulated agents.
P1112 Megaw,J.M., Lerman,S. Application of miniosmotic pumps for liposomal drug delivery to the ocular lens. Invest.Ophthalmol.Vis.Sci. 1987; 28(--):1429-1433. >>> Methoxypsoralen, 8-; Radio-isotopes; Sorbinil; 3H tracer; Eye; rabbit; 2ML1; 7 days; mp connected to PE 60 tubing in eye; tissue perfusion.
123. Sphingosine
Q0900 Jang,S., Kim,D., Lee,Y., Moon,S., Oh,S. Modulation of Sphingosine 1-Phosphate and Tyrosine Hydroxylase in the Stress-Induced Anxiety. Neurochemical Research 2011; 36(-2-):258-267. >>> Sphingosine 1-phosphate; CSF/CNS; Rat; 2ML1; 7 days; Controls received mp w/ saline; animal info (Sprague-Dawley, male, 260-280 g); pump implanted following 1 week recovery period after cannulation; PE-60 tubing used.
P8757 Zanin,M., Germinario,E., Libera,L.D., Sandona,D., Sabbadini,R.A., Betto,R., nieli-Betto,D. Trophic action of sphingosine 1-phosphate in denervated rat soleus muscle. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY 2008; 294(-1-):C36-C46. >>> Sphingosine 1-phosphate; sphingosine, N,N-dimethyl-; Sphingosine; Saline, physiological; IM (soleus); Rat; 2002; 7, 14 days; Controls received mp w/ vehicle; dos-response (Fig. 3); half-life (pg. C39, C43) S1P: "short"; enzyme inhibitor (Sph Kinase); animal info (male, Wistar, 2-3 months old, 280-300g, muscle denervation).
P8420 Jang,S., Lee,J.H., Choi,K.R., Kim,D., Yoo,H.S., Oh,S. Cytochemical alterations in the rat retina by LPS administration. Neurochemical Research 2007; 32(-1-):1-10. >>> Endotoxin, LPS; sphingosine-1-phosphate; CSF/CNS; Rat; 2ML1; 7 days; Controls received mp w/ saline; cyanoacrylate adhesive; animal info (male, Sprague-Dawley, 260-280g).
124. TOFA
P5656 Gilbert,M., Magnan,C., Turban,S., Andre,J., Guerre-Millo,M. Leptin receptor-deficient obese Zucker rats reduce their food intake in response to a systemic supply of calories from glucose. Diabetes 2003; 52(-2-):277-282. >>> TOFA; DMSO; CSF/CNS; Rat; ; Controls received mp w/ vehicle; enzyme inhibitor (acetyl CoA carboxylase); TOFA is 5-(tetraderyloxy)-2-furoic acid..
125. TY-51469
P8639 Palaniyandi,S.S., Nagai,Y., Watanabe,K., Ma,M., Veeraveedu,P.T., Prakash,P., Kamal,F.A., Abe,Y., Yamaguchi,K., Tachikawa,H., Kodama,M., Aizawa,Y. Chymase inhibition reduces the progression to heart failure after autoimmune myocarditis in rats. EXPERIMENTAL BIOLOGY AND MEDICINE 2007; 232(-9-):1213-1221. >>> TY-51469; Phosphate buffer; NaOH; IV (jugular); Rat; 2ML4; 4 weeks; Controls received mp w/ vehicle; dose-response (fig. 2); stability verified by study in rat plasma at 40oC for 1 hour; enzyme inhibitor (chymase); cardiovascular; animal info (male, Lewis, 9 wks old).
126. Temocaprilat
P8612 Ito,N., Ohishi,M., Yamamoto,K., Tatara,Y., Shiota,A., Hayashi,N., Komai,N., Yanagitani,Y., Rakugi,H., Ogihara,T. Renin-angiotensin inhibition reverses advanced cardiac remodeling in aging spontaneously hypertensive rats. Am.J.Hypertens. 2007/7; 20(-7-):792-799. >>> Temocaprilat; olmesartan; hydralazine; IV (vena cava); Rat; 2ML4; 4 weeks; Controls received mp w/ saline; enzyme inhibitor (ACE); cardiovascular; antihypertensive; animal info (male, SHR, 50 weeks old, male, Wistar-Kyoto, 10 weeks old).
P7315 Emoto,N., Raharjo,S.B., Isaka,D., Masuda,S., Adiarto,S., Jeng,A.Y., Yokoyama,M. Dual ECE/NEP inhibition on cardiac and neurohumoral function during the transition from hypertrophy to heart failure in rats. Hypertension 2005; 45(-6-):1145-1152. >>> CGS-24592; CGS-26303; temocapril; NaHCO3; SC; Rat; 6 weeks; Controls received mp w/ vehicle; enzyme inhibitor (ACE, Neutral endopeptidase, ECE); antihypertensive.
127. Thiazoloquinazoline, Compound 54
P7807 Jung,F.H., Pasquet,G., Lambert-van der Brempt,C., Lohmann,J.J.M., Warin,N., Renaud,F., Germain,H., De Savi,C., Roberts,N., Johnson,T., Dousson,C., Hill,G.B., Mortlock,A.A., Heron,N., Wilkinson,R.W., Wedge,S.R., Heaton,S.P., Odedra,R., Keen,N.J., Green,S., Brown,E., Thompson,K., Brightwell,S. Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors. Journal of Medicinal Chemistry 2006; 49(-3-):955-970. >>> Thiazoloquinazoline, compound 54; Tris buffer; SC; Mice (nude); 2001D; 48 hours; Controls received mp w/ vehicle; half-life (pg. 963) 0.7 hours in mouse plasma; enzyme inhibitor (aurora A/B kinase); cancer (colorectal carcinoma); animal info (Swiss nu/nu, male, 8-10 wk old).
128. Thiorphan
Q0458 Belinson,H., Michaelson,D.M. ApoE4-dependent A-beta-mediated neurodegeneration is associated with inflammatory activation in the hippocampus but not the septum. Journal of Neural Transmission 2009; 116(-11-):1427-1434. >>> Thiorphan; CSF, artificial; ascorbic acid; CSF/CNS; Mice; ; Animal info (ApoE, 3-4 months old, male); neurodegenerative (Alzheimer's disease).
Q0427 Li,W.D., Wu,Y., Min,F.G., Li,Z., Huang,J.Y., Huang,R. A nonhuman primate model of Alzheimer's disease generated by intracranial injection of amyloid-beta42 and thiorphan. METABOLIC BRAIN DISEASE 2010; 25(-3-):277-284. >>> Thiorphan; Saline; ascorbic acid; CSF/CNS (basal ganglia); Monkey; 2ML4; 28 days; Controls received mp w/saline; animal info (middle aged, rhesus, male, 16-17 years old); neurodegenerative (Alzheimer's disease).
P9241 Amantini,C., Mosca,M., Lucciarini,R., Perfumi,M.C., Santoni,G. Thiorphan-induced survival and proliferation of rat thymocytes by activation of Akt/survivin pathway and inhibition of caspase-3 activity. Journal of Pharmacology and Experimental Therapeutics 2008; 327(-1-):215-225. >>> Thiorphan; SR140333; substance P; Ethanol; water, distilled; SC; Rat; 2001; 7 days; Controls received mp w/ vehicle or no treatment; no stress (see pg. 216); enzyme inhibitor (peptidase (NEP/CD10)); immunology; animal info (male, Wistar, 21 days old); 10% EtOH used; "We chose to delivery SP, SR140333, and Thiorphan by a continuous route of administration, because this modality closely mimics the pathophysiological state observed in immune-mediated diseases." (p. 216).
P8952 Dolev,I., Michaelson,D.M. The nucleation growth and reversibility of Amyloid-beta deposition in vivo. JOURNAL OF ALZHEIMERS DISEASE 2006; 10(-2-3-):291-301. >>> Thiorphan, DL-; CSF, artificial; ascorbic acid; CSF/CNS; Mice (transgenic); 2004; 4 weeks; Controls received mp w/ vehicle; enzyme inhibitor (neprilysin); animal info (male, C57BL/6, ApoE3 tg, ApoE4 tg, wt, 5 months old); neurodegenerative (Alzheimer's disease).
P7804 Zou,L.B., Mouri,A., Iwata,N., Saido,T.C., Wang,D.Y., Wang,M.W., Mizoguchi,H., Noda,Y., Nabeshima,T. Inhibition of neprilysin by infusion of thiorphan into the hippocampus causes an accumulation of amyloid beta and impairment of learning and memory. Journal of Pharmacology and Experimental Therapeutics 2006; 317(-1-):334-340. >>> Thiorphan; Saline; ascorbic acid; CSF/CNS (hippocampus); Rat; 2ML4; 4 weeks; Controls received mp w/ vehicle; enzyme ihibitor (neprilysin); neurodegenerative (Alzheimer's disease); animal info (male, Wistar, 8 wk old, 260-300g.).
P7719 Mouri,A., Zou,L.B., Iwata,N., Saido,T.C., Wang,D.Y., Wang,M.W., Noda,Y., Nabeshima,T. Inhibition of neprilysin by thiorphan (i.c.v.) causes an accumulation of amyloid beta and impairment of learning and memory. Behavioural Brain Research 2006; 168(-1-):83-91. >>> Thiorphan; Saline; NaOH; ascorbic acid; CSF/CNS; Rat; 2ML4; 4 weeks; Controls received mp w/ vehicle; enzyme inhibitor (neprilysin (aka enkephalinase)); neurodegenerative (Alzheimer's disease); animal info (male, wistar, 8 wk. old, 260-300g.); memory; learning.
P6872 Dolev,I., Michaelson,D.M. A nontransgenic mouse model shows inducible amyloid-beta (Abeta) peptide deposition and elucidates the role of apolipoprotein E in the amyloid cascade. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2004; 101(-38-):13909-13914. >>> Thiorphan; CSF, artificial; ascorbic acid; CSF/CNS; Mice; mice (transgenic); 2004; 1 month; 2,4 weeks; Controls received mp w/ vehicle; enzyme inhibitor (neprilysin); ALZET brain infusion kit used; cyanoacrylate adhesive (Loctite 454); post op. care (oxytetracycline); neurodegenerative disease (Alzheimer's).
P6341 Newell,A.J., Sue,L.I., Scott,S., Rauschkolb,P.K., Walker,D.G., Potter,P.E., Beach,T.G. Thiorphan-induced neprilysin inhibition raises amyloid beta levels in rabbit cortex and cerebrospinal fluid. Neuroscience Letters 2003; 350(-3-):178-180. >>> Thiorphan; Ethanol, absolute; water, distilled; DMSO; CSF/CNS; Rabbit; 2ML1; 5 days; Controls received mp w/ vehicle; enzyme inhibitor (Neprilysin, an endopeptidase); 50% DMSO.
P6283 Marr,R.A., Guan,H.J., Rockenstein,E., Kindy,M., Gage,F.H., Verma,I., Masliah,E., Hersh,L.B. Neprilysin regulates amyloid beta peptide levels. Journal of Molecular Neuroscience 2003; 22(-1-2-):5-11. >>> Phosphoramidon; thiorphan; CSF/CNS; Mice (transgenic); ; Neurodegenerative (Alzheimer's disease); pump model not listed; neurotoxicity; agents are enzyme inhibitors (neprilysin).
P5050 Hauss-Wegrzyniak,B., Wenk,G.L. Beta-amyloid deposition in the brains of rats chronically infused with thiorphan or lipopolysaccharide: the role of ascorbic acid in the vehicle. Neurosci.Lett. 2002/4/5; 322(--):75-78. >>> Endotoxin, LPS; Thiorphan, DL-; CSF, artificial; Ascorbic acid; CSF/CNS (fourth ventricle); rat; 2004; 37 days; controls received mp w/ vehicle; neurodegenerative (Alzheimer's disease); ascorbic acid in vehicle examined; some controls received vehicle without ascorbic acid.
P0500 Bean,A.J. Physical dependence produced by chronic intracerebroventricular infusion of (D-Arg)kyotorphin or thiorphan to rats. Eur.J.Pharmacol. 1984; 105(--):333-337. >>> Kyotorphin, D-arg-; Morphine; Thiorphan; Ethanol; Water; CSF/CNS; rat; 2001; 2ML2; 6 days; comparison of agents effects; peptides.
P0482 Schulz,R., Wuster,M., Herz,A. Receptor preference of dynorphin A fragments in the mouse vas deferens determined by different techniques. J.Pharmacol.Exp.Ther. 1984; 230(-1-):200-204. >>> Dynorphin A(1-8); Bestatin; Captopril; Dynorphin A; Enkephalin agonist DADL; Fentanyl; Thiorphan; Saline; SC; vas deferens; Mice; 2001; 2ML1; no duration posted; Comparison of agents effects; 2ML1 pump used w/ captopril, thiorphan, and bestatin; DADL&FEN admin. sc; peptides; antihypertensive.
129. Topotecan
Q0582 Carcaboso,A.M., Elmeliegy,M.A., Shen,J., Juel,S.J., Zhang,Z.W.M., Calabrese,C., Tracey,L., Waters,C.M., Stewart,C.F. Tyrosine Kinase Inhibitor Gefitinib Enhances Topotecan Penetration of Gliomas. Cancer Research 2010; 70(-11-):4499-4508. >>> Topotecan; Water, sterile; SC; Mice (nude); 2001D; 8-12 hours; Animal info (CD1, nude); cancer (glioma).
P9579 Shah,D.K., Shin,B.S., Veith,J., Toth,K., Bernacki,R.J., Balthasar,J.P. Use of an Anti-Vascular Endothelial Growth Factor Antibody in a Pharmacokinetic Strategy to Increase the Efficacy of Intraperitoneal Chemotherapy. Journal of Pharmacology and Experimental Therapeutics 2009; 329(-2-):580-591. >>> Topotecan; SC; IP; Mice; 1003D; 72 hours; Cancer (peritoneal).
P9109 Ng,B., Kramer,E., Liebes,L., Wasserheit,C., Hochster,H., Blank,E., Ceriani,R., Furmanski,P. Radiosensitization of tumor-targeted radioimmunotherapy with prolonged topotecan infusion in human breast cancer xenografts. Cancer Res. 2001/4/1; 61(-7-):2996-3001. >>> Antibody, monoclonal, BrE3; topotecan; SC; Mice (nude); 1007D; 14 days; Controls received no treatment; dose-response (fig. 3, pg. 2999); enzyme inhibitor (topoisomerase-1); cancer (breast); animal info (athymic, female, Swiss, 8-10 wks old); BrE3 antibody is a murine IgG1 monoclonal antibody.
P8699 Chen,J., Lu,Q., Balthasar,J.P. Mathematical modeling of topotecan pharmacokinetics and toxicodynamics in mice. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 2007; 34(-6-):829-847. >>> Topotecan HCl; KH2PO4 buffer; IP; Mice; 1003D; 1007D; 7 days; 24, 72 hours; Controls received mp w/ vehicle; dose-response (fig. 4); comparison of IV, IP injections vs. mp; enzyme inhibitor (topoisomerase); cancer (ovarian); animal info (male, Swiss Webster, 20-30g).
P4283 Pollina,J., Plunkett,R.J., Ciesielski,M.J., Lis,A., Barone,T.A., Greenberg,S.J., Fenstermaker,R.A. Intratumoral infusion of topotecan prolongs survival in the nude rat intracranial U87 human glioma model. Journal of Neuro-oncology 1998; 39(--):217-225. >>> Topotecan;; Saline;; CSF/CNS (glioma);; rat (nude);; 1003D;; 10 hours;; controls received mp w/ vehicle or no treatment; tissue perfusion (tumor); functionality of mp verified by examining pumps to see if they were empty; no stress (p. 220); cancer; peptides; topotecan is a DNA topoisomerase I inhibitor;.
130. U0126
P9149 Han,Y.J., Hu,W.Y., Piano,M., de Lanerolle,P. Regulation of myosin by angiotensin II in light chain kinase expression hypertension. American Journal of Hypertension 2008; 21(-8-):860-865. >>> U0126; ML-7; DMSO; SC; Rat; 2ML4; 3 weeks; Controls received mp w/ vehicle; enzyme inhibitor (smMLCK or MEK or MAP kinase); animal info (male, SHR, WKY, 16 wks old); 50% DMSO used.
P8410 Putignano,E., Lonetti,G., Cancedda,L., Ratto,G., Costa,M., Maffei,L., Pizzorusso,T. Developmental Downregulation of histone post translational modifications regulates visual cortical plasticity. Neuron 2007; 53(-5-):747-759. >>> U0126; DMSO; saline; CSF/CNS (visual cortex); Mice; 1007D; ; Controls received mp w/ vehicle; enzyme inhibitor (MEK); animal info (C57BL6/J, 4 wks old, 12-14 wks old); 0.5% DMSO.
P8127 Han,Y.J., Hu,W.Y., Chernaya,O., Antic,N., Gu,L.Z., Gupta,M., Piano,M., de Lanerolle,P. Increased myosin light chain kinase expression in hypertension: Regulation by serum response factor via an insertion mutation in the promoterD. MOLECULAR BIOLOGY OF THE CELL 2006; 17(-9-):4039-4050. >>> U0126; ML-7; DMSO; SC; Rat; 2ML4; 3 weeks; Controls received mp w/ vehicle; enzyme inhibitor (myosin light chain kinase); cardiovascular; animal info (SHR, Wistar-Kyoto, 1, 16 wks old); 50% DMSO.
P7956 Di,Cristo G., Berardi,N., Cancedda,L., Pizzorusso,T., Putignano,E., Ratto,G.M., Maffei,L. Requirement of ERK activation for visual cortical plasticity. Science 2001/6/22; 292(-5525-):2337-2340. >>> U0126; PD-98059; SB203580; CSF/CNS (visual cortex); Rat; 1 week; Controls received mp w/ vehicle; stability verified by inhibition of ERK activation by picrotoxin; enzyme inhibitor (p38 MAP kinase); animal info (Dark-reared, P28); tissue perfusion (visual cortex).
P7023 Obata,K., Yamanaka,H., Kobayashi,K., Dai,Y., Mizushima,T., Katsura,H., Fukuoka,T., Tokunaga,A., Noguchi,K. Role of mitogen-activated protein kinase activation in injured and intact primary afferent neurons for mechanical and heat hypersensitivity after spinal nerve ligation. Journal of Neuroscience 2004; 24(-45-):10211-10222. >>> U0126; SB203580; FR167653; SP 600125; antibody, anti-NGF, sheep; DMSO, saline; CSF/CNS (intrathecal); Rat; 2001; 7 days; Controls received mp w/ vehicle; enzyme inhibitors (MAPK kinase, p38, JNK); 50% DMSO used.
P6780 Obata,K., Yamanaka,H., Dai,Y., Mizushima,T., Fukuoka,T., Tokunaga,A., Noguchi,K. Differential activation of MAPK in injured and uninjured DRG neurons following chronic constriction injury of the sciatic nerve in rats. European Journal of Neuroscience 2004; 20(-11-):2881-2895. >>> U0126; SB203580; DMSO; CSF/CNS (intrathecal); Rat; 1003D; 2001; 7 days; Controls received mp w/ vehicle; enzyme inhibitor (p38 MAP kinase); 50% DMSO used.
P6128 Cancedda,L., Putignano,E., Impey,S., Maffei,L., Ratto,G.M., Pizzorusso,T. Patterned vision causes CRE-mediated gene expression in the visual cortex through PKA and ERK. Journal of Neuroscience 2003; 23(-18-):7012-7020. >>> U0126; Rp-8-cl-cAMPS; DMSO; CSF/CNS; Rat; mice (transgenic); 1007D; 7 days; Enzyme inhibitor (PKA and extracellular singal-regulated kinase); U0126 (ERK inhibitor) and Rp-8-cl-cAMPS (PKA inhibitor) were dissolved in 1% DMSO.
P5614 Obata,K., Yamanaka,H., Dai,Y., Tachibana,T., Fukuoka,T., Tokunaga,A., Yoshikawa,H., Noguchi,K. Differential activation of extracellular signal-regulated protein kinase in primary afferent neurons regulates brain-derived neurotrophic factor expression after peripheral inflammation and nerve injury. Journal of Neuroscience 2003; 23(-10-):4117-4126. >>> U0126; DMSO; CSF/CNS (intrathecal); Rat; 1003D; 2001; 3 or 7 days; Controls received mp/w vehicle; enzyme inhibitor (mitogen-activated protein kinase (MAPK)); 50% DMSO vehicle used; U0126 is a mitogen-activated protein kinase 1/2 inhibitor..
131. UCN-01
P9774 Khan,N., Mupparaju,S.P., Hou,H., Lariviere,J.P., Demidenko,E., Swartz,H., Eastman,A. Radiotherapy in Conjunction with 7-Hydroxystaurosporine: A Multimodal Approach with Tumor pO2 as a Potential Marker of Therapeutic Response. RADIATION RESEARCH 2009; 172(--):592-597. >>> UCN-01; Sodium acetate; SC; Mice; 1003D; 3 days; Functionality of mp verified by plasma UCN-01 concentrations; cancer (radiation therapy); animal info (female, C3H/HEJ, 18-20 g.).
P3783 Tsuchida,E., Urano,M. The effect of UCN-01 (7-hydroxystaurosporine), a potent inhibitor of protein kinase C, on fractionated radiotherapy or daily chemotherapy of a murine fibrosarcoma. Int.J.Radiat.Oncol.Biol.Phys. 1997; 39(-5-):1153-1161. >>> UCN-01; Citric acid; intratumoral; mice; 2001; 7 days; tissue perfusion (tumor); cancer; enzyme inhibitor.
132. Vardenifil
Q0167 Sahara,M., Sata,M., Morita,T., Nakajima,T., Hirata,Y., Nagai,R. A Phosphodiesterase-5 Inhibitor Vardenafil Enhances Angiogenesis Through a Protein Kinase G-Dependent Hypoxia-Inducible Factor-1/Vascular Endothelial Growth Factor Pathway. Arterioscler Thromb Vasc Biol 2010; 30(--):1315-1324. >>> Vardenifil; PBS; SC; Mice; ; Controls received mp w/ vehicle; enzyme inhibitor (PDE5, phosphodiesterase-5); ischemia (hind limb); animal info (C57BL/6, C3H/He, 12-16 wks old, eNose -/-).
133. Vigabatrin
R0242 Loescher,W. The pharmacokinetics of antiepileptic drugs in rats: Consequences for maintaining effective drug levels during prolonged drug administration in rat models of epilepsy. Epilepsia 2007; 48(-7-):1245-1258. >>> Levetiracetam; phenobarbital; phenytoin; valproic acid; vigabatrin; Water, distilled; PEG 300; glycerol; PEG 400; propylene glycol; SC; IP; Rat; mice; gerbils; 2ML1; 2ML2; 1-4,2 weeks; 7 days; Comparison of IV, IP injections vs. food or water delivery vs mp; pumps replaced (every week in one set of experiments); stress/adverse reaction: (see pg. 1255); peritoneal irritation, peritonitis in some of the IP experiments); half-life (p. 1247) table 1 (18 compounds); animal info (epileptic, Sprague-Dawley, Wistar); review; see p. 1254-1255; see table 4 for advantages + disadvantages of different applicatoin routes.
R0177 Pitkanen,A. Efficacy of current antiepileptics neurodegeneration in epilepsy to prevent models. Epilepsy Research 2002; 50(-1-2-):141-160. >>> Vigabatrin; Tiagabine; SC; Rat; 2 months; Neuroprotection; pump use mentioned on p. 147 and 155.
P4904 Halonen,T., Nissinen,J., Pitkanen,A. Chronic elevation of brain GABA levels beginning two days after status epilepticus does not prevent epileptogenesis in rats. Neuropharmacology 2001; 40(--):536-550. >>> Vigabatrin; Saline; SC; rat; 2ML2; 10 weeks; controls received mp w/ vehicle; long-term study, pumps replaced every 2 weeks for 10 weeks; epilepsy; seizures..
P4343 Pitkanen,A., Nissinen,J., Jolkkonen,E., Tuunanen,J., Halonen,T. Effects of vigabatrin treatment on status epilepticus-induced neuronal damage and mossy fiber sprouting in the rat hippocampus. Epilepsy Research 1999; 33(--):67-85. >>> Vigabatrin;; Saline;; SC;; rat;; 2ML1;; 2 months;; controls received mp with vehicle; functionality of mp verified by plasma levels and residual volume; long-term study, pumps replaced every 2 weeks; enzyme inhibitor;.
P4249 Golombek,D.A., Ralph,M.R. Inhibition of GABA transaminase enhances light-induced circadian phase delays but not advances. J.Biol.Rhythms 1994; 9(-3-4-):251-261. >>> Vigabatrin; Saline; IP; hamster; 2002; 14 days; controls received mp w/saline or no treatment; comparison of injections vs. mp; GABA transaminase inhibitor.
134. Wortmannin
Q0620 Pinkenburg,O., Pfosser,A., Hinkel,R., Boettcher,M., Dinges,C., Lebherz,C., Sultana,S., Enssle,J., El-Aouni,C., Buening,H., Boekstegers,P., Bals,R., Kupatt,C. Recombinant Adeno-Associated Virus-Based Gene Transfer of Cathelicidin Induces Therapeutic Neovascularization Preferentially via Potent Collateral Growth. Human Gene Therapy 2009; 20(-2-):159-167. >>> Wortmannin; SC; Rabbit; 14 days; Animal info (New Zealand, white, 3.5 kg); enzyme inhibitor (PI3K, phosphatidylinositol 3-kinase).
P9421 Kobayashi,N., Takeshima,H., Fukushima,H., Koguchi,W., Mamada,Y., Hirata,H., Machida,Y., Shinoda,M., Suzuki,N., Yokotsuka,F., Tabei,K., Matsuoka,H. Cardioprotective Effects of Pitavastatin on Cardiac Performance and Remodeling in Failing Rat Hearts. American Journal of Hypertension 2009; 22(-2-):176-182. >>> Pitavastatin; Wortmannin; Y-27632; DMSO; saline; SC; Rat; 2ML4; 7 weeks; Controls received mp w/ vehicle; long-term study; pumps replaced; enzyme inhibitor (phosphatidyl inositol 3-kinase, Rho kinase); cardiovascular; multiple pumps per animal (2); animal info (male, Dahl S, Dahl R, 11 wks old); 8% DMSO used.
P7818 Dell,S., Peters,S., Muether,P., Kociok,N., Joussen,A.M. The role of PDGF receptor inhibitors and PI3-kinase signaling in the pathogenesis of corneal neovascularization. INVESTIGATIVE OPHTHALMOLOGY&VISUAL SCIENCE 2006; 47(-5-):1928-1937. >>> AG-1296; wortmannin; LY294002; PBS; IP; Mice; 2001; 1 week; Controls received mp w/ vehicle; dose-response (fig. 6); enzyme inhibitor (PDGF receptor kinase, phosphatidylinositol 3-kinase); animal info (male, C57BL/6,7-10wk old 20g.).
P6915 Poulaki,V., Joussen,A.M., Mitsiades,N., Mitsiades,C.S., Iliaki,E.F., Adamis,A.P. Insulin-like growth factor-I plays a pathogenetic role in diabetic retinopathy. American Journal of Pathology 2004; 165(-2-):457-469. >>> Wortmannin; ly294002; antibody, monoclonal aLR-3; SP600125; SN50; geldanamycin; IP; Rat; 2002; 7 days; Enzyme inhibitor (P1-3K, JNK); diabetes.
P6194 Mizuno,M., Yamada,K., Takei,N., Tran,M.H., He,J., Nakajima,A., Nawa,H., Nabeshima,T. Phosphatidylinositol 3-kinase: a molecule mediating BDNF-dependent spatial memory formation. Molecular Psychiatry 2003; 8(-2-):217-224. >>> Oligonucleotide, antisense; oligonucleotide, sense; wortmannin; Saline, pyrogen-free; DMSO; CSF/CNS; Rat; 2004; 1 week; 25 days; Enzyme inhibitor (phosphatidylinositol 3-kinase); sense and antisense (BDNF).
P6045 Kobayashi,N., Mita,S., Yoshida,K., Honda,T., Kobayashi,T., Hara,K., Nakano,S., Tsubokou,Y., Matsuoka,H. Celiprolol activates eNOS through the PI3K-Akt pathway and inhibits VCAM-1 via NF-kappa B induced by oxidative stress. Hypertension 2003; 42(-5-):1004-1013. >>> Wortmannin; DMSO; SC; Rat; 2ML4; 4 weeks; Wortmannin (P13K inhibitor) was dissolved in 8% DMSO.
135. Y-27632
Q0260 Zulauf,L., Coste,O., Marian,C., Moeser,C., Brenneis,C., Niederberger,E. Cofilin phosphorylation is involved in nitric oxide/cGMP-mediated nociception. Biochemical and Biophysical Research Communications 2009; 390(-4-):1408-1413. >>> Y-27632; CSF, artificial; CSF/CNS (intrathecal); Rat; 2001; 5 days; Enzyme inhibitor (ROCK); behavioral testing (paw withdrawal latency).
P9421 Kobayashi,N., Takeshima,H., Fukushima,H., Koguchi,W., Mamada,Y., Hirata,H., Machida,Y., Shinoda,M., Suzuki,N., Yokotsuka,F., Tabei,K., Matsuoka,H. Cardioprotective Effects of Pitavastatin on Cardiac Performance and Remodeling in Failing Rat Hearts. American Journal of Hypertension 2009; 22(-2-):176-182. >>> Pitavastatin; Wortmannin; Y-27632; DMSO; saline; SC; Rat; 2ML4; 7 weeks; Controls received mp w/ vehicle; long-term study; pumps replaced; enzyme inhibitor (phosphatidyl inositol 3-kinase, Rho kinase); cardiovascular; multiple pumps per animal (2); animal info (male, Dahl S, Dahl R, 11 wks old); 8% DMSO used.
P9254 Xue,F., Takahara,T., Yata,Y., Xia,Q., Nonome,K., Shinno,E., Kanayama,M., Takahara,S., Sugiyama,T. Blockade of Rho/Rho-associated coiled coil-forming kinase signaling can prevent progression of hepatocellular carcinoma in matrix metalloproteinase-dependent manner. HEPATOLOGY RESEARCH 2008; 38(-8-):810-817. >>> Y-27632; PBS; SC; Mice; 1002; 4 weeks; Controls received mp w/ vehicle; pumps replaced after 2 weeks; enzyme inhibitor (Rho/ROCK); cancer (hepatocellular carcinoma); animal info (female, B6C3F1).
P8999 Sagara,Y., Hirooka,Y., Nozoe,M., Ito,K., Kimura,Y., Sunagawa,K. Pressor response induced by central angiotensin II is mediated by activation of Rho/Rho-kinase pathway via AT1 receptors. Journal of Hypertension 2007; 25(-2-):399-406. >>> Angiotensin II; phenylephrine; Y-27632; valsartan; CSF, artificial; SC; CSF/CNS; Rat; 1002; 2001; 7 days; Controls received mp w/ vehicle; enzyme inhibitor (Rho-kinase); antihypertensive; peptides; animal info (male, Wistar-Kyoto, SHR, 280-340 g.); catheter tip placement and connection confirmed.
P8765 Kobayashi,N., Ohno,T., Yoshida,K., Fukushima,H., Mamada,Y., Nomura,M., Hirata,H., Machida,Y., Shinoda,M., Suzi,N., Matsuoka,H. Cardioprotective mechanism of telmisartan via PPAR-gamma-eNOS pathway in Dahl salt-sensitive hypertensive rats. American Journal of Hypertension 2008; 21(-5-):576-581. >>> Y-27632; Saline; SC; Rat; 2ML2; 5 weeks; Enzyme inhibitor (Rho Kinase); cardiovasculcar; animal info (male, Dahl salt-sens., Dahl salt-resistant, 6 wks old).
P8374 Chan,C.C.M., Wong,A.K., Liu,J., Steeves,J.D., Tetzlaff,W. ROCK inhibition with Y27632 activates astrocytes and increases their expression of neurite growth-inhibitory chondroitin sulfate proteoglycans. Glia 2007; 55(-4-):369-384. >>> Y-27632; Saline; CSF/CNS (intrathecal); Rat; 1007D; 1 week; Controls received mp w/ vehicle; dose-response (fig. 1); enzyme inhibitor (Rho kinase); animal info (male, Sprague-Dawley, dorsal column transection).
P7757 Winaver,J., Ovcharenko,E., Rubinstein,I., Gurbanov,K., Pollesello,P., Bishara,B., Hoffman,A., Abassi,Z. Involvement of Rho kinase pathway in the mechanism of renal vasoconstriction and cardiac hypertrophy in rats with experimental heart failure. American Journal of Physiology-Heart and Circulatory Physiology 2006; 290(-5-):H2007-H2014. >>> Y-27632; Saline; IP; Rat; 2001; 7 days; Controls received mp w/ vehicle; stability verified by assesment in saline and plasma at 37celsius for up to 500 min.; enzyme inhibitor (Rho Kinase); cardiovascular; animal info (male, Wistar, 280-350g., CHF).
P7559 Chan,C.C.M., Khodarahmi,K., Liu,J., Sutherland,D., Oschipok,L.W., Steeves,J.D., Tetzlaff,W. Dose-dependent beneficial and detrimental effects of ROCK inhibitor Y27632 on axonal sprouting and functional recovery after rat spinal cord injury. Experimental Neurology 2005; 196(-2-):352-364. >>> Y-27632; streptomycin; PBS, sterile; penicillin; CSF/CNS (intrathecal); Rat; 2002; 2 weeks; 2, 4 days; Controls received mp w/ vehicle; functionality of mp verified by ROCK inhibitory activity in CSF; dose-response (fig. 3); stability of Y27632 verified by ROCK inhibitory activity after 13 days in mp at 37 C; enzyme inhibitor (RHO Kinase); animal info (male, Sprague-Dawley); cervical 4/5 dorsal column transection.
P7357 Nakagawa,H., Yoshioka,K., Miyahara,E., Fukushima,Y., Tamura,M., Itoh,K. Intrathecal administration of Y-27632, a specific Rho-associated kinase inhibitor, for rat neoplastic meningitis. MOLECULAR CANCER RESEARCH 2005; 3(-8-):425-433. >>> Y-27632; uridine, fluorodeoxy-; PBS; CSF/CNS (Intrathecal, cisterna magna); Rat; 2002; ; Cancer (breast); enzyme inhibitor (rho-associated kinase inhibitor).
P7333 Tahara,M., Kawagishi,R., Sawada,K., Morishige,K., Sakata,M., Tasaka,K., Murata,Y. Tocolytic effect of a Rho-kinase inhibitor in a mouse model of lipopolysaccharide-induced preterm delivery. American Journal of Obstetrics and Gynecology 2005; 192(-3-):903-908. >>> 4-27632; Water, distilled; saline; IP; Mice (pregnant); 1007D; <1 week; Controls received mp w/ vehicle; enzyme inhibitor (Rho-kinase); teratology; "There was no complications of insertion of the pumps (including bleeding, infection, or death)..." p. 904.
P7122 Kobayashi,N., Hara,K., Tojo,A., Onozato,M.L., Honda,T., Yoshida,K., Mita,S., Nakano,S., Tsubokou,Y., Matsuoka,H. Eplerenone shows renoprotective effect by reducing LOX-1-mediated adhesion molecule, PKCepsilon-MAPK-p90RSK, and rho-kinase pathway. Hypertension 2005; 45(-4-):538-544. >>> Y-27632; Saline; Rat; 2ML2; 5 weeks; Controls received no treatment; enzyme inhibitor (Rho-kinase); cardiovascular.
P7026 Ramer,L.M., Borisoff,J.F., Ramer,M.S. Rho-kinase inhibition enhances axonal plasticity and attenuates cold hyperalgesia after dorsal rhizotomy. Journal of Neuroscience 2004; 24(-48-):10796-10805. >>> Y-27632; Saline, sterile; CSF/CNS (intrathecal); Rat; 7,10,28 days; Controls received mp w/ vehicle; enzyme inhibitor (Rho kinase).
P6809 Fagan,K.A., Oka,M., Bauer,N.R., Gebb,S.A., Ivy,D.D., Morris,K.G., McMurtry,I.F. Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY 2004; 287(-4-):L656-L664. >>> Y-27632; Saline; SC; Mice; 1002; 14 days; Controls received mp w/ vehicle; no stress (see pg. L657); enzyme inhibitor (Rho Kinase); "There were no complications of insertions of the pumps, including bleeding, infection, or deaths, in the 30 mg/kg Y-27632 or vehicle treated animals." (p. L657).
P6768 Tanaka,H., Yamashita,T., Yachi,K., Fujiwara,T., Yoshikawa,H., Tohyama,M. Cytoplasmic p21Cip1/WAF1 enhances axonal regeneration and functional recovery after spinal cord injury in rats. Neuroscience 2004; 127(-1-):155-164. >>> p21-Cip1/WAF-1, TAT fusion protein, cytoplasmic-; Y-27632; HA-1077; PBS; CSF/CNS (spinal cord, intrathecal); Rat; 2002; 2 weeks; Controls received mp w/ vehicle or control protein; functionality of mp verified by BDA-labeled fibers; dose-response (Fig.2); enzyme inhibitor (Rho kinase); peptides.
P6516 Ito,K., Hirooka,Y., Kishi,T., Kimura,Y., Kaibuchi,K., Shimokawa,H., Takeshita,A. Rho/Rho-kinase pathway in the brainstem contributes to hypertension caused by chronic nitric oxide synthase inhibition. Hypertension 2004; 43(-2-):156-162. >>> Y-27632; CSF, artificial; CSF/CNS (cisterna); Rat; 1002; 2 weeks; 10 days; Controls received mp w/ vehicle; enzyme inhibitor (Rho-kinase); cardiovascular.
P6266 Harper,J.M., Krishnan,C., Darman,J.S., Deshpande,D.M., Peck,S., Shats,I., Backovic,S., Rothstein,J.D., Kerr,D.A. Axonal growth of embryonic stem cell-derived motoneurons in vitro and in motoneuron-injured adult rats. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2004; 101(-18-):7123-7128. >>> PBS; Y-27632; dcbAMP; CSF; CSF/CNS (intrathecal, lumbar); Rat; 1007D; 7 days; Transplantation of cells.
P6104 Murata,T., Arii,S., Mori,A., Imamura,M. Therapeutic significance of Y-27632, a Rho-kinase inhibitor, on the established liver fibrosis. Journal of Surgical Research 2003; 114(-1-):64-71. >>> Y-27632; Saline; IP; Rat; 2002; 6 weeks; Controls received mp w/ vehicle; pumps replaced every two weeks; enzyme inhibitor (rho-kinase).
P5597 Fournier,A.E., Takizawa,B.T., Strittmatter,S.M. Rho kinase inhibition enhances axonal regeneration in the injured CNS. Journal of Neuroscience 2003; 23(-4-):1416-1423. >>> C3 Transferase; Glutathione S-transferase; Y-27632; PBS; CSF/CNS (intrathecal); Rat; 2002; 2-3 weeks; Enzyme inhibitor (protein kinase); peptides; spinal cord injury; Y-27632 is a Rho-associated kinase (ROCK) inhibitor.
P5465 Kobayashi,N., Horinaka,S., Mita,S., Nakano,S., Honda,T., Yoshida,K., Kobayashi,T., Matsuoka,H. Critical role of Rho-kinase pathway for cardiac performance and remode ling in failing rat hearts. Cardiovascular Research 2002; 55(-4-):757-767. >>> Y-27632; Saline; Rat; 2ML4; 7 weeks; Enzyme inhibitor (specific Rho-kinase).
P5229 Kobayashi,N., Nakano,S., Mita,S., Kobayashi,T., Honda,T., Tsubokou,Y., Matsuoka,H. Involvement of Rho-kinase pathway for angiotensin II-induced plasminogen activator inhibitor-1 gene expression and cardiovascular remodeling in hypertensive rats. J Pharmacol Exp.Ther. 2002/5; 301(-2-):459-466. >>> Angiotensin II; Y-27632; Saline; SC; Rat; 2ML2; 14 days; Controls received mp w/ vehicle; cardiovascular; peptides; Y-27632 is a specific Rho-kinase inhibitor.
P4302 Itoh,K., Yoshioka,K., Akedo,H., Uehata,M., Ishizaki,T., Narumiya,S. An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nature Medicine 1999; 5(-2-):221-225. >>> Y-27632; IP;; rat;; 11 days;; cancer; 2 pumps were implanted in each animal; Y-27632 is a specific ROCK inhibitor; enzyme inhibitor;.
136. YVAD-CMK, Ac-
P8655 Gemma,C., Bachstetter,A.D., Cole,M.J., Fister,M., Hudson,C., Bickford,P.C. Blockade of caspase-1 increases neurogenesis in the aged hippocampus. European Journal of Neuroscience 2007; 26(-10-):2795-2803. >>> YVAD-CMK, Ac-; DMSO; saline; CSF/CNS; Rat; 2004; 28 days; Controls received mp w/ vehicle; functionality of mp verified by mp weight (not suggested by manufacturer); enzyme inhibitor (caspase-1); animal info (male, Fischer 344; 4 and 22 months old); 0.6% DMSO.
P7589 Gemma,C., Fister,M., Hudson,C., Bickford,P.C. Improvement of memory for context by inhibition of caspase-1 in aged rats. European Journal of Neuroscience 2005; 22(-7-):1751-1756. >>> YVAD-CMK, Ac-; CSF/CNS; Rat; 2004; 28 days; Controls received mp w/ 0.6% DMSO in saline; functionality of mp verified by mp weight (not suggested by manufacturer); enzyme inhibitor (caspase -1); immunology; animal info (young, aged, make, Fischer 344 g); mp primed 48 hr in 37 C sterile saline.
137. Z-DEVD-FMK
P9808 Thompson,C.K., Brenowitz,E.A. Neurogenesis in an Adult Avian Song Nucleus Is Reduced by Decreasing Caspase-Mediated Apoptosis. Journal of Neuroscience 2009; 29(-14-):4586-4591. >>> Z-VAD-FMK; Z-DEVD-FMK; Z-LEHD-FMK; DMSO; CSF/CNS (telencephalon); Bird (sparrow); 1002; ; Negative controls received mp w/ Z-FA-FMK; enzyme inhibitor (caspase); animal info (10 months old, male, Gambels white crowned); 1% DMSO used; pumps externalized, used "custom-made backpacks", pg 4587; pumps replaced after 11 days; brain tissue distribution.
P9806 Tang,H.D., Wang,Y.M., Xie,L., Mao,X.O., Won,S.J., Galvan,V., Jin,K.L. Effect of neural precursor proliferation level on neurogenesis in rat brain during aging and after focal ischemia. NEUROBIOLOGY OF AGING 2009; 30(-2-):299-308. >>> Z-DEVD-FMK; DMSO; CSF, artificial; CSF/CNS; Rat; 1003D; 3 days; Controls received mp w/ vehicle; enzyme inhibitor (peptide methylketone caspase-3); animal info (5 days old, 3, 11, 24, months old, Fischer 344); brain tissue distribution.
P9690 Thompson,C.K., Brenowitz,E.A. Caspase inhibitor infusion protects an avian song control circuit from seasonal-like neurodegeneration. Journal of Neuroscience 2008; 28(-28-):7130-7136. >>> Z-VAD; Z-DEVD-FMK; Z-LEHD; Z-FA-FMK; DMSO; CSF/CNS (telencephalon); Bird (sparrow); 1, 3, 7 days; Negative controls received mp w/ Z-FA-FMK; good methods (pg 3); animal info (white-crowned, male); 1% DMSO used; pumps externalized via backpack; brain tissue distribution.
P9452 Teschendorf,P., Vogel,P., Wippel,A., Krumnikl,J.J., Spoehr,F., Boettiger,B.W., Popp,E. The effect of intracerebroventricular application of the caspase-3 inhibitor zDEVD-FMK on neurological outcome and neuronal cell death after global cerebral ischaemia due to cardiac arrest in rats. RESUSCITATION 2008; 78(-1-):85-91. >>> Z-DEVD-FMK; CSF/CNS; Rat; 1007D; 7 days; Controls received mp w/ artificial CSF; no stress (see pg. 87); enzyme inhibitor (caspase-3); cardiovascular; ischemia (cardiac, cerebral); animal info (male, Wistar, 350-450 g., cardiac arrest); Z-DEVD-FMK also known as N-benzyloxycarbonyl-Asp(OMe)-Glu(OMe)-Val-Asp(OMe)-fluoromethylketone.
P7069 Jing,W., Ladrech,S., Pujol,R., Brabet,P., Van de Water,T.R., Puel,J.L. Caspase inhibitors, but not c-Jun NH2-terminal kinase inhibitor treatment, prevent cisplatin-induced hearing loss. Cancer Research 2004; 64(-24-):9217-9224. >>> z-DEVD-fmk; z-IETD-fmk; z-LEHD-fmk; z-FA-fmk; JNKI-1, D-; Perilymph, artificial; Ear (cochlea); Guinea-pig; 2001; 7 days; Controls received mp w/ vehicle; enzyme inhibitor (caspases (-3,-8,-9), cathepsinB, JNK); peptides; tissue perfusion (cochlea).
P6140 Mao,J.R., Sung,B.K., Ji,R.R., Lim,G. Neuronal apoptosis associated with morphine tolerance: Evidence for an opioid-induced neurotoxic mechanism. Journal of Neuroscience 2002; 22(-17-):7650-7661. >>> Morphine; MK-801; zVAD-fmk; AC-DEVD-CHO; Saline; CSF/CNS (intrathecal); Rat; 2001; 7 days; Controls received mp w/ vehicle; good methods p. 7651; enzyme inhibitor (pan caspase); tolerance; analgesic; AC-DEVD-CHO and zVAD-fmk are caspase inhibitors.
P5765 Clark,R.S.B., Kochanek,P.M., Watkins,S.C., Chen,M, Dixon,C.E., Seidberg,N.A., Melick,J., Loeffert,J.E., Nathaniel,P.D., Jin,K.L., Graham,S.T. Caspase-3 mediated neuronal death after traumatic brain injury in rats.. J Neurochem 2000; 74(-2-):740-753. >>> Z-DEVD-FMK; DMSO; CSF, artificial; CSF/CNS (hippocampus); Rat; 1003D; 72 hours; Controls received mp w/ vehicle; enzyme inhibitor (caspase-3); ALZET brain infusion kit used; 0.2%DMSO used; ischemia (cerebral).
P5256 Gillardon,F., Kiprianova,I., Sandkuhler,J., Hossmann,K.A., Spranger,M. Inhibition of caspases prevents cell death of hippocampal CA1 neurons, but not impairment of hippocampal long-term potentiation following global ischemia. Neuroscience 1999; 93(-4-):1219-1222. >>> Z-DEVD-FMK; CSF, artificial; CSF/CNS; Rat; 1007D; 7 days; Controls received mp w/ vehicle; enzyme inhibitor (caspase inhibitor); ischemia (cerebral); neuroprotection.
138. ZD9331
P4834 Aherne,G.W., Hardcastle,A., Ward,E., Dobinson,D., Crompton,T., Valenti,M., Brunton,L., Jackman,A.L. Pharmacokinetic/pharmacodynamic study of ZD9331, a nonpolyglutamatable inhibitor of thymidylate synthase, in a murine model following two curative administration schedules. Clinical Cancer Research 2001; 7(--):2923-2930. >>> ZD9331; Sodium bicarbonate; SC; Mice; 2001D; 24 hours; Cancer; enzyme inhibitor; ZD9331 is a thymidylate synthase inhibibitor; "As expected for a compound that is unable to be polyglutamated, significant antitumor activity in mouse models was achieved when ZD9331 was administered by continuous infusion; Thus, a 3mg/kg sc infusion of ZD9331 over 24h (delivered via osmotic minipumps) was curative..." p. 2923;.
Looking for references? We can help!
Since 1977, scientist around the world have used ALZET pumps to conduct their research, publishing their results in high-impact journals. The ALZET bibliography now contains over 13,500 publications! We can perform a custom search for references relevant to your research.
Researchers are saying ...
“...In comparison to bolus IP injection, continuous administration of angiogenesis inhibitors by an osmotic pump implanted IP resulted in a decrease of the required dosage and improved the effectiveness of therapy.” (p.451) Cheng et al., Neoplasia 2003;5:445-456